Synthesis of Novel Calix[4]arene Based Dendrimers

and their Biological Applications by Atzori, Simone
  
 
 
 
Synthesis of Novel Calix[4]arene Based Dendrimers 
and their Biological Applications 
 
 
Simone Atzori 
 
 
School of Pharmacy 
University of East Anglia 
 
 
A thesis submitted to the University of East Anglia for the degree of 
Doctor of Philosophy 
 
 
March 2013 
 
 
 
  
Declaration 
 
This thesis is submitted to the University of East Anglia for the Degree of Doctor of 
Philosophy and has not been previously submitted at this, or any other university for 
assessment or for any other degree. Except where stated, and reference or 
acknowledgement is given, this work is original and has been carried out by the author 
alone. 
  
Abstract 
 
This thesis describes the development and synthesis of multicalixarenes and their 
application in gene and drug delivery. 
Chapter 1 provides an introduction to gene therapy and calixarenes. The synthesis of two 
families of amino functionalised multicalixarenes are described. Evaluation of their toxicity 
and transfection studies are reported and a number of candidates for development identified. 
Chapter 2 describes the development of calixarene glycoconjugates using a wide range of 
approaches. The synthesis of calixarene glycoconjugates through click chemistry is 
reported and the development of the first multicalixarene glycoconjugate is discussed. 
Chapter 3 reviews the development of large multicalixarenes assemblies. The synthesis of 
large (9 and 21 member) click based multicalixarenes is described. 
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Chapter 1: Synthesis of Multicalixarene 
Based Transfection Agents 
1 
 
Chapter 1: Synthesis of multicalixarene 
based transfection agents 
 
1.1. Introduction 
 
Deoxyribonucleic acid (DNA) is a macromolecule which encodes the genetic information in all 
living organism and also in some viruses. Most DNA molecules are double-stranded helices 
formed of two long polymer chains. Each chain is composed of a sequence of simple units called 
nucleotides. Each unit is made up of three components: a heterocyclic base, a sugar and one or 
more phosphate groups. The heterocyclic bases present in the DNA, can be classified into two 
families: purines and pyrimidines.1 Purine bases are bicyclic molecules containing four nitrogen 
atoms, formed by the fusion of six and five member heteroaromatic rings (Figure 1.1). Adenine 
(A) and guanine (G) belong to this family. The pyrimidine bases present in DNA are called 
thymine (T) and cytosine (C). These are heterocyclic aromatic molecules containing two 
nitrogen atoms and four carbon atoms. Purines and pyrimidines are bound to a molecule of 2-
deoxyribose. This sugar is a pentose monosaccharide which differs from ribose in the lack of an 
oxygen in position 2. The nucleotide is completed by one or more or more phosphate groups 
which bind the sugar in position 5’ and connect to the phosphate groups of other nucleotides 
forming a strand held by a negatively charged phosphate back bone. The nitrogenous bases 
adenine and guanidine can selectively form hydrogen bonds with thymine and cytosine 
respectively forming the base pairs AT and GC. 
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adenine thymine
guanine cytosine
 
Figure 1. 1: Complementary base pairs adenine-thymine and guanine-cytosine 
2 
 
In double helix DNA each member of the base pair is on a different strand of nucleotides, which 
run in opposite directions and it is therefore complementary and anti-parallel. In cells the DNA 
is located in the nucleus and is organised in chromosomes. The set of chromosomes in a cell 
forms the genome. The human genome is composed of 23 sets of chromosomes which consist of 
approximately 3 billion base pairs. The Human Genome Project, started in 1990, aimed to 
determine the base pairs which form the human genes and to identify and map those genes. 
Since the completion of the project on 20032 the use of nucleic acid as a therapeutic agent has 
become an area of great interest for the scientific community. 
 
Figure 1. 2: Helical structure of double stranded DNA3 
 
1.1.1. Gene therapy 
 
Excluding those caused by traumatic incidents, virtually all diseases have a hereditary 
component.4 The predisposition to a disease can be found in misspellings (mutations) of the 
genetic code. The likelihood of developing the disease then depends on environmental factors 
such as chemicals, viruses, stress etc.  
Gene therapy aims to treat human diseases by transferring genetic material into specific cells of 
the patient.5, 6The therapeutic effect of gene therapy is obtained by replacing defective genes 
with DNA containing the correct sequence.7 It is straightforward to imagine the treatment of 
diseases strictly related to a genetic deficiency such as haemophilia,8 muscular dystrophy9 or 
cystic fibrosis10 through substitution of the faulty genes within the affected cells with correct 
ones. However research is focused also in developing genetic therapies for the treatment of 
cardiovascular,11 neurological12, 13 and infectious diseases14 wound healing15 and cancer16, 17, 18 
3 
 
through enhancing naturally occurring proteins by the introduction of genes which alter the 
expression of the existing genes. 
In 1987 Flegner et al. were the first to succeed in transfecting DNA in to a mammalian cell 
using unilamellar liposomes.19 The first human gene therapy trial started in the USA in 1990.20 
Blaese et al .transfected, the adenosine deaminase gene using a modified retrovirus as 
transfection agent into the T cells of two children affected with severe combined 
immunodeficiency. Two years after the therapy ended the gene expression still persisted. This 
first clinical trial demonstrated that gene therapy could be safe and efficient in the treatment of 
some immunodeficiency diseases. 
The two main methods to introduce nucleic acids into the cell are ex-vivo and in-vivo.21 In the 
ex-vivo approach, the target cells are removed from the patient, purified and re-inoculated after 
being genetically modified.22 This method has the disadvantage of being invasive for the patient. 
With the in-vivo approach the genes are directly delivered into the patient’s tissues using vectors. 
23
 The delivery of nucleic acid directly in to the patient cells can be achieved using two main 
categories of vectors: recombinant viral vectors or synthetic vectors. Each delivery approach has 
some disadvantages.  
 
1.1.1.1. Viral vectors 
 
The use of various types of viral vectors has been widely used to transfect genes in to cells.24 
The primary function of a virus is to carry its genetic material from one host cell to another. 
Once entered into the new host cell, the virus navigates to the cell nucleus where it begins the 
expression of its genome. Replacing part of the viral genome with therapeutic genes makes it 
possible to exploit this property creating gene-delivery vehicles. In order to be employed the 
pathogenic effect of the virus needs to be disabled.25 The most used viral carriers are the 
retroviruses and the adenovirus.24 The use of a virus is a powerful tool for the delivery of genes 
because nature has evolved them as specific machinery to deliver genetic material into cells. 
Despite their efficiency in transfecting the target cells the use of viral vectors has some 
drawbacks. The human immune system fights off the virus and therefore the viral gene delivery 
has always to face the host response. Although the recombinant viral vectors are rendered non-
replicative and non pathogenic there is still the risk that the virus reverts into a wild-type virion 
or co-purify with replication-competent virions.24 
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1.1.1.2. Synthetic vectors 
 
Another approach towards the cellular delivery of nucleic acids involves the use of synthetic 
carriers. These vectors have the advantage of being safer because they do not trigger immune 
reactions in the host organism.24 Their manufacturing is more facile compared to the preparation 
of viral vectors. Synthetic vectors need to match a number of requirements to be suitable 
candidates for gene delivery. The ideal vector for gene therapy must fulfil several criteria: bind 
nucleic acid electrostatically, condense the genetic material, preserve the genes from enzymatic 
degradation, mediate the cellular entry and release the nucleic acid load and have low toxicity. 
In order to be able to bind the negatively charged nucleic acid the vectors need to be positively 
charged. Several independent groups have reported that a minimum of six to eight charges are 
required for efficient DNA condensation and consequent transfection.26, 27, 28 Complexes of 
plasmid DNA with cationic lipid or cationic polymers are called lipoplexes and polyplexes 
respectively. Although synthetic vectors have been employed for in-vitro studies since the 1960s, 
the development of in-vivo transfection has to confront several problems such as low gene-
transfer efficiency, toxicity and the in-vivo stability.  
Figure 1.3 summarizes all the steps involved in the gene delivery process and all the barriers that 
the complex DNA-synthetic vector must overcome in order to transfect the genetic material into 
the cell. It is now commonly accepted that polyplexes and lipoplexes are internalized via 
endocytosis.29, 30, 31 Although clarithrin dependent endocytosis has been considered for a while to 
be the only pathway involved in the internalization of exogenous molecule into the cells, the 
past two decades have shown that also other routes, so-called “clathrin independed endocytosis”, 
may be involved. The mechanism of such pathways is still not completely understood, but seems 
to differ, for a given formulation, with the cell type and molecular composition of the cell 
surface.32 The size and the global charge of the complex also seem to influence the 
internalisation process involved. Functionalisation of the complexes with motifs capable of 
binding cellular membrane receptors is expected to improve the transfection efficiency, via 
receptor-mediated internalisation which can be faster than non-specific uptake.  
Once the DNA-carrier complex has penetrated the cell through endocytosis, it is confined in the 
endosome, which can either fuse with a lysosome or recycle its cargo back to the cell surface. 
Endosomal escape is considered one of the major limitations for non-viral transfection vectors. 
Cationic polymers bearing unportonated amino groups at neutral pH act upon protonation in the 
endosomes as a proton sponge leading to swelling, rupture of the vescicle and consequent 
release of its content.33 
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Figure 1. 3: Cellular gene delivery process  
The movement of the plasmid DNA in the cytosol is another crucial step in the transfection 
process. The cytoskeleton components seem to be involved with the cytoplasmic motion of the 
nucleic acid either free or complexed with the carrier. In particular it has been found that 
unspecific binding of DNA with actin, vimentin and keratin impairs the movement of the 
plasmid in the cytosol.34 On the other hand microtubules are required to trasnsport the DNA 
efficiently through the cytosol.35 Inibition of histone deacetylase 6 (HDAC6), an enzyme which 
regulates the deacetylation of the microtubules, appears to be associated with an increase of 
plasmid trafficking and entry into the nucleus.31 Therefore HDAC6 inhibitors could be good 
candidates to increase the efficiency of gene transfection by non viral vectors. Furthermore the 
migration of polyplexes and lipoplexes could be improved by functionalising the complexes 
with signal molecules capable of enhancing the binding to the microtubules. 
The last barrier between the plasmid DNA and the transcription is nuclear import. The access to 
the nucleus in non-dividing cells is regulated by pores. Molecules larger than 40 kDa must 
display specific nuclear localization signals (NLS) to be actively transported. Wagstaff and 
Janson reported that only 0.1% of DNA microinjected to the cell was transcribed.36 Nevertheless 
the entry of the genetic material into the nucleus could be improved by coupling of either the 
synthetic vector or the back bone of the DNA with NLS. 
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1.1.1.2.1. Lipid based vectors 
 
The first synthetic vector was used in 1987 by Flegner et al. Small unilamellar liposome 
containing a synthetic cationic lipid interacted spontaneously with DNA to form a lipoplex.19 
The cationic lipid facilitated the fusion of the complex with the plasma membrane. The structure 
of the cationic lipid and of the neutral “helper” lipid forming the liposome has a great influence 
on the interactions between the lipids and the DNA and on the properties of the liposome 
membrane; both these factors have a major influence in the transfection efficiency.37 Since 
Flegner’s success, lipofection has been widely used in-vitro and in-vivo studies as well as in 
many human clinical trials. Despite the wide impact this gene delivery approach has some 
limitations which need to be overcome such as reproducibility in fabricating the lipoplex, 
toxicity towards some cell types and colloidal stability especially if administrated 
systemically.37,38  
 
1.1.1.2.2. Polymer based vectors 
 
Cationic polymers comprise linear, branched and dendritic structures.24 Polymers such as 
polylysine,39 branched polyethylenimine (PEI)40 or polyamidoamine dendrimer (PAMAM)41 
have been used since the early stages of polymer based transfection research. Because of the 
flexibility of polymer chemistry it is possible to embroider the structures with functionalities 
required for efficient gene delivery while maintaining biocompatibility, facile manufacturing 
and robust and stable formulations.24 Despite the great potential that cationic polymers have in 
human gene therapy, their use in clinical applications has been limited by their poor gene 
transfer efficiency.   
 
1.1.1.2.3. Dendrimers in gene delivery 
 
Among the polymer based vectors, dendrimers have unique properties which make them 
attractive materials for gene therapy applications.42 The first polycationic dendrimer to find its 
use as a nucleic acid vector was a polyamidoamine (PAMAM) based dendrimer (figure 1.4).43 
Its in-vitro transfection property was first reported by Haensler and Szodka in 1993.41 This kind 
of dendrimer is normally based on an ethylendiamine or ammonia core with four or three 
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branching point respectively,43, 44 Polymers based on polypropyleneimine (PPI),45, 46, 47 with 
similar features to PAMAM dendrimers, have also been widely explored as gene delivery 
systems. 48 The commercial availability of these polymers made them and their derivatives the 
most used in this research area.42, 49, 50, 51  
Dendrimers interact with the nucleic acids on the base of electrostatic interactions52 and lack 
sequence specifitity. 45 The resulting complex is called a dendriplex and protects the DNA from 
degradation.53 Upon complexation of the DNA with PAMAM the formation of toroidal structure 
around 50 nm can be observed. 45 The binding between the polyplex and the cell membrane is 
initially based on an electrostatic attraction between the cationic complex and the negatively 
charged cell surface groups followed by an inclusion via endocytosis.29, 42 The stability of the 
complexes and transfection properties were found to increase nearly exponentially with an 
increase in the number of generations.54 On the other hand, regardless of the repeat unit structure, 
haemolysis and cytotoxity are also strictly dependant on the number or size and number of 
surface amino groups.55  
 
Figure 1. 4: PAMAM structure  
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1.1.2. Dendrimers 
 
Dendrimers can be defined as a class of polymeric materials. They can be described as highly 
branched tridimensional macromolecules which develop from an inner central core with a series 
of repeating units. The name dendrimer originates from the Greek “dendron” which means tree 
or branch and “meros” meaning part. The unique properties such as such as uniform size, high 
degree of branching, water solubility, multivalency, well-defined molecular weight and available 
internal cavities has made these molecules a focus of interest in the scientific community since 
their conception in the late 1970s. They emerged from a new class of polymers called “cascade 
molecules” reported for the first time by Vogtle.56 In the early 1980s pioneering work carried out 
by different groups developed these molecules to larger dendritic structures.57, 57b, 58, 59 
 
1.1.2.1. Dendrimers structure and synthesis 
 
Dendrimers are large and complex molecules generally characterised by well defined molecular 
structures.60 They are built of three distinguishing architectural components: a central core, a 
number of layers of repeating units, called generations, readily attached to the central core and 
the exterior, the outermost generation which carry the terminal functionalities. For the purpose 
of this thesis we will call the central core G0, the second series of repeating units G1 and so on. 
Each individual “branch” of a dendrimer is named a dendron.42 In contrast to linear polymers the 
dendrimer viscosity does not have a linear correlation with the mass but shows a maximum at a 
specific number of generations. This is explainable considering the shape change of a dendrimer 
with the increase in number of generations from a more open-planar elliptical to a more compact 
spherical shape.61, 62 Because of their structure, dendrimers have the highest molecular density 
on the outer generation. These molecules are obtained with a stepwise synthesis which bring 
well defined sizes and structures.42 The synthetic pathway can follow either a convergent or a 
divergent strategy. 
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1.1.2.2. Convergent dendrimer synthesis 
 
The synthesis of dendrimers via a convergent approach exploits the symmetric nature of these 
polymers (figure 1.5). The molecule is built up layer after layer starting with the higher 
generation and terminating with the central core (G0).63 A number of peripheral units are 
covalently linked with an equivalent number of corresponding binding sites into single joining 
units. A number of the branched molecules are covalently linked to an equivalent number of 
binding sites of another joining molecule and so on. Each cycle of reactions enables the growth 
of one generation. The synthesis ends when the branched polymeric dendrons of the target size 
are attached to the central core. The advantage of this strategy is that only a limited number of 
reactions take place at each step.64 As result the reactions can be driven to completion with only 
a slight excess of reagent reducing to a minimum the formation of side products.  
 
Figure 1. 5: Convergent dendrimer synthesis 
 
1.1.2.3. Divergent dendrimer synthesis 
 
In the divergent approach the synthesis starts from the multivalent central core G0 and builds up 
one monolayer at a time (figure 1.6).58 In the first step the central core is allowed to react with 
G1 units bearing one active binding site and a number of inactive binding sites. Once the first 
= G3 
= G2 
= G1 
= G0 
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generation of the dendrimer is formed, the additional binding sites can be activated for the next 
step and can then be reacted with an equivalent number of next generation monomers. This 
process can be repeated for several generations until steric effects prevent the peripheral groups 
from reacting with a new generation of monomers.42 Because of the high number of reactions 
occurring at one time, the majority of divergent dendrimer syntheses require an excess load of 
monomer for each generation growth and lengthy chromatographic purifications for each step, in 
particular for the higher generations.60 
 
Figure 1. 6: Divergent dendrimer synthesis  
 
1.2.  Calixarenes 
 
The calixarenes are macrocyclic molecules formed from the condensation of phenols and 
aldehydes.65 This type of reaction was first performed by the Nobel Prize winner Adolph von 
Baeyer whom, in two papers published in 1872, described the product obtained by mixing 
formaldehyde and phenols in the presence of a strong acid as a “cement like substance”.66, 67 
About twenty years later two other German chemists, namely L. Lederer and O. Manasse, 
working independently on the reaction between phenol and formaldehyde succeeded in isolating 
as crystalline compounds o-hydroxymethylphenol and p-hydroxymethylphenol.68, 69 (Figure 1.7) 
= G3 
= G2 
= G1 
= G0 
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OH OH
CH2OH
CH2OH
o-hydroxymethylphenol p-hydroxymethylphenol
 
Figure 1. 7:. Lederer and Manasse product. 
The Lederer-Manasse reaction did not lead to the formation of the tar like material because of 
the milder conditions used. In fact when the reaction is performed under more strenuous 
conditions, e.g. acid or base catalysed, the resinous tar is obtained.65  
Research in this area was resumed in the beginning of the twentieth century by Leo Baekeland 
who patented the cement like substance with the name of Bakelite giving birth to the age of the 
synthetic plastics.70 The Bakelite process has been a source of inspiration for many other 
scientists. Among them Zinke and Ziegler perceived that the resin obtained from the phenol-
formaldehyde condensation was due to the cross linked polymerization which occurs in the 
reaction.71, 72 Both the ortho and para positions are equally reactive in basic or acid conditions 
for electrophilic aromatic substitution. Thus the phenol ring reacts at all the three reactive 
positions to yield the polymer. Starting from this hypothesis they aimed to obtain a more 
tractable product using para-alkyl substituted phenols. These compounds can react only in the 
ortho position leading to the formation of a linear polymer. From their experiments they noted 
that the resin obtained on heating formaldehyde and p-tert-butylphenol was soluble in linseed oil 
at 100-120oC. Upon further heating to 200-220oC they noted the formation of a precipitate 
which once washed with EtOAc and precipitated from chloroform with methanol gave a 
crystalline compound which decomposed above 300oC. Whilst, at this point, it was not 
postulated that this product was cyclic, further work by Niederl and Vogel on an analogous 
reaction between resorcinol and aldehydes led to the suggestion of a cyclic structure for both this 
condensation and for the Zinke product.73 
Proof of this theory arrived only in the 1950s from the work of Hayes and Hunter,74 whom with 
a stepwise synthesis obtained the structure postulated by Niederl. Starting from p-methylphenol 
they blocked one of the reactive ortho positions, allowing the other to react with formaldehyde 
under basic conditions to give 2-bromo-4-methyl-6-hydroxymethylphenol which when treated 
with HCl and p-cresol at 70oC yielded the dimer: 3-bromo-2:2`-dihydroxy-5:5`-
dimethyldiphenylmethane. 
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Scheme 1. 1: Dimer formation 
After repeating this cycle two times, the tetramer obtained was de-protected via catalytic 
hydrogenation and cyclization of the oligomer was achieved by acid treatment (scheme 1.2). 
CH3
OH
Br
CH3
OH
CH3 CH3
OHOH
OH
CH3
OH
CH3
OH
CH3 CH3
OHOH
OH
CH3
OH
OHHO
OH
CH3
CH3H3C
H
 
Scheme 1.2: Cyclization of the linear oligomer  
The light brown material obtained had a melting point above 300oC and did not undergo 
coupling with benzenediazonium chloride, showing the lack of ortho and para reactive positions. 
Another chemist involved in the history of the phenol-aldehyde condensation chemistry is the 
English Nobel Prize winner John Cornforth. On repeating the Zinke reaction he isolated two 
compounds,75, 76 with different melting points, rather than one. To explain this result he 
postulated two hypotheses. In the first place he suggested that the condensation could yield 
macrocycles containing more than four members or alternatively the tetramer could be present in 
different rotational diastereoisomers. Now is it known that the product he isolated was the cyclic 
octamer, nevertheless his second suggestion of the presence of diastereoisomers has also been 
demonstrated to be correct.65  
In the same period, in the USA, phenol-formaldehyde chemistry found a new application. 
Melvin DeGroote from the Petrolite Corporation, in Missouri, discovered that treatment of the 
product obtained by reacting p-alkyl-substituted phenols and formaldehyde, with ethylene oxide 
produces a surfactant with demulsifier characteristics. The product patented was thought to be a 
linear polymer rather than a cyclic oligomer. The real structure was discovered only twenty 
years later when as a consequence of customers’ complaints of the formation of a sludgy 
precipitate, the product came back to the chemistry research laboratories. They simulated the 
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same conditions used in production plants; reflux of p-tert-butyl-phenol and formaldehyde in 
xylene in the presence of 50% KOH solution with in-situ removal of excess water. In order to 
determinate what was causing the sludge, the precipitate formed during the reaction was filtered 
and discovered to have a very high melting point and very low solubility. The “Petrolite” 
procedure was immediately patented in 1976 as a new route for the synthesis of cyclic oligomers. 
Almost 40 years from their discovery, these macrocycles remained nameless, until 1978 when 
the name calixarene appeared in print for the first time. 77 This name was coined by Gutsche, an 
American chemist, who was studying the tetramers as potential enzyme mimics. The name 
“calix” was given as the three-dimensional structure of these molecules resembles the shape of 
the “calix crater” an ancient Greek vase, and the term “arene” indicates the presence of aryl 
moieties in the molecule. 
 
1.2.1.Synthesis of calixarenes  
As proposed by Cornforth the condensation of aldehydes and phenols leads the formation of 
macrocycles of different sizes. The most common products are the 4, 6, and 8 membered rings. 
It is possible to selectively form each ring size by using different synthetic conditions. 
In the Modified Zinke-Cornforth Procedure, which leads selectively to the formation of the 
cyclic tetramer, p-tert-butyl phenol is heated for 2 hours at 110-120oC in the presence of 37% 
formaldehyde and 0.045 equivalents of NaOH per phenol unit. The thick mass produced, called 
the “precursor” is then refluxed for a further two hours in diphenyl ether and the product 
collected by filtration and re-crystallized from toluene. The optimum amount of base that has to 
be used in order to obtain the cyclic tetramer is about 0.03-0.04 equivalent. The yield of the 
tetramer falls both below and above this range, in the former case, no reaction occurs and in the 
latter the reaction yields the cyclic hexamer.78 
The hexamer can also be prepared according to the Modified Pertrolite Procedure a mixture of 
p-tert-butylphenol and formaldehyde is heated for two hours with 0.3 equivalent of KOH per 
phenol unit.65 The formed precursor is then dissolved in xylene and refluxed for three hours. The 
crude product collected by filtration is then neutralized and re-crystallized from chloroform-
methanol to yield calix[6]arene.  
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Preparation of calix[8]arene is described in the Standard Petrolite Procedure, in which 
paraformaldehyde and p-tert-butylphenol are heated for 4 hours in xylene with 0.3 equivalent of 
NaOH. And the crude product removed by filtration is crystallized from chloroform. 
The syntheses of calix[5]- and calix[7]arene have also been described but these products have 
been isolated only in much lower yields65.  
The mechanism of the reaction has been studied for many years and proceeds as shown in 
scheme 1.3. The reaction in mild conditions can be stopped at this stage and the Lederer-
Mannasse product can be isolated.79 
 
OH
OH
O
H
H
O
O
H
CH2O
OH
CH2OH
 
Scheme 1.3: Base catalysed formaldehyde - p-tert-butylphenol condensation mechanism 
However in more strenuous conditions the reaction proceeds with the reaction shown in scheme 
1.4. 
 
Scheme 1.4: Mechanism of the linear oligomer formation  
The linear oligomers or “precursor” depending on the conditions used then cyclises to give the 
calix[4]arene, calix[6]arene or calix[8]arene (figure 1.8). 
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Figure 1. 8: Structure of calix[4]arene, calix[6]arene and calix[8]arene  
Base catalysis is not the only route for condensing aldehydes and phenols, the reaction can occur 
also under acid catalysed conditions. However due to lower yields this method is not commonly 
used for the synthesis of phenol derived calixarenes but it remains a valid method for the 
synthesis of resorcinol derived calixarenes otherwise known as resorcinarenes.  
 
1.2.2.Calix[4]arene conformations 
 
As proposed by Cornforth, calix[4]arenes can exist in different conformations.75 In the absence 
of bulky substituents (larger than ethyl) on the phenolic OH, the benzene rings can swing around 
the methylene bridges, resulting in four different conformations; the cone, partial cone 1,3 
alternate and 1,2 alternate.  
 
 
Figure 1.9: Calix[4]arene possible conformations 
The rate of the rotation depends on the reaction conditions (temperature, solvent and base)80 In 
non-polar solvents such as chloroform or benzene the rotational energy barrier is higher than in 
more polar solvents such as acetone or acetonitrile resulting in an increased rate of 
conformational changes in the latter case.81  
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It is possible to lock selectively the conformation of the calix[4]arenes by alkylating the 
phenolic OH in presence of a suitable base and solvent. The choice of the right reaction 
conditions allows moreover the selective synthesis of mono-, di-, tri- and tetra substituted 
derivatives. 
For example sodium hydride is the most common base used for full alkylation.82 83 84 85 81 The 
use of this base at high temperature yields a mixture of cone and partial cone conformations,86 
whilst at lower temperature the cone conformer is the favoured product. In contrast, the use of 
bases such as lithium, potassium or sodium carbonate results in the formation of the di–alkylated 
product, whereas utilizing barium hydroxide combined with barium oxide it is possible to obtain 
the tri-alkylated product.  
 
Scheme 1.5: Selective alkylation 
An example of the importance of the counter ion of the base on determining the conformation of 
the calix[4]arene is shown by the reaction between p-t-butylcalix[4]arene and ethylbromoacetate. 
When the reaction is performed in the presence of potassium carbonate it gives the tetra 
alkylated derivative in the cone conformation, if caesium carbonate is used instead the tetra 
alkylated product is obtained in the 1,3 alternate conformation.85  
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Scheme 1.6: Effect of the counter ion on the conformation 
In the calixarenes it is possible to identify three regions. The first is called the upper or wide rim, 
the second the methylene bridges and the third the lower or narrow rim.  
 
 
Figure 1.10: Calix[4]arene regions 
It is possible to functionalise selectively these three regions with different functional groups. 
The phenolic oxygens at the narrow rim can be selectively linked to aryl or alkyl moieties either 
via ether or ester bonds. The upper rim is activated for electrophlic substitutions and reactions 
such as nitration can be performed in this position. Treatment of the acetates of p-tert-
butylcalix[4,6,8]arenes with CrO3 leads to the conversion of the methylene bridge to a carbonyl 
group,87 which can be reduced with NaBH4 to the corresponding alcohol.88 The same position in 
the tetramethyl ether of p-tert-butylcalix[4]arenes can be brominated89 or lithiated89 using N-
bromosuccinimide and n-butyllithium respectively.  
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1.2.3.Biological application of calixarenes 
 
Although the antitubercular properties of calixarenes were known since 1954 thanks to the 
pioneering work of Cornforth,75 for many years these molecules, have been mainly exploited as 
host for ions and neutral molecules.90 Only in more recent years have calixarenes found 
applications in various biological areas. Their unique three dimensional structure along with 
their lack of toxicity and the relative ease of functionalisation has made this molecule the focus 
of many biological investiagtions in the.91 Calixarenes have been widely used as a multivalent 
platform to anchor biological active molecules such as carbohydrates and peptides.90 Such 
conjugates have been used by Ungaro et al for their lectin binding properties and protein surface 
recognition respectively. Calixarenes have also found important application in the field of the 
biotechnology as ion channels. Davis et al have reported the synthesis of calix[4]arenes 
functionalised with tetrabutylamide groups which are capable of binding to a lipid bilayer and 
transport ions effectively across the membrane. 92, 93, 94, 95 In recent years modified calixarenes 
have shown antiviral,96 antibacterial,97 antifungal,98 antitubercolosis99 and anticancer100 activities. 
In the past decade the interaction between cationic calixarenes and DNA has drawn the attention 
of several researchers. Since 2004 Ungaro et al have reported the synthesis of several calixarene 
derivatives bearing guanidinium functionality either on the upper or on the lower rim. These 
molecules were capable of binding nucleic acids and in some cases to transfect genes in to the 
cells.101, 102, 103 
 
Figure 1.11: Guanidinium-functionalised Calix[4]arenes with Transfection properties 
Schrader reported in 2006 a dimeric calix[4]arene structure with DNA recognition properties.104 
This molecule was composed of two calixarenes functionalised on the upper rim with amino 
groups linked through a hexanedioic bridge. The multicationic dimer exhibited selective binding 
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to the major groove of double stranded DNA without causing destabilisation or conformational 
change to the nucleic acid. 
 
 
Figure 1.12: Schrader’s cationic Bis-calix[4]arene 
Recently Rodik et al. reported the synthesis of cationic amphiphilic calix[4]arenes in the cone 
conformation (scheme 1.6). These molecules are capable of self-assembling into micelles which 
on aggregating can complex DNA and transfect it into cells. 
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 Scheme 1.7: Rodik’s self-assembled micelles  
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1.2.4.Calixarene dendrimers as transfection agents 
 
Previous work in the group has shown that calix[4]arene based dendrimers, functionalised with 
amino groups and therefore positively charged were able to bind to the negative back bone of 
nucleic acids.105 The low toxicity of these molecules makes them suitable candidates for gene 
delivery in to cells. The central core for these multicalixarenes were synthesised by 
functionalizing all four available positions on the narrow rim with activated carboxylic acid 
groups. Three of the four hydroxyl positions on the narrow rim of the generation 1 calixarenes 
were alkylated with n-bromopropane to lock the conformation. The last position available was 
alkylated with n-bromopropyl phthalimide in order to introduce a protected amino group which 
could be deprotected and coupled to the activated carboxylic acid after the functionalisation of 
the wide rim with four amino groups either aromatic or aliphatic (figure 1.13).   
 
Figure 1.13: Cationic calix[4]arene based dendrimers.  
The aim of our work is develop new strategies to improve the links between more calixarene 
scaffolds in order to obtain macromolecules with different shapes, functionalization and linkages 
to develop new analytical tools for the evaluation of novel DNA transfection vectors. 
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1.3. Click chemistry based multicalixarenes 
Multicalixarenes can be described as multimeric structures formed by linking covalently two or 
more calixarenes scaffolds. By the selective functionalisation of the wide rim and/or the narrow 
rim of the central core (G0) it is possible to connect it to the lower rim of other calixarenes (G1). 
The formed multicalixarene can therefore have either a narrow rim-narrow rim or a wide rim-
narrow rim linkage (figure 1.14).  
 
Figure 1.14: Schematic representation of multicalixarene linkages 
 
To achieve the synthesis of the described dendrimeric multicalixarenes structures various linkers 
have been explored in literature and include: amide bonds 105, 106 aryl linkers,107 ethers,108 and 
alkyl chains.109 These linkers can be obtained by functionalizing the central core and generation 
1 with different groups which can then be coupled together. The most used, up till now, has been 
the amide bond in which one of the parts of the multicalixarene is functionalised with amino 
moieties and the other with an activated carboxylic acid. 
A different approach to the synthesis of multicalixarenes involves click chemistry as a method to 
create the links between calix[4]arene scaffolds. Click chemistry is a branch of chemistry which 
features the joining of small units together with heteroatom links.110 In order to belong to this 
category the reaction must be modular, wide in scope, give very high yield, generate only 
inoffensive byproducts, and be stereospecific, moreover the process must employ simple 
reaction conditions, readily available starting materials and reagents, the use of no solvent or a 
solvent that is benign or easily removable, and simple product isolation.111 These requirements 
have been introduced by K.B. Sharpless and coworkers, promoters of click chemistry.112 A 
number of different reactions can be classified in this category:  
a) cycloadditions of unsaturated species, especially 1,3-dipolar cycloaddition reactions, but 
also the Diels-Alder family of transformations; 
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Scheme 1.8: Huisgen Cycloaddition 
b)  nucleophilic substitution chemistry, particularly ring-opening reactions of strained 
heterocyclic electrophiles such as epoxides, aziridines, aziridinium ions, and episulfonium ions; 
N H
NH2NH2*H2O
NH4Cl
NH2
NH2NH2
 
Scheme 1.9: Aziridine ring opening 
c)  carbonyl chemistry of the non-aldol type, such as formation of ureas, thioureas, 
aromatic heterocycles, oxime ethers, hydrazones, and amides; 
 
Scheme 1.10: Heterocycle formation from carbonyl compound 
d)  additions to carbon-carbon multiple bonds, especially oxidative cases such as 
epoxidation, dihydroxylation, aziridination, and sulfenyl halide addition, but also Michael 
additions of Nu-H reactants.   
 
Scheme 1.11: Epoxidation of olefins 
One particularly popular reaction is the modified azide-alkyne Huisgen cycloaddition. This 
reaction is a 1,3 cycloaddition between an alkyne and an azide group in presence of Cu(I) with 
the formation of a triazole ring. The catalyst leads selectively to the formation of the 1-4 
substituted product instead of a mixture of the 1-4 and 1-5 substituted.113 
 
1.3.1.Previous examples  
The first example of the use of triazole rings as linkers between calix[4]arene scaffolds was 
published in 2000 by Calvo-Flores et al (figure 1.15).114 This was achieved by functionalising 
two of the hydroxyl groups on a calix[4]arene with azido groups. This molecule was then used 
as a central core and was reacted with two calix[4]arenes functionalised with a single alkyne 
moiety, introduced by alkylating the hydroxyl group with propargyl bromide. The reaction 
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yielded a mixture of two trimers. In one of the trimers the triazole rings were both 1,4 
substituted. In the second trimer, one of the triazole rings was 1,4 substituted and the second one 
was 1,5 substituted. Interestingly a trimer in which both triazole rings were 1,5 substituted was 
not found in the mixture . These molecules were the first multicalixarenes linked with triazole 
rings to be described. 
 
Figure 1.15: First example of a triazole linked multicalixarene 
The mixture of products obtained by Calvo-Flores et al, can be explained considering that the 
Huisgen Cycloaddition can occur simply by thermal activation and requires a long time (up to 
few days) to yield the 1,4 and the 1,5 substituted products.115 This is a disadvantage in the 
reaction if only one of the two products is required. The use of copper (I) catalysts was 
introduced for the first time in 2002 in two independent studies carried out by Sharpless’ and 
Meldal’s groups. This metal drives the reaction between azides and terminal alkynes toward the 
1,4 substituted stereoisomer. Furthermore the reaction times are drastically reduced and thermal 
activation is not crucial.113, 111  
The mechanism of the cycloaddition is still a matter of debate. Everyone agrees that the catalytic 
cycle begins with the insertion of the Cu(I) on the terminal alkyne through the formation of a π 
complex with the triple bond. This lowers the pKa for the terminal C-H in the alkyne resulting in 
the loss of the proton even in the lack of a base and forming the copper(I) acetylide.111, 113, 116-117 
The catalytic cycle continues with the reaction of the copper(I) acetylide with the terminal azide. 
The direct addition proposed in 2002 by Meldal et al. does not explain the increased rate of the 
reaction. The calculated activation barrier for this proposed mechanism is even higher than the 
one found without catalyst.118 A series of intermediate steps have been proposed.111, 116-119 The 
essential steps are summarised in scheme 1.12. The azide binds the copper atom through the 
lone pair of the nitrogen proximal to the carbon. Cyclization occurs with the formation of a bond 
between the distal nitrogen of the azide and the alkyne carbon. The six membered cycle which 
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includes also the metal rearranges, contracting to a five atom ring. Final protonation yields the 
triazole and the catalyst which can undergo another catalytic cycle. 
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Scheme 1.12: Copper catalysed Huisgen Cycloaddition catalytic cycle. 
With a similar approach to the one used by Calvo-Flores, previous work in the group 
(unpublished results) has developed a route towards pentameric multicalixarenes (figure 1.16). 
These were obtained using as a central core a tetra azido functionalised calix[4]arene to which 
were then “clicked” in the presence of copper (I) catalyst, four generation 1 calix[4]arenes 
functionalised with an alkyne group each.   
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Figure 1.16: Triazole linked calix[4]arene based dendrimer 
This first pentamer proved that the triazole ring was a valid linker to synthesise dendritic 
multicalixarenes. However, these molecules did not feature any functionalisation on the wide 
rim. In this study we have developed a strategy towards the synthesis of multicalixarene families 
carrying on the outer rim multiple positive charges with potential nucleic acid binding properties.  
 
1.3.2.Synthesis of central cores 
 
The aim of this work is to synthesise different families of amino functionalised multicalixarene 
able to bind nucleic acids and to act as transfection agents on a cellular level. This purpose has 
been achieved by functionalising the generation 1 of the multicalixarenes with either aromatic or 
aliphatic amines. Previous work in the Matthews’ group has shown that the conformation of the 
central core, which affects the geometry of the dendrimer, can influence the tranfection 
properties.105 This evidence suggested that it is worthwhile to synthesise central cores in both the 
cone and 1,3-alternate conformations to compare their behaviour in the biological systems.   
In order to investigate whether the rigidity of the system had an influence in the transfection 
activities the central cores were linked to the generation 1 through their narrow rims with 2, 4, 
and 6 carbon atom chain linkers. To gain more rigidity, a wide rim-narrow rim junction was also 
developed, in which the generation 1 is attached directly to the aromatic ring functionalised with 
azido groups.  
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1.3.2.1. Synthesis of central cores in the cone conformation  
 
The central core can be alkylated at all four hydroxyls at the lower rim with functional groups 
which can be converted in to azides. This leads to the formation of a central core which has four 
reactive groups that can be coupled with an equal number of alkyne functionalised generation 1 
calixarenes to prepare the desired dendrimers.  
 
1.3.2.1.1. Tosyl method (C2)  
p-Tert-butyl calix[4]arene (1) was the precursor of all the multicalixarene scaffolds described in 
this work. This can be synthesised via condensation of p-tert-butyl phenol and formaldehyde in 
the presence of a catalytic amount of sodium hydroxide.120, 78 The reaction can be divided into 
two stages. The first stage was the formation of the linear polymer, a yellow mass which was 
obtained by heating and stirring the three reagents for about two hours. The second stage was the 
cyclization. After the dissolution of the solid in diphenyl ether, the water formed in the reaction 
was removed by distillation and the solution heated at reflux for a further two hours. The cyclic 
tetramer was precipitated from the resulting black solution by the addition of ethyl acetate 
(scheme 1.13). 
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Scheme 1.13: Synthesis of p-tert-butyl calix[4]arene 
The first two central cores were synthesised using as the starting compounds p-tert-butyl 
calix[4]arene and calix[4]arene. This latter compound was obtained by removing the tert-butyl 
group on the para position of p-tert-butyl calix[4]arene with aluminium trichloride in toluene in 
the presence of phenol (scheme 1.14).121 82 This reaction, a Friedel-Crafts reverse alkylation is a 
common strategy frequently used to replace the tert-butyl group with a proton. The desired 
product was precipitated from methanol as an off white powder in excellent yield (80%) 
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Scheme 1.14: Friedel-Crafts reverse alkylation 
The four hydroxyl groups of 1 and 2 were then alkylated using ethyl bromoacetate in the 
presence of an excess of potassium carbonate, a base known to lead the formation of the cone 
conformation (scheme1.15).81 In this way the central core was functionalised with four 
carboxylic esters at the narrow rim and locked in the cone conformation as these moieties are 
too large to allow rotation through the annulus of the macrocycle and consequent change of 
conformation.86 Recrystallisation at -20 ºC for several days from ethanol yielded the desired 
compounds 3 (79%) and 4 (66%) as colourless crystals. The ester groups were reduced in the 
following step using lithium aluminium hydride in diethyl ether to yield the respective tetra 
alcohol compounds as white powders 5 (84%) and 6 (53%).122   
 
Scheme 1.15: Alkylation and reduction 
Hydroxyl groups are not good leaving groups in nucleophilic substitutions.123 In order to be 
replaced they need therefore to be activated (scheme 1.16). The tetrahydroxy compounds 5 and 
6 were activated by stirring with pyridine in the presence of tosyl chloride.122 The active 
tosylated compounds were then stirred and heated at 70oC in dimethylformamide in the presence 
of sodium azide to yield the tetra azido functionalised central cores 9 and 10 (100% and 97%) 
(scheme 1.10).124  
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Scheme 1.16: Synthesis of tetra-azido functionalised calixarene via tosylate pathway 
 
1.3.2.1.2. Direct alkylation (C4, C6) 
 
The long synthetic pathway to obtain the tetra azido compounds led the way to an exploration of 
alternative synthetic strategies to functionalize the central cores with four azide groups. The new 
strategy involved the use of 1,4-dibromobutane125, 126 and 1,6-dibromohexane as alkylating 
agents using sodium hydride as a base to deprotonate the hydroxyl groups of the starting 
materials 1 and 2 (scheme 1.17).127 This base is known to lead the reaction to the formation of 
the cone conformation because of the sodium ion template effect.81 The use of a strong base 
such as sodium hydride was required because of the poorer reactivity of the bromo-alkane 
compared to ethyl bromoacetate. The products were isolated by precipitation from 
dichloromethane/methanol as white powders. 
 
Scheme 1.17: Alkylation with dibromo alkanes and substitution of the halogen with azido 
groups 
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The final step for the preparation of this series of central cores was the substitution of the 
bromine with sodium azide, a reaction which was carried out using the same conditions used for 
the formation of 9 and 10 to yield the tetra azido compounds with respectively four and six 
carbon atom chains (scheme 1.17).124 
The same approach was attempted for the synthesis of the two carbon atom chain derivatives 9 
and 10. However, this approach failed which may be due to the very high reactivity of the 1,2-
dibromo ethane compared to the analogues with longer chains . 
 
1.3.3.Synthesis of central cores in the 1,3 alternate 
conformation  
 
As discussed earlier in the chapter it would be interesting to determine whether different 
conformations of multicalixarenes act differently in biological systems and have different 
transfection efficiencies. Another family of central cores based on the 1,3 alternate conformation 
was required for this study. As previously explained it is possible to lock the conformation of a 
calix[4]arene in the 1,3-alternate conformation by performing the alkylation of the four 
hydroxyls groups in the presence of Cs2CO3.128 In order to retain the conformation, the 
alkylating agent selected has to be bulky enough to prevent the rotation through the anulus.65, 129 
In this particular case the alkylating groups chosen had to be readily convertible to azides. To 
have the azido groups on different sides of the calixarene results in a less hindered position for 
the functional groups and a consequently larger space for the insertion of the generation 1 
calixarenes which could mean better yields and improved DNA binding properties. Two 
different pathways have been explored to achieve the synthesis of these molecules. 
 
1.3.3.1. Tosylate pathway (C2, C4, C6) 
 
The first approach towards the synthesis of central cores in the 1,3-alternate conformation was to 
follow the tosylate pathway which had given successful results in the synthesis of the central 
core in the cone conformation. Calix[4]arene 2 was heated at reflux in acetone, in the presence 
of Cs2CO3 as a base, and using ethyl-bromoacetate, ethylbromobutyrate or ethyl 
bromohexanoate as alkylating agent to yield after purification using column chromatography 
respectively 19, 20 and 21 (scheme 1.18). 
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Scheme 1.18: Synthesis of tetra alcohol functionalised calixarene in 1,3-alternate conformation 
The carboxylic acid derivatives obtained were processed using the same sequence of reactions 
described for the synthesis of 10. In this fashion the three central cores 28, 29 and 30 with a 
spacer respectively of two, four, and six carbon atoms were obtained after reduction, tosylation 
and conversion to the azide (scheme 1.13). 
 
Scheme 1.19: Alcohol activation and substitution 
The limiting step of this synthetic pathway was the tosylation reaction. The reason for the large 
difference in yields between the two carbon atoms derivative and the longer chains derivative is 
probably due to the very low solubility of their alcohol derivatives. 
 
1.3.3.2. Direct alkylation 
 
Although the central cores in the 1,3 alternate conformation were successfully synthesized, the 
low yields obtained in the tosylation step and the number of steps in the synthesis led the way 
towards the exploration of other strategies to alkylate the central core. In an alternative strategy 
di-bromoethane, di-bromobutane and di-bromohexane were investigated as the alkylating agent 
in the presence of Cs2CO3 (scheme 1.20). 
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Scheme 1.20: Attempted synthesis of central cores in the 1,3-alternate conformation via direct 
alkylation with di-bromo alkane derivatives. 
An excess of alkylating agent was used to avoid the formation of dimers. Increasing the amount 
of alkylating agent was thought to decrease the likelihood of two calixarenes reacting with the 
same di-halo alkane molecule. Unfortunately none of these attempts yielded the desired 
compound. This may be due to the identical reactivity of the bromine atoms on the two termini 
of the alkyl chains. Following from this the same reactions have been repeated using as 
alkylating agents alkanes functionalised with bromine at one terminus and the less reactive 
chlorine at the other. The reaction was successful in the case of the four and six carbon atom 
chain demonstrating that the difference in reactivity leads the reaction only towards the 
substitution of the bromine leaving the chlorine on the aliphatic chains available for further 
substitution with the azide in the next step (scheme 1.21).  
 
Scheme 1.21: Synthesis of central cores in the 1,3-alternate conformation via direct alkylation 
with bromo-chloro-alkane derivatives. 
On the other hand, the reaction of 2 with 1-bromo-2-chloroethane did not yield the desired 
compound. The result was a complex mixture of products which were not possible to assign 
with NMR spectroscopy. Probably the short distance between the halogens makes both the 
carbon atoms very electrophilic. The partial positive charge of the carbons, due to the 
electronegativity of the halogens directly attached to them, is increased because of the inductive 
effect of the electronegative halogen on the next carbon. This may result in an increased 
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reactivity which would drive the reaction toward the formation of complex structures therefore 
this method was not further investigated.  
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Figure 1.17: Symmetry of the central cores 10 and 28 
The central cores 10 and 28 are conformers (figure 1.17). They have two plans of symmetry. 
The differences in conformation can be detected by 1H NMR analysis (figure 1.18). The 
symmetry of the central core in the cone conformation 10 (red) is shown by the two doublets at 
4.46 ppm and at 3.72 ppm corresponding to the methylene bridge protons which are axial (Hax) 
and equatorial (Heq) respectively. Although Hax and Heq are chemically equivalent they are 
located in different magnetic environments. The first points down, and is therefore closer than 
the other to the oxygen which deshields it and falls at higher ppm than the other. In contrast, in 
the 1,3 alternate conformation (blue) the methylene bridges give only one signal: the singlet, 
integrating for 8 protons, at 3.84 ppm. This signal is typical of calixarenes in the 1,3-alternate 
conformation. In this case axial and equatorial protons are chemically and magnetically 
equivalent, each being at the same distance from the oxygen and the aromatic rings.  
 
Figure 1.18: Comparison between the 1H NMR spectra of the cone and the 1,3-alternate 
conformation central cores 10 and 28 
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In the spectrum for the cone conformation (red), between the signals of the two methylene 
bridges, two triplets with a coupling constant (J) value of 6.0 Hz can be observed at 4.12 and 
3.82 ppm. The most deshielded belongs to the protons on the carbon proximal to the oxygen in 
the ethoxy chain (HR’) and the other, more shielded, belongs to the protons on the second carbon 
of the ethoxy chain (HR’’), the one proximal to the azido group. In the 1,3-alternate conformation 
(blue) it is possible to observe the same set of signals at 3.52 ppm and 2.96 ppm. The aromatic 
protons in the cone conformation give a multiplet which integrates for twelve protons (red). This 
is due to the overlap of the signals for the aromatic protons in meta (HAr(m)) and para position 
(HAr(p)). In the 1,3-alternate conformation the signals for the aromatic protons do not overlap and 
it is possible to detect a doublet for HAr(m) and a triplet for HAr(p), both with a coupling constant of 
7.5 Hz. 
 
1.3.4.Synthesis of upper rim azido functionalised central core  
 
As previously mentioned the generation 1 calixarenes can be connected to the central core with a 
narrow rim-wide rim linkage. Thus it was necessary to design a central core functionalised with 
four azido group on the wide rim. The first step of the synthesis was the locking of the 
calixarene conformation by alkylating the hydroxyl groups with n-bromopropane in the presence 
of sodium hydride (scheme 1.22). Using this base the calixarene was fixed in the cone 
conformation. The first reaction performed to modify the upper rim was an ipso-nitration. With 
this reaction it is possible to replace the tert-butyl groups in the para position with four nitro 
groups via electrophilic substitution. This reaction has been widely explored in literature and it 
is an effective route to insert a nitrogen atom at the para position of the aromatic ring. Different 
procedures use as nitrating agents, a mixture of nitric acid (HNO3) either fuming or 65% with 
another acid: trifluoroacetic acid (TFA), sulphuric acid or glacial acetic acid.130- 131 The starting 
material 36 was dissolved in dichloromethane and treated with a nitrating mixture composed of 
glacial acetic acid and fuming nitric acid mixed together in equal amounts.130 The product was 
precipitated from dichloromethane/methanol as a pale yellow powder. 
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Scheme 1.22: Lock of the calixarene conformation and ipso-nitration 
The nitro groups can be easily reduced to amino groups. Different methods have been described 
in literature. It is possible to perform the hydrogenation using hydrogen gas and catalysts such as 
palladium on activated carbon (Pd/C),132 , 133 or platinum oxide (PtO2).134 Another possible 
widely used approached is the use of hydrazine as a source of hydrogen and Raney nickel as 
catalyst.135, 131 Although these methods are all valid tools toward the synthesis of tetra amino 
calix[4]arenes, in our synthesis the nitro groups were reduced by heating at reflux temperature in 
ethanol in the presence of tin chloride as reducing agent (scheme 1.23).136  
 
Scheme 1.23: Nitro-reduction and introduction of azido groups via diazonium salt.  
The four amino groups on the wide rim were then transformed into diazionium salts. 
Substitution of these with azido groups yielded the target compound. This reaction has been 
described before on calix[6]arenes but not on calix[4]arenes.137- 138, To form the diazonium salt it 
was necessary to dissolve the free amine in 10% aqueous hydrochloric acid in order to have the 
protonated form of the amine. The solution was then allowed to react with sodium nitrite. 
Subsequently a solution of sodium azide in water was added drop wise. The crude compound 
was extracted with dichloromethane and purified by column chromatography to yield the desired 
compound. 
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Figure 1.19: Symmetry of central core 39 and of its precursors. 
Figure 1.20 shows the 1H NMR analysis for each step in the synthetic pathway towards the 
synthesis of the central core carrying four azido groups on the upper rim. The conformation of 
the molecule is confirmed by the two doublets given by the methylene bridges Hax and Heq 
present in all the spectra. The propyl chains give three signals at around 4 ppm (HP’), 2 ppm (HP’’) 
and 1 ppm (HP’’’), a triplet, a sextet and another triplet respectively. The singlet at 1.08 ppm in 
the spectrum of 36 (blue) integrates for 36 protons and belongs to the tert-butyl group. The 
replacement of this group by the nitro groups is shown by the disappearance of the signal in the 
spectra of 37 (red) and the shift of the aromatic protons signal. The electron withdrawing 
properties of the nitro group deshields the aromatic protons, shifting the singlet from 6.77 ppm 
for 36 to 7.57 ppm. Reduction of the nitro group to an amine, an electron donating group, shifts 
the signal upfield to 6.06 ppm (green). In the last spectrum (purple) the substitution of the amino 
groups with azides is shown by a further shift of the aromatic protons towards 6.30 ppm.  
 
Figure 1.20: Comparison between the 1H NMR spectra of each synthetic step of the synthesis of 
central core 39 
 
 
HAr(
m)  
HAr(
m) & 
Hax  
Hax 
HR’  
Heq 
 HR’’  
HAr(
  
HR’  
HR’  
HAr  
HAr  
HAr  
HAr  
Hax  
Hax 
Hax  
Hax 
HP’  
HP’  
HP’  
HP’  Heq 
36 
 
1.3.5.Synthesis of generation 1 calixarenes 
 
1.3.5.1. Synthesis of aromatic amino functionalised 
generation 1 calixarenes  
 
The generation 1 calixarenes were designed to have on the lower rim an alkyne moiety to be 
“clicked’’ to one of the azides present on the central core and on the upper rim four protected 
amino groups. In the first step of the synthesis three of the four hydroxyl groups of p-tert-Butyl 
calixarene were alkylated with n-bromopropane. A mixture of bases composed of barium 
hydroxide octahydrate and barium oxide was used.85 This mixture of bases has been widely used 
in the functionalisation of calix[4]arenes because of its peculiarity of allowing the alkylation 
only on three of the four position available. The barium ion coordinates very strongly with the 
fourth hydroxyl position on the calix restricting its reaction with the alkylating agent. The cone 
conformation is favoured in this reaction because of the interaction of the four oxygens with a 
single barium ion.85 Crystallization from dichloromethane and methanol yielded the pure 
product as off white crystals (scheme 1.24).  
 
Scheme 1.24: Selective tri-O-alkylation and functionalisation with propargyl group. 
By alkylating only three of the four positions available, the molecule gains more complex 
symmetry which results in three distinct regions indicated with the colours in figure 1.21. This 
variation is shown in the 1H NMR spectra (figure 1.22) and explains the increased number of 
signals that can be observed compared with the spectra of the central cores previously described 
in figure 1.20 and 1.22.  
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Figure 1.21: Symmetry of calixarene 40 
As it is possible to observe from the spectrum in figure 1.22, the methylene protons give four 
different doublets, two around 2.2 ppm for the equatorial protons and two around 4.3 ppm for 
the axial protons. It should be noted that in the case of the axial protons we observe an apparent 
triplet due to overlap. It is possible to observe two signals for each type of propyl proton, one of 
which integrates to the double of the other. The tert-butyl protons give three peaks, one of which 
integrates to the double of the others. The aromatic region shows three signals from 6.51 to 7.13 
ppm. Also in this case there is overlap and the peak at 6.51 ppm is broad and integrates for four 
protons against the integral of two found for the other two aromatic signals. The multiplicity of 
the signals is due to the four different magnetic regions present in the aromatics. 
 
Figure 1.22: 1H NMR spectrum of compound 40 
The alkyne was introduced on the last free phenolic position available. This was achieved by 
deprotonating the hydroxyl group with sodium hydride and alkylating it with propargyl bromide. 
The choice of the base allowed the retention of the cone conformation. After filtration over silica 
gel the product was collected as an off white powder.139  
The synthesis was continued with the ipso nitration reaction described previously. Although this 
reaction gave the desired product the yield was not satisfactory and the product obtained after 
the precipitation was not pure enough to carry on with the synthesis. This is probably due to a 
side reaction between the electrophilic nitronium ion and the electron rich alkyne.140 This 
Heq Heq Heq HP’’  HP’’  HP’’  HP’’  HP’’’  
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inconvenience was overcome by introducing a protecting group on the propargyl group. The 
selected protecting group to be used for this purpose was tert-butyl-dimethyl-silyl-chloride 
(scheme 1.25).141  
 
Scheme 1.25: Alkyne protection and ipso-nitration 
This protecting group was selected over the other silanes because of its higher stability in acid 
and basic conditions.142 Alkyne protons are basic and can be removed using bases such as 
lithium bis(trimethylsilyl)amide. The reaction was performed at -78oC in THF. The starting 
alkyne was allowed to react with the base for about 20 minutes to allow the formation of the 
acetylide before the silylchloride derivative was added. The product was obtained in excellent 
yield after precipitation from dichloromethane and methanol.  
The insertion of the propargyl group is shown in the 1H NMR in figure 1.23. The characteristic 
signals of the terminal alkyne are the triplet at 2.37 ppm, which integrates for one proton (Ha), 
and the doublet at 4.97 ppm, which integrates for two protons (Hb). These two peaks have a J 
value of 2.5 Hz due to the long range coupling. In the spectrum of the protected compound 42 it 
is possible to notice the disappearance of the triplet, evidence of the removal of the proton Ha. A 
further proof of this is the loss of the splitting of the signal given by Hb. The singlet observed 
confirms that Hb lacks of any neighbouring proton to couple with. The two singlets shown at 
0.00 and 0.8 ppm are typical of the newly introduced silyl protecting group and are given by Hc 
and Hd respectively.  
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Figure 1.23: Comparison between 1H NMR of 42 (red) and 41 (blue) 
The protected compound was a much better material for the ipso nitration (scheme 1.19) than 
the unprotected analogue. The pure nitro derivative was achieved after precipitation from 
dichloromethane and methanol as a pale yellow powder. The tetra amino compound was 
obtained from the reduction of the nitro compound with tin chloride using the same procedure 
described for the synthesis of 38 (scheme 1.26). 
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Scheme 1.26: Reduction of the lower-rim protected nitro calixarene. 
Di-tert-butyl dicarbonate (BOC) was selected as protecting group for the amino moieties on the 
wide rim because it is easily removable by treatment with HCl gas and the free product does not 
need to be purified because of the volatility of the side products formed in the reaction.143 
Although it can be removed by tetrabutylamonium fluoride (TBAF), the reagent used to 
deprotect the alkyne from the silane, its removal requires stronger conditions than the ones used 
to free the propargyl group.144 The reaction was carried out at 0oC in the presence of the 
protecting group and of diisopropylamine (DIPEA) as a base (scheme 1.27).145   
 
Scheme 1.27: Boc protection of the aromatic amino groups and alkyne deprotection. 
The compound was purified by column chromatography. The final step of the synthesis was the 
deprotection of the alkyne. The compound was stirred for 16 hours in THF in the presence of 
tetrabutylamonium fluoride, a reagent commonly used to remove silyl groups (scheme 1.27).146 
The reaction was performed at room temperature because at higher temperature the Boc-
protecting group can also be removed from aromatic amines which are less stable than aliphatic 
amines.144 Precipitation from dichloromethane and hexane yielded the desired compound as an 
off white powder. 
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1.3.5.2. Synthesis of aliphatic amino functionalised 
generation 1 calixarenes 
 
The synthesis ofa suitable tetra amino substrate for the introduction of aliphatic amines on the 
wide rim of the generation 1 calixarene followed the same route described in the previous 
sections. The four amino groups were coupled with the BOC protected amino acid glycine 
(scheme 1.28). Different coupling reagents can be used to achieve this reaction. Previous work 
in the group has shown that is possible to insert this group using the succinimide activated ester 
of Boc-glycine with N,N-Diisopropylethylamine (DIPEA) and a catalytic amount of 4-
dimethylaminopyridine (DMAP), in DCM, by stirring for 48 hours.105 Another method 
described in literature uses the Boc-protected aminoacid, benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBop) and DIPEA in dry DMF at room 
temperature.143 Although these methods are both valid we have explored the use of carbodiimide 
coupling reagents. This family of reagents is widely used in peptide synthesis and could be used 
also to couple peptides on calixarenes.147 The Boc-protected amino acid was stirred for half an 
hour in anhydrous DCM at 0oC in the presence of the coupling reagent to allow the formation of 
the adduct. The tetra-amino calix[4]arene, dissolved in the same solvent was then added. The 
reaction was conducted in anhydrous conditions under Argon to prevent the nucleophilic attack 
of water to the adduct formed by the amino acid and the coupling reagent. 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) was preferred to other 
coupling reagents such as dicyclohexylcarbodiimide (DCC) and diisopropylcarbodiimide (DIC) 
because of the water solubility of its urea derivative, the side product in the reaction. 
 
Scheme 1.28: Coupling of the aromatic amino groups with the Boc protected glycine and alkyne 
deprotection. 
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In the final step the TBDMS protecting group was removed by heating the compound at reflux 
in THF in the presence of TBAF to yield after precipitation from DCM and n-hexane the free 
alkyne as a pale yellow powder. This compound was not affected by the temperature, indicating 
the higher stability of the aliphatic amine derivatives. 
 
1.3.5.3. Synthesis of guanidinium functionalised generation 
1 calixarenes 
 
Single calix[4]arenes functionalised on the wide or on the lower rim with guanidinium groups 
have been reported by Ungaro’s group to bind and transfect nucleic acids.103, 101 ,102, 148 ,148It 
would be therefore interesting to explore their transfection potential when they are incorporated 
on a multicalixarene system. For this purpose we initially attempted to synthesise a calixarene 
carrying a guanidinium group protected with BOC on the upper rim and an alkyne function on 
the narrow rim. The tetra amino derivative 44 was dissolved in DMF and stirred in the presence 
of mercury chloride and N,N'-bis-Boc-2-methylthiourea. The resulting dark suspension was 
filtered and the resulting solution concentrated and purified by column chromatography.101 
Unfortunately the deprotection of the alkyne, performed by stirring the compound in THF in the 
presence TBAF, did not yield the desired compound. One of the reasons may be partial loss of 
the Boc protecting group on the guanidinium moiety. 
To overcome this problem an alternative strategy was developed, the protecting group on the 
alkyne was removed before the insertion of the guanidinium, on the free amine. In this way we 
obtained the tetra amino derivative carring the free alkyne on the narrow rim (scheme 1.29).  
 
Scheme 1.29: Deprotection of the alkyne group and functionalisation with Boc-protected 
Guanidinim groups. 
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1.3.6.Synthesis of multicalixarenes families 
The multicalixarenes were assembled by reacting each central core carrying four azides with the 
mono alkyne functionalised generation 1 calix[4]arenes. Santoyo-Gonzales was the first to link 
calixarenes scaffolds using the the Azide-Alkyne Huisgen Cycloaddition.114 As mentioned 
earlier in the chapter his investigation yielded a mixture of the 1,4 and 1,5 substituted products 
because the reaction was carried out without the copper(I) catalyst. To lead the reaction towards 
the formation of the 1,4 substituted product it is possible to use as a source of copper(I) catalyst 
either copper iodide or a mixture of copper sulphate and sodium ascorbate. In the first case the 
copper is already in the oxidation state required for the catalysis, whilst with the second 
approach it is reduced from copper(II) to copper(I) by the sodium ascorbate in the reaction 
mixture. Since Santoyo-Gonzales first example, a number of click reactions on calixarenes have 
been reported in literature using either the copper iodide149 150 151 139 or the copper sulphate 
method.152 139 In our investigation for the synthesis of the multicalixarenes carring the Boc-
protected aromatic amino groups a mixture of copper(II) sulphate penta hydrate and sodium 
ascorbate was chosen as source of copper(I) ions. The conditions followed were developed 
during previous work in the group (unpublished results). A slight excess of the mono alkyne 
functionalised derivative 46 (1.2 equivalents for each azido group) was heated at 70 Co in DMF 
for two hours in the presence of each azido functionalised central core, the copper sulphate 
pentahydrate (0.16 eq) and the sodium ascorbate (1.25 eq). Purification by column 
chromatography yielded the desired multicalixarenes. The slight excess of generation 1 
calixarene was used to ensure that all of the azido groups in the central core would undergo 
reactions. Partial reaction of the azido groups of the central core could lead to the formation of 
dimers, trimers, and tetramers resulting in a mixture of products with difficult separations. 
However when the same conditions were reproduced using the Boc-gly calixarene derivative 48 
as the generation 1 calixarene the reaction yielded a complex mixture of product. This failure led 
to the exploration of alternative conditions.  
The second multicalixarene family, bearing Boc-gly functionalisations, was obtained by 
increasing the amount of catalyst (0.5 equivalents of CuSO4 ·  5 H2O and 2 equivalents of sodium 
ascorbate), the amount of alkyne functionalised generation 1 calixarene (1.25 equivalents) and 
the reaction temperature up to 110 oC.139 In total twenty different multicalixarenes were 
synthesised. Ten different azido functionalised central cores were linked with two different types 
of generation 1 calix[4]arenes bearing either aromatic amines or aliphatic amines at the upper 
rim summarised in table1.1 
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Table 1.1: Multicalixarene families. 
In figure 1.26 is displayed a superimposition of the 1H NMR spectra for compounds 51 (blue), 
54 (red), 57 (green) and 60 (purple). It is possible to notice how the spectra change according to 
the conformation of the central cores. The spectra can be divided into three main regions: the 
aromatic region, above 6 ppm, the methylene region between 6 ppm and 2.75 ppm and the 
aliphatic region below 2.75 ppm. In all the spectra the two signals of the “click” protons can be 
seen. The first of these signals falls in the aromatic region at the highest ppm. It integrates for 
four protons and can be attributed to the proton present on the triazole ring. The second peak 
falls in the methylene region. It integrates for eight protons and is due to the methylene located 
between the generation 1 calixarenes and the triazole rings. This last signal in some cases 
overlaps with the signal given by the methylene next to the oxygen in the central core The 
spectra for the multicalixarenes 51 (blue), 57 (green) and 60 (purple), having the central cores in 
the cone conformation, show between 4.75ppm and 2.75 ppm six doublets. Four of these signals 
are due to the asymmetric methylene bridge protons of the generation 1 calixarene. The other 
two doublets, integrating for four protons each, belong to the symmetrical methylene bridge 
protons in the central core. 
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As expected, the same region of the spectra for compound 54 (red), bearing the central core in 
the 1,3-alternate conformation, shows only four doublets corresponding to the asymmetric 
methylene bridge protons of the generation 1 calixarene. The signal for the methylene bridge 
protons of the central core, a singlet, falls around 4.8-4.9 ppm and overlaps with the signals of 
the methylene protons on the alkyl chain of the generation 1 close to the phenolic oxygens.  
In compound 60 (purple) the central core in the cone conformation is linked to the generation 1 
calixarene with a wide rim-narrow rim. Comparing the aliphatic region of the spectra of this 
compound with the others it is possible to notice an extra sextet and extra triplet belonging to the 
propyl chains on the central core. 
 
Figure 1.24: 1H NMR Spectra for compound 51 (blue), 54 (red), 57 (green) and 60 (purple)  
 
1.3.7. Removal of Boc-protecting groups from aliphatic and 
aromatic amino multicalixarenes. 
 
In the final step of the synthesis the Boc protecting group was removed. As previously 
mentioned in the chapter this can be achieved by bubbling HCl gas through a solution of the 
protected multicalixarene. The multicalixarene bearing the masked amino moieties was 
dissolved in DCM and the gas was bubbled into the solution until the formation of a white 
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precipitate due to the formation of the chloride salt of the cationic multicalixarene, was observed. 
Removal of the solvent under reduced pressure yielded the desired compounds. This method 
was applied to all the multicalixrenes families and was successful in most cases. Four 
compounds in the cone conformation (78, 79, 83 and 89) showed an unexpected complexity in 
the 1H NMR probably due to conformational issues. These compounds did not undergo 
biological evaluation although the MALDI TOF analysis confirmed the mass for compound 79 
and 83. 
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1.4. Biological evaluation 
 
The two families of dendrimeric multicalixarenes bearing on the upper rim of their generation 1 
free amino group were biologically tested. The fifteen compounds which underwent biological 
evaluation where functionalised with either aromatic amino groups (71, 72, 73, 74, 75, 76, 77, 
78 and 80) or aliphatic amines ( 81, 82, 84, 85, 86, 87 and 88). The first test aimed to evaluate 
the toxicity of the compound on HL-60 cells through an MTS assay. HL-60 cells are commonly 
used in toxicity studies on calixarenes because their high sensitivity to toxins makes cell death 
easily detectable by colorimetric assay. 105, 153,154 
Once the lack of toxicity at therapeutically relevant concentrations was ascertained the ability to 
deliver nucleic acid into cells was tested with transfection studies. 
 
1.4.1.Toxicity 
 
Other studies have shown that compounds bearing amino groups could be toxic. It was therefore 
of major relevance to assess whether the amino multicalixarene families were compatible for 
biological applications in order to be used as a therapeutic tool for the transfection of DNA into 
the cells. Toxicity studies were carried out using an MTS assay. 
The MTS assay is a colorimetric assay which uses a tetrazolium compound (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethylphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS) and 
an electron-coupling agent (phenazine methosulfate, PMS). This method allows determination 
of the cell viability and proliferation. The MTS reagent is converted by the dehydrogenase 
enzymes in metabolically active cells into a formazan that is soluble in the cell culture medium. 
The absorbance of the formazan in each well can be read using a microtiter plate reader, and is 
directly proportional to the number of living cells in culture. 
The study was carried out incubating Human promyelocytic leukemia cells (HL-60) for 72 hours 
in the presence of a range of concentrations of multicalixarenes varying from 1mM to 100 nM. 
As control the cells were incubated in the media in the presence of the solvent used to solubilise 
the studied compounds. The multicalixarenes bearing aromatic amino functionalisation were 
dissolved in ethanol, whilst DMSO was used to solubilise the compounds bearing aliphatic 
amines. After 72 hours incubation, precipitation was observed for the two highest concentrations 
of all compounds, therefore the resulting data were not taken in to consideration. Before 
48 
 
performing the absorbance measurement 10µL of CellTiter 96® was added to each well and the 
plate was incubated for a further 4 hours. The asorbance was read at Absorbance was read at 
495nm using BMG Labtech, Fluostar Galaxy 96 well plate reader. For concentrations between 
10 µM and 100 nM none of the tested compounds showed signs of toxicity. 
 
Figure 1.25: Graphic representation of cell viability for HL-60 cells after 72 hours incubation 
with a) aromatic amino multicalixarenes and b) aliphatic amino multicalixarenes 
Figure 1.25 summarises the results of the toxicity studies carried out on the amino functionalised 
calixarenes. As it is possible to observe none of the tested compounds show toxicity in the range 
of concentrations evaluated. On the left hand side is shown the study at variable concentration 
whilst on the right hand side are summarised the results obtained at 20 µM concentration. 
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1.4.2. Transfection studies 
 
The ability of the multicalixarenes to transfect genetic material in to the cell was investigated 
using Chinese hamster ovary cells. The experiment aimed to introduce into the cells plasmid 
DNA (pDs2-mito) which had been engineered to express MitoDsRed2, a fluorescent protein 
localised in the mitochondria? of the cells. In the case of successful transfection the fluorescence 
can be observed in the cell mitochondria. The commercially available transfection agent 
FuGENE® was used as positive control. Plasmid DNA and DMSO were used as negative 
controls. 
The compounds under investigation, including the positive FuGENE®, in a concentration of 5 x 
10-4 M were incubated with pDs2-mito for 15 minutes at room temperature. The mixture was 
then added to the cells and incubated for 24 hours. Following the incubation the cells were tested 
for mitocondria fluorescence to assess whether the compound had transfection properties. 
Fluorescence was observed in all the cells treated with the multicalixarenes bearing aliphatic 
amines. The result proved that these compounds were capable of transfecting the nucleic acid 
into the cells. In particular the cells treated with compound 81 appeared to show the highest 
fluorescence. 
 
 
Figure 1.26: Transfection studies result a) negative control (DMSO and DNA); b) experiment 
(81 and DNA); c) positive control (FuGENE® and DNA) 
Figure 1.26 shows the results of the transfection studies carried out cells incubated with the 
DNA in the presence of multicalixarene 81. The cells treated with this incubated with the 
positive control FuGENE® (figure 1.26b). 
On the other hand among all the multicalixarenes bearing aromatic amines on their generation 1 
only compound 80 was able to transfect the plasmid into the cells (figure 1.27).  
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Figure 1.27: Transfection studies result a) negative control (DMSO and DNA); b) experiment 
(80 and DNA); c) positive control (FuGENE® and DNA) 
This result was unexpected because previous work in the group had shown that only the 
multicalixarene bearing aliphatic amines were able to transfect DNA. In this compound the 
generation 1 calixarenes are directly attached to the upper rim of the central core. 
From the results obtained from these first transfection experiments it can be concluded that the 
presence of aliphatic amines is of major importance for the transfection efficiency of cationic 
multicalixarenes. The potency of the transfection seems to be higher with shorter linkers, having 
the maximum for multicalixarene 81 . The sum of these two results have led the study toward 
the synthesis of compound 90, the analogue of compound 80, bearing on the generation 1 
aliphatic amino functionalities. 
 
1.5. Conclusion and future work 
 
In this chapter we have reported the synthesis of a library of cationic multicalixarene dendrimers 
which were investigated as transfection agents for the intracellular delivery of nucleic acid. The 
multicalixarenes were synthesised linking generation 1 calixarenes, prefunctionalised with 
protected either aromatic or aliphatic amines, with 10 different central cores through azide 
alkyne 1,3-dipolar cycloaddition. Central cores functionalised with four azido groups were 
reacted with mono-alkyne functionalised generation 1 calixarene in the presence of copper(I) 
catalyst. In this fashion 20 functionalised multicalixarenes with varing conformation and linker 
length were prepared. Once the dendrimers were formed the amino groups on the generation 1 
calixarenes were revealed and the compounds underwent biological evaluation. Toxicity and 
transfection properties were evaluated. The toxicity was evaluated by performing an MTS assay 
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for 72 hours with HL-60 cells. None of the compound tested showed toxicity in a concentration 
between 10 µM and 100 nM. Transfection experiments were carried out using CHO cells and 
pDs2-mito, a plasmid DNA, which is translated in the cell into a fluorescent protein. All the 
cells treated with the plasmid in the presence of multicalixarenes functionalised with aliphatic 
amines were successfully transfected. In particular the cells treated with compound 81 showed 
the highest fluorescence. On the other hand, only one of the aromatic amino functionalised 
multicalixarenes, compound 80 was able to transfect the plasmid into the cells even if with less 
efficiency than the multicalixarene carrying the aliphatic amine. This result has led the way 
toward the rational design of compound 90, analogue of 80 functionalised with aliphatic amines. 
The compound has been successfully synthesised and is now under biological investigation. 
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1.6. Experimental 
 
5,11,17,23-p-Tert-butylcalix[4]arene (1)78 
p-Tert-butyl phenol (200 g, 1,33 mmol), NaOH (1,20 g, 0.04 mol) and formaldehyde (128 mL, 
4.43 mol) were heated to 120 °C over 2 h. The resultant yellow solid was dissolved in diphenyl 
ether (750 mL, 4.73 mol). Water of condensation (120 mL) was removed by distillation heating 
the solution at 100 oC under a stream of air, after which the solution was heated at reflux for 2 h. 
Following cooling, EtOAc (750 mL) was added to precipitate the crude product, which was 
collected by filtration, washed with EtOAc (2 x 150 mL), AcOH (2 x 150 mL), and H2O (4 x 
150 mL) to yield the desired compound as white crystals (106.42 g, 49%). Mp > 325 ° C 
(decomp); 1H NMR
 
(400 MHz, CDCl3); 10.33 (4H, s, ArOH), 7.07 (8H, s, ArH), 4.24 (4H, br s, 
ArCH2Ar), 3.49 (4H, br s, ArCH2Ar), 1.10 (36H, s, C(CH3)3). 
Calix[4]arene (2)82 
AlCl3 (11.27 g, 80.52 mmol) was added carefully to a stirred solution of p-t-butyl calixarene (1) 
(10 g, 15.34 mmol) and phenol (6.49 g, 80.52 mmol) in toluene (100 mL). After 2h stirring 
under air flow the mixture was poured in to 200 mL of 0.2 N HCl and stirred for a further 30 
minutes. The separated organic layer was then washed twice with H2O and the excess of solvent 
was removed under reduced pressure. The residue was precipitated from MeOH to give the pure 
compound (5.27g 80.3%). Mp > 250 oC (decomp); 1H NMR (400 MHz, CDCl3); 10.23 (4H, s, 
ArOH), 7.08 (8 H, d, J =7.6 Hz, ArH), 6.75 (4H, t, J =7.6 Hz, ArH), 4.29 (4H, b s, ArCH2Ar), 
3.57 (4H, b s, ArCH2Ar). 
5,11,17,23-p-Tert-butyl-25,26,27,28-tetra(ethoxycarbonyl)methoxycalix[4]arene (3)155 
A solution of 1 (16.00 g, 24.70 mmol) and potassium carbonate (10.00 g, 72.46 mmol) were 
heated at reflux in MeCN (250 mL) for 2 h before the addition of ethylbromoacetate (40 mL, 
360.72 mmol), after which the solution was heated at reflux overnight. After cooling, the solvent 
was removed under reduced pressure and the residue taken up in DCM/H2O. The organic layer 
was separated and washed with H2O (3 x 100 mL), dried over MgSO4 and the solvent removed 
in vacuo. Precipitation from DCM/MeOH yielded 3 (19.29 g, 79%) as white crystals. Mp; 121-
123 ˚C; 1H NMR (400 MHz, CDCl3); 6.77 (8H, s, ArH), 4.85 (4H, d, J = 12.9 Hz, ArCH2Ar), 
4.80 (8H, s, OCH2C(O)OEt) 4.20 (8H, q, J = 7.2 Hz, C(O)OCH2CH3), 3.19 (4H, d, J = 12.9 Hz, 
ArCH2Ar), 1.29 (12H, t, J = 7.2 Hz, C(O)OCH2CH3), 1.07 (36H, s, C(CH3)3). 
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25,26,27,28-Tetra(ethoxycarbonyl)methoxycalix[4]arene (4)81  
K2CO3 (5 g, 36.23 mmol) was added to a stirred solution of 2 (5 g, 11.79 mmol) in CH3CN (165 
mL). After 30 minutes ethylbromoacetate (12.5 ml, 112.72 mmol) was added and the reaction 
was heated at reflux for 18 hours. The suspension was cooled, filtered and the solvent removed 
from the filtrate under reduced pressure The residue was dissolved in DCM (150 mL) and 
washed with water (3x 100 mL). The organic layer was evaporated under reduced pressure to 
give a yellow oil, which was re-crystallized from EtOH at -20oC to give the desired pure 
compound as white crystals (5.95 g, 65.7%). Mp 94-96 °C; 1H NMR (400 MHz, CDCl3); 6.62 
(12H, m, ArH), 4.88 (4H, d, J =13.6 Hz, ArCH2Ar), 4.74 (8H, s,OCH2CO2Et), 4.21 (8H, q, J = 
7.8 Hz, C(O)OCH2CH3), 3.24 (4H, d, J = 13.6 Hz, ArCH2CH2Ar), 1.29 (12H, t, J =7.8 Hz, 
C(O)OCH2CH3). 
5,11,17,23-p-Tert-butyl-25,26,27,28-hydroxyethoxycalix[4]arene (5)124 
A solution of 3 (2.5 g, 2.67 mmol) in Et2O (15 mL) was added dropwise to a stirred solution of 
LiAlH4 (0.8 g, 21 mmol) in Et2O (50 mL) at 0oC. After 24 hours the reaction mixture was 
quenched carefully with 10% HCl (100 mL) and was diluted with DCM (100 mL). The organic 
layer was separated, washed with H2O (2x100 mL), dried over MgSO4 and the excess of solvent 
was evaporated under reduced pressure to give the title compound (2.0 g, 84%). Mp = 105-107 
oC; 1H NMR (400 MHz, CDCl3) δ 6.86 (s, 8H, ArH), 5.12 (s, 4H, OCH2CH2OH), 4.36 (d, J = 
13.0 Hz, 4H, ArCH2Ar), 4.16 – 3.88 (m, 16H, OCH2CH2OH, OCH2CH2OH), 3.23 (d, J = 13.0 
Hz, 4H, ArCH2Ar), 1.09 (s, 36H). 13C NMR (101 MHz, CDCl3) δ 152.44, 145.83, 133.67, 
125.69, 77.94, 61.83, 34.08, 31.52, 30.57. 
25,26,27,28-Hydroxyethoxycalix[4]arene (6)122 
A solution of 4 (1.5 g, 1.95 mmol) in Et2O (10 mL) was added dropwise to a solution of LiAlH4 
(0.5 g, 13.2 mmol) in Et2O (25 mL) and was stirred for 24 hours at 0oC. The reaction mixture 
was quenched carefully with 10% HCl (100 mL) and was diluted with DCM (100 mL). The 
organic layer was separated, washed with H2O (2x100), dried over MgSO4 and the excess of 
solvent was evaporated to give the title compound (620 mg, 53%). Mp = 111-113 oC 1H NMR 
(400 MHz, CDCl3) δ 6.72 – 6.62 (m, 12H, ArH), 4.95 (bs, 4H, OCH2CH2OH), 4.39 (d, J = 13.5 
Hz, 4H, ArCH2Ar), 4.06 – 3.99 (m, 8H, OCH2CH2OH), 3.98 – 3.93 (m, 8H, OCH2CH2OH), 3.26 
(d, J = 13.5 Hz, 4H, ArCH2Ar). 13C NMR (101 MHz, CDCl3) δ 155.18, 134.74, 128.92, 123.34, 
77.99, 61.69, 30.44. 
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5,11,17,23-p-Tert-butyl-25,26,27,28-tosylethoxycalix[4]arene (7)122 
Tosyl Chloride ( 6.38 g, 33.6 mmol) was added to a stirred solution of 5 (2.5 g, 2.8 mmol) in 
DCM (50 mL) in the presence of Et3N (2.26 g, 22.4 mmol) at 0oC. After 24 hours the reaction 
was quenched with water (50 mL) and the organic layer was washed with 10% HCl (2 x 50 mL) 
and with brine (2 x 50 mL). The organic layer was separated, dried over MgSO4 and the excess 
of solvent was removed under reduced pressure. Purification by column chromatography over 
silica gel (DCM:n-hexane:EtOAc=5:5:1) gave the desired compound as a white solid (2,66 g, 
66%). Mp = 104-106 oC; 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.0 Hz, 8H, 
CH3ArHSO3Ar), 7.33 (d, J = 8.0 Hz, 8H, CH3ArHSO3Ar), 6.70 (s, 8H, ArH), 4.41 – 4.37 (m, 8H, 
OCH2CH2O), 4.22 (d, J = 13.0 Hz, 4H), 4.11 – 4.06 (m, 8H, OCH2CH2O), 3.00 (d, J = 13.0 Hz, 
4H, ArCH2Ar), 2.43 (s, 12H, CH3ArHSO3Ar), 1.05 (s, 36H, CH3CAr). 13C NMR (101 MHz, 
CDCl3) δ 152.27, 145.36, 144.91, 133.57, 133.23, 130.09, 128.15, 125.32, 71.79, 69.67, 33.96, 
31.50, 21.80. 
25,26,27,28-Tosylethoxycalix[4]arene (8) 122 
Tosyl Chloride (1.27 g, 6.68 mmol) was added to a stirred solution of 6 (0.5 g, 0.83 mmol) in 
DCM (10 mL) in the presence of Et3N (2.17 g, 5 mmol) at 0oC. After 24 hours the reaction was 
quenched with water (20 mL) and the organic layer was washed with 10% HCl (2 x 20 mL) and 
with brine (2 x 20 mL). The organic layer was separated, dried over MgSO4 and the excess of 
solvent was removed under reduced pressure. Purification by column chromatography over 
silica gel (DCM:n-hexane:EtOAc=5:5:1) gave the desired compound as a white solid (0.73 g, 
72%). Mp = 108-111 oC 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.5 Hz, 8H, CH3ArHSO3Ar), 
7.32 (d, J = 8.4 Hz, 8H, CH3ArHSO3Ar), 6.56 (s, 12H, ArH), 4.42 – 4.36 (m, 8H, OCH2CH2O), 
4.30 (d, J = 13.5 Hz, 4H, ArCH2Ar), 4.16 – 4.11 (m, 8H, OCH2CH2O), 3.05 (d, J = 13.5 Hz, 4H, 
ArCH2Ar), 2.43 (s, 12H, CH3ArHSO3Ar).13C NMR (101 MHz, CDCl3) δ 155.33, 144.97, 
134.70, 133.09, 130.10, 128.57, 128.07, 122.89, 71.86, 69.86, 30.90, 21.79. 
5,11,17,23-p-Tert-butyl-25,26,27,28-azaethoxycalix[4]arene (9)124 
NaN3 (641 mg, 15.84 mmol) was added to a stirred solution of 7 (590 mg, 0.41 mmol) in DMF 
(30 mL) and heated for 24 hours at 70 oC. The reaction was cooled, quenched with H2O (50 mL) 
and extracted with Et2O (3 x 50 mL). The combined organic layer was dried over MgSO4 and 
the excess of solvent was removed under reduced pressure to yield the pure compound (0.38 g, 
100%). Mp = 183-185 oC. 1H NMR (400 MHz, CDCl3) δ 6.83 (s, 8H, ArH ), 4.38 (d, J = 12.5 
Hz, 4H, ArCH2Ar), 4.09 (t, J = 6.0 Hz, 8H. OCH2CH2N3), 3.89 (t, J = 6.0 Hz, 8H, OCH2CH2N3), 
3.22 (d, J = 12.5 Hz, 4H, ArCH2Ar), 1.10 (s, 36H, CH3CAr). 13C NMR (101 MHz, CDCl3) δ 
152.48, 145.53, 133.54, 125.42, 72.11, 51.08, 34.00, 31.48, 30.87 
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25,26,27,28-Azaethoxycalix[4]arene (10) 124  
NaN3 (641 mg, 15.84 mmol) was added to a stirred solution of 8 (500 mg, 0.41 mmol) in DMF 
(30 mL) and heated for 24 hours at 70 oC. The reaction was cooled, quenched with H2O (50 mL) 
and extracted with Et2O (3 x 50 mL). The combined organic layer was dried over MgSO4 and 
the excess of solvent was removed under reduced pressure to yield the pure compound (0.28 g, 
97%). Mp = 188-191 oC. 1H NMR (400 MHz, CDCl3) δ 6.84 – 6.44 (m, 12H, ArH), 4.46 (d, J = 
13.5 Hz, 4H, ArCH2Ar), 4.12 (t, J = 6.0 Hz, 8H, OCH2CH2N3), 3.82 (t, J = 6.0 Hz, 8H, 
OCH2CH2N3), 3.27 (d, J = 13.5 Hz, 4H, ArCH2Ar). 13C NMR (101 MHz, CDCl3) δ 155.53, 
134.63, 128.64, 122.99, 72.16, 51.25, 30.79 
5,11,17,23-p-Tert-butyl-25,26,27,28-bromobutoxy-calix[4]arene (11)125 
NaH (0.936 g, 36.8 mmol) was added to a stirred solution of 1 (3 g, 4.6 mmol) in DMF (100 
mL). After 30 mintutes 1,4-dibromobutane (23.85 g, 110 mmol ) was added and the reaction was 
stirred at room temperature for 24 hours. The mixture was carefully quenched with H2O (100 
mL) and extracted with DCM (3 x 100 mL). The combined organic layer was washed with 10% 
HCl (2 x 100 mL) and brine (2 x 100 mL), dried over MgSO4 and the excess of solvent was 
removed under reduced pressure. The residue was precipitated from DCM:MeOH to give the 
product as a white solid (4.30 g, 78%). Mp = 141-143 oC. 1H NMR (400 MHz, CDCl3) δ 6.79 (s, 
8H, ArH ), 4.36 (d, J = 12.5 Hz, 4H, ArCH2Ar), 3.91 (t, J = 7.5 Hz, 8H, OCH2CH2CH2CH2Br), 
3.53 (t, J = 6.5 Hz, 8H, OCH2CH2CH2CH2Br), z, 4H, 3.15 (d, J = 12.5 H ArCH2Ar), 2.23 – 2.11 
(m, 8H, OCH2CH2CH2CH2Br), 2.06 – 1.97 (m, 8H, OCH2CH2CH2CH2Br), 1.09 (s, 36H, 
CH3CAr). 13C NMR (101 MHz, CDCl3) δ 152.42, 143.77, 132.78, 124.18, 73.36, 33.03, 32.98, 
30.57, 30.25, 28.71, 28.22. 
25,26,27,28-Bromobutoxy-calix[4]arene (12)156  
NaH (2.24 g, 93.6 mmol) was added to a stirred solution of 2 (5 g, 11.7 mmol) in DMF (150 
mL). After 30 mintutes 1,4-dibromobutane (60.65 g, 280.8 mmol) was added and the reaction 
was stirred at room temperature for 24 hours. The mixture was then carefully quenched with 
H2O (150 mL) and extracted with DCM (3 x 150 mL). The combined organic layer was washed 
with 10% HCl (2 x 150 mL) and brine (2 x 150 mL), dried over MgSO4 and the excess of 
solvent was removed under reduced pressure. The residue was precipitated from DCM:MeOH to 
give the product as a white solid (4.98 g, 44%). Mp = 124-126 oC. 1H NMR (400 MHz, CDCl3) 
δ 6.73 – 6.51 (m, 12H, ArH), 4.40 (d, J = 13.5 Hz, 4H, ArCH2Ar), 3.94 (t, J = 7 Hz, 8H, 
OCH2CH2CH2CH2Br), 3.51 (t, J = 6.5 Hz, 8H, OCH2CH2CH2CH2Br), 3.20 (d, J = 13.4 Hz, 4H, 
ArCH2Ar), 2.23 – 1.90 (m, 16H, OCH2CH2CH2CH2Br and OCH2CH2CH2CH2Br). 13C NMR 
(101 MHz, CDCl3) δ 156.26, 135.01, 128.44, 122.41, 74.10, 33.83, 31.13, 29.76, 29.11. 
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5,11,17,23-p-Tert-butyl-25,26,27,28-bromohexoxy-calix[4]arene (13) 
NaH (0.936 g, 36.8 mmol) was added to a stirred solution of 1 (3 g, 4.6 mmol) in DMF (100 
mL). After 30 mintutes 1,6-dibromohexane (26.84 g, 110 mmol) was added and the reaction was 
stirred at room temperature for 24 hours. The mixture was carefully quenched with H2O (100 
mL) and extracted with DCM (3 x 100 mL). The combined organic layer was washed with 10% 
HCl (2 x 100 mL) and brine (2 x 100 mL), dried over MgSO4 and the excess of solvent was 
removed under reduced pressure. The residue was precipitated from DCM:MeOH to give the 
product as a white solid (3.23 g, 54%). Mp = 81–83 oC. 1H NMR (400 MHz, CDCl3) δ 6.78 (s, 
8H, ArH ), 4.38 (d, J = 12.5 Hz, 4H, ArCH2Ar), 3.86 (t, J = 8 Hz, 8H, 
OCH2CH2CH2CH2CH2CH2Br), 3.45 (t, J = 7 Hz, 8H, OCH2CH2CH2CH2CH2CH2Br), 3.13 (d, J 
= 12.5 Hz, 4H, ArCH2Ar), 2.09 – 1.99 (m, 8H, OCH2CH2CH2CH2CH2CH2Br), 1.97 – 1.87 (m, 
8H, OCH2CH2CH2CH2CH2CH2Br ), 1.62 – 1.52 (m, 8H, OCH2CH2CH2CH2CH2CH2Br), 1.49 – 
1.39 (m, 8H, OCH2CH2CH2CH2CH2CH2Br), 1.08 (s, 36H, CH3CAr). 13C NMR (101 MHz, 
CDCl3) δ 153.56, 144.37, 133.75, 124.95, 75.08, 33.95, 33.83, 33.00, 31.47, 31.11, 30.22, 28.48, 
25.53. IR v = 2950; 2857.10; 1738; 1581; 1480; 1462; 1437.37; 1390; 1359; 1297; 1245; 1198; 
1122; 1108; 1047; 1025. 
25,26,27,28-Bromohexoxy-calix[4]arene (14) 
NaH (0.936 g, 36.8 mmol) was added to a stirred solution of 2 (2 g, 4.6 mmol)in DMF (100 mL). 
After 30 mintutes 1,6-dibromohexane (26.84 g, 110 mmol ) was added and the reaction was 
stirred at room temperature for 24 hours. The mixture was carefully quenched with H2O (100 
mL) and extracted with DCM (3 x 100 mL). The combined organic layer was washed with 10% 
HCl (2 x 100 mL) and brine (2 x 100 mL), dried over MgSO4 and the excess of solvent was 
removed under reduced pressure. The residue was precipitated from DCM:MeOH to give the 
product as a white solid (2.28 g, 46%) . Mp = 74-76 oC. 1H NMR (400 MHz, CDCl3) δ 6.75 – 
6.60 (m, 12H, ArH), 4.50 (d, J = 13.5 Hz, 4H, ArCH2Ar), 3.96 (t, J = 7.5 Hz, 8H, 
OCH2CH2CH2CH2CH2CH2Br), 3.50 (t, J = 6.5 Hz, 8H, OCH2CH2CH2CH2CH2CH2Br), 3.24 (d, 
J = 13.5 Hz, 4H, ArCH2Ar), 2.07 – 1.92 (m, 16H, OCH2CH2CH2CH2CH2CH2Br and 
OCH2CH2CH2CH2CH2CH2Br), 1.69 – 1.57 (m, 8H, OCH2CH2CH2CH2CH2CH2Br), 1.57 – 1.42 
(m, 8H, OCH2CH2CH2CH2CH2CH2Br). 13C NMR (101 MHz, CDCl3) δ 156.42, 135.02, 128.19, 
122.07, 74.81, 33.89, 32.93, 31.03, 30.15, 28.36, 25.52. M/z (MALDI-TOF) 1076.2 m/z [M]+. 
IR v = 2930; 2855; 2358; 2342; 1584; 1453; 1429; 1381; 1290; 1244; 1207; 1088; 1027.   
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5,11,17,23-p-Tert-butyl-25,26,27,28-azabutoxycalix[4]arene (15) 
NaN3 (4 g, 61.54 mmol) was added to a stirred solution of 11 (3.03 g, 2.56 mmol) in DMF (100 
mL) and heated for 24 hours at 70 oC. The reaction was cooled, quenched with H2O (50 mL) and 
extracted with Et2O (3 x 50 mL). The combined organic layer was dried over MgSO4 and the 
excess of solvent was removed under reduced pressure to yield the pure compound (2.42 g, 
92%). Mp= 118-120 oC. 1H NMR (400 MHz, CDCl3) δ 6.79 (s, 8H, ArH ), 4.35 (d, J = 12.5 Hz, 
4H, ArCH2Ar), 3.89 (t, J = 7.5 Hz, 8H, OCH2CH2CH2CH2N3), 3.40 (t, J = 7.0 Hz, 8H, 
OCH2CH2CH2CH2N3), 3.15 (d, J = 12.5 Hz, 4H, ArCH2Ar), 2.17 – 1.98 (m, 8H, 
OCH2CH2CH2CH2N3), 1.77 – 1.67 (m, 8H, OCH2CH2CH2CH2N3), 1.09 (s, 36H, CH3CAr). 13C 
NMR (101 MHz, CDCl3) δ 153.07, 144.47, 133.43, 124.87, 74.31, 51.38, 33.66, 31.25, 30.93, 
27.37, 25.52. M/z (MALDI-TOF) 1036.7 m/z [M]+. IR v = 2951; 2867; 2093; 1601; 1480; 
1391; 1361; 1298; 1246; 1198; 1122; 1032. 
25,26,27,28-Azabutoxycalix[4]arene (16) 
NaN3 (4 g, 61.54 mmol) was added to a stirred solution of 12 (2.47 g, 2.56 mmol) in DMF (100 
mL) and heated for 24 hours at 70 oC. The reaction was cooled, quenched with H2O (50 mL) and 
extracted with Et2O (3 x 50 mL). The combined organic layer was dried over MgSO4 and the 
excess of solvent was removed under reduced pressure to yield the pure compound (2.0 g, 
84.5%). 1H NMR (400 MHz, CDCl3) δ 6.66 – 6.55 (m, 12H, ArH), 4.39 (d, J = 13.5 Hz, 4H, 
ArCH2Ar), 3.92 (d, J = 7.5 Hz, 8H, OCH2CH2CH2CH2Br), 3.38 (t, J = 7.0 Hz, 8H, 
OCH2CH2CH2CH2Br), 3.19 (d, J = 13.5 Hz, 4H, ArCH2Ar), 2.08 – 1.89 (m, 8H, 
OCH2CH2CH2CH2Br), 1.83 – 1.63 (m, 8H, OCH2CH2CH2CH2Br). 13C NMR (101 MHz, CDCl3) 
δ 156.26, 135.01, 128.45, 122.43, 74.39, 51.62, 31.15, 27.63, 25.90. M/z (MALDI-TOF) 
812.4m/z [M]+. IR v = 2916; 2865; 2090; 1583; 1452; 1382; 1349; 1290; 1243; 1211; 1188; 
1087.   
5,11,17,23-p-Tert-butyl-25,26,27,28-azahexoxycalix[4]arene (17) 
NaN3 (2.6 g, 40.08 mmol) was added to a stirred solution of 13 (2.17 g, 1.67 mmol) in DMF 
(100 mL) and heated for 24 hours at 70 oC. The reaction was cooled, quenched with H2O (50 mL) 
and extracted with Et2O (3 x 50 mL). The combined organic layer was dried over MgSO4 and 
the excess of solvent was removed under reduced pressure to yield the pure compound as a 
colorless oil (1.9 g; 97 %). 1H NMR (400 MHz, CDCl3) δ 6.79 (s, 8H, ArH), 4.39 (d, J = 12.4 
Hz, 4H, ArCH2Ar), 3.87 (t, J = 7.5 Hz, 8H, OCH2CH2CH2CH2CH2CH2N3), 3.32 (t, J = 7.0 Hz, 
8H, OCH2CH2CH2CH2CH2CH2N3), 3.14 (d, J = 12.5 Hz, 4H, ArH), 2.10 – 1.97 (m, 8H, 
OCH2CH2CH2CH2CH2CH2N3), 1.72 – 1.61 (m, 8H, OCH2CH2CH2CH2CH2CH2N3), 1.58 – 1.38 
(m, 16H, OCH2CH2CH2CH2CH2CH2N3 and OCH2CH2CH2CH2CH2CH2N3), 1.09 (s, 32H, 
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CH3CAr). 13C NMR (101 MHz, CDCl3) δ 153.66, 144.49, 133.85, 125.07, 75.16, 51.56, 33.94, 
31.57, 31.23, 30.34, 29.23, 27.15, 26.01. M/z (MALDI-TOF) 1148.8 m/z [M]+. IR v = 2948; 
2861; 2091; 1739; 1601; 1480; 1390; 1360; 1297; 1247; 1198; 1122; 1014.   
25,26,27,28-Azahexoxycalix[4]arene (18) 
NaN3 (2.6 g, 40.08 mmol) was added to a stirred solution of 14 (1.80 g, 1.67 mmol) in DMF 
(100 mL) and heated for 24 hours at 70 oC. The reaction was cooled, quenched with H2O (50 mL) 
and extracted with Et2O (3 x 50 mL). The combined organic layer was dried over MgSO4 and 
the excess of solvent was removed under reduced pressure to yield the pure compound as a 
colorless oil (1.35 g, 88 %). 1H NMR (400 MHz, CDCl3) δ 6.69 – 6.54 (m, 12H, ArH ), 4.44 (d, 
J = 13.5 Hz, 4H, ArCH2Ar), 3.91 (t, J = 7.5 Hz, 8H, OCH2CH2CH2CH2CH2CH2N3), 3.32 (t, J = 
7.0 Hz, 8H, OCH2CH2CH2CH2CH2CH2N3), 3.19 (d, J = 13.5 Hz, 4H, ArCH2Ar), 2.01 – 1.89 (m, 
8H, OCH2CH2CH2CH2CH2CH2N3), 1.71 – 1.61 (m, 8H, OCH2CH2CH2CH2CH2CH2N3), 1.54 – 
1.40 (m, 16H, OCH2CH2CH2CH2CH2CH2N3 and OCH2CH2CH2CH2CH2CH2N3). 13C NMR (101 
MHz, CDCl3) δ 156.49, 135.10, 128.27, 122.14, 74.85, 51.47, 31.10, 30.22, 29.11, 27.01, 25.94. 
IR v = 2934; 2859; 2091; 1683; 1584; 1456; 1390; 1360; 1291; 1245; 1195; 1088; 1013.   
25,26,27,28-Tetra(ethoxycarbonyl)methoxycalix[4]arene (1,3 alternate) (19)157. 
Cs2CO3 (38 g, 116.80 mmol) was added to a stirred solution of 2 (5 g, 11.68 mmol) in acetone 
(150 mL) at 56 oC. After 30 minutes ethylbromoacetate (25.84 ml, 233.64 mmol) was added and 
the reaction was heated at reflux for 24 hours. The excess of solvent was removed under reduced 
pressure. The residue was dissolved in DCM (150 mL) and washed with water (100 mL). The 
separated organic layer was washed with 10% HCl (2 x 100 mL) and with brine (2 x 100 mL). 
The excess of solvent was evaporated under reduced pressure to give an yellow oil, which was 
re-crystallized from EtOH at -20oC to give the desired pure compound as white crystals (5.50 g, 
61%). Mp 95-97 °C. 1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 7.5 Hz, 8H, ArH), 6.71 (t, J = 
7.5 Hz, 4H, ArH), 4.25 (q, J = 7.0 Hz, 8H, OCH2COOCH2CH3), 4.05 (s, 8H, 
OCH2COOCH2CH3), 3.78 (s, 8H, ArCH2Ar), 1.33 (t, J = 7.0 Hz, 12H, OCH2COOCH2CH3). 13C 
NMR (101 MHz, CDCl3) δ 169.74, 155.61, 133.67, 130.50, 123.07, 69.84, 60.93, 35.65, 14.34.  
25,26,27,28-Hydroxyethoxycalix[4]arene (1,3 alternate) (22) 158 
A solution of 19 (1.5 g, 1.95 mmol) in Et2O (10 mL) was added dropwise to a solution of 
LiAlH4 (0.5 g, 13.2 mmol) in Et2O (25 mL) and was stirred for 24 hours at 0oC. The reaction 
mixture was quenched carefully with 10% HCl (100 mL) and was diluted with DCM (100 mL). 
The organic layer was separated, washed with H2O (2x100), dried over MgSO4 and the excess of 
solvent was evaporated under reduced pressure to give the title compound (950 mg, 81%). Mp > 
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263 (decompose). 1H NMR (400 MHz, CDCl3) δ 7.11 (d, J = 7.5 Hz, 8H, ArH), 6.96 (t, J = 7.5 
Hz, 4H, ArH), 3.96 (s, 8H, ArCH2Ar), 3.67 – 3.55 (m, 8H, OCH2CH2OH), 3.25 – 3.18 (m, 8H, 
OCH2CH2OH), 2.16 – 2.03 (m, 4H, OCH2CH2OH). 13C NMR (101 MHz, CDCl3) δ 156.30, 
133.47, 129.67, 123.85, 71.60, 61.03, 38.23. 
25,26,27,28-Tosylethoxycalix[4]arene (25)158 
Tosyl Chloride ( 1.27 g, 6.68 mmol) was added to a stirred solution of 22 (0.5 g, 0.83 mmol) in 
DCM (10 mL) in the presence of Et3N (2.17 g, 5 mmol) at 0oC. After 24 hours the reaction was 
quenched with water (20 mL) and the organic layer was washed with 10% HCl (2 x 20 mL) and 
with brine (2 x 20 mL). The organic layer was separated, dried over MgSO4 and the excess of 
solvent was removed under reduced pressure. Purification by column chromatography over 
silica gel (DCM:n-hexane:EtOAc=5:5:1) to give the desired compound as a white solid (0.61 g, 
60%). Mp 193-195 oC. 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.0 Hz, 8H, CH3ArHSO3Ar), 
7.39 (d, J = 8.0 Hz, 8H, CH3ArHSO3Ar), 6.91 (d, J = 7.5 Hz, 8H, ArH), 6.60 (t, J = 7.5 Hz, 4H, 
ArH), 3.68 – 3.62 (m, 16H, OCH2CH2OTos, ArCH2Ar), 3.48 (t, J = 6.0 Hz, 8H, 
OCH2CH2OTos), 2.47 (s, 12H, CH3ArHSO3Ar). 13C NMR (101 MHz, CDCl3) δ 155.44, 145.15, 
133.72, 133.09, 130.10, 129.75, 128.07, 123.27, 67.90, 67.67, 37.21, 21.80. 
25,26,27,28-Azaethoxycalix[4]arene (1,3 alternate) (28)159 
NaN3 (641 mg, 15.84 mmol) was added to a stirred solution of 25 (500 mg, 0.41 mmol)in DMF 
(30 mL) and heated for 24 hours at 70 oC. The reaction was cooled, quenched with H2O (50 mL) 
and extracted with Et2O (3 x 50 mL). The combined organic layer was dried over MgSO4 and 
the excess of solvent was removed under reduced pressure to yield the pure compound (0.28 g, 
97%). Mp 103-105 oC. 1H NMR (400 MHz, CDCl3) δ 7.11 (d, J = 7.5 Hz, 8H, ArH), 6.91 (t, J = 
7.5 Hz, 4H, ArH), 3.84 (s, 8H, ArCH2Ar), 3.53 (t, J = 6.5 Hz, 8H, OCH2CH2N3), 2.96 (t, J = 6.5 
Hz, 8H, OCH2CH2N3). 13C NMR (101 MHz, CDCl3) δ 155.90, 133.84, 129.62, 123.22, 68.15, 
50.25, 37.54 
25,26,27,28-Chlorobutoxy-calix[4]arene (32) 
Cs2CO3 (30.5 g, 93.4 mmol) was added to a stirred solution of 2 (5 g, 11.68 mmol) in acetone 
(150 ml) at 56 oC. After 30 minutes 1-bromo-4-chlorobutane (10.82 mL, 93.4 mmol) was added 
and the reaction was heated at reflux for 12 hours. The solvent was removed under reduced 
pressure. The residue was dissolved in DCM and washed with water. The organic layer was 
separated, washed with 10% HCl (2 x 100 mL) and with brine (2x100 mL), dried over dried 
over MgSO4 and the solvent was evaporated under reduced pressure to give a yellow oil. 
Purification by column chromatography over silica gel (DCM:n-hexane=1:1) and re-
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crystallisation from DCM:EtOH gave the desired pure compound as white crystals (2.60g, 28%). 
Mp = 129-131 oC. 1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 7.5 Hz, 8H, ArH ), 6.83 (t, J = 7.5 
Hz, 4H, ArH ), 3.78 (s, 8H, ArCH2Ar), 3.55 – 3.39 (m, 16H, OCH2CH2CH2CH2Cl and 
OCH2CH2CH2CH2Cl), 1.69 – 1.56 (m, 8H, OCH2CH2CH2CH2Cl), 1.50 – 1.39 (m, 8H, 
OCH2CH2CH2CH2Cl). 13C NMR (101 MHz, CDCl3) δ 156.80, 134.09, 129.69, 122.38, 69.86, 
45.41, 38.08, 29.30, 27.26. M/z (MALDI-TOF) 804.3 m/z [M + NH4]+. IR v = 2954; 2867; 
1742; 1585; 1453; 1381; 1245; 1205; 1089; 1045; 1025.  
25,26,27,28-Chlorohexoxy-calix[4]arene (33) 
Cs2CO3 (12 g, 36.8 mmol) was added to a stirred solution of 2 (2 g, 4.6 mmol) in acetone (150 
ml) at 56 oC. After 30 minutes 1-bromo-4-chlorobutane (5.47 mL, 36.8 mmol) was added and 
the reaction was heated at reflux for 12 hours. The solvent was removed under reduced pressure. 
The residue was dissolved in DCM and washed with water. The organic layer was separated, 
washed with 10% HCl (2 x 100 mL) and with brine (2 x 100 ml), dried over dried over MgSO 
and the solvent was evaporated to give an yellow oil. Purification by column chromatography 
over silica gel (DCM:n-hexane=1:1) and re-crystallisation from DCM:EtOH gave the desired 
pure compound as white crystals (2.03g, 50 % yield). Mp = 111-113 oC. 1H NMR (400 MHz, 
CDCl3) δ 7.01 (d, J = 7.5 Hz, 8H, ArH ), 6.72 (t, J = 7.5 Hz, 4H, ArH ), 3.68 (s, 8H, ArCH2Ar), 
3.64 – 3.50 (m, 16H, OCH2CH2CH2CH2CH2CH2Cl and OCH2CH2CH2CH2CH2CH2Cl), 1.90 – 
1.78 (m, 8H, OCH2CH2CH2CH2CH2CH2 Cl), 1.54 – 1.36 (m, 16H, OCH2CH2CH2CH2CH2CH2 
Cl and OCH2CH2CH2CH2CH2CH2 Cl), 1.42 – 1.22 (m, 8H, OCH2CH2CH2CH2CH2CH2 Cl). 13C 
NMR (101 MHz, CDCl3) δ 156.66, 133.87, 129.70, 121.73, 71.41, 45.17, 37.02, 32.76, 29.95, 
27.07, 25.42. M/z (MALDI-TOF) 916.4 m/z [M + NH4]+. 
25,26,27,28-Azabutoxycalix[4]arene (1,3 alternate) (34) 
NaN3 (4.0 g, 61.54 mmol) was added to a stirred solution of 32 (2.0 g, 2.56 mmol) in DMF (100 
mL) and heated for 24 hours at 70 oC. The reaction was cooled, quenched with H2O (50 mL) and 
extracted with Et2O (3 x 50 mL). The combined organic layer was dried over MgSO4 and the 
excess of solvent was removed under reduced pressure to yield the pure compound as white 
solid (2.08 g, 88% yield). Mp = 120-122 oC. 1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 7.5 Hz, 
8H, ArH), 6.81 (t, J = 7.5 Hz, 4H, ArH), 3.77 (s, 8H, ArCH2Ar), 3.49 (t, J = 6.9 Hz, 8H, 
OCH2CH2CH2CH2N3), 3.21 (t, J = 6.6 Hz, 8H, OCH2CH2CH2CH2 N3), 1.52 – 1.35 (m, 16H, 
OCH2CH2CH2CH2 N3 and OCH2CH2CH2CH2 N3). 13C NMR (101 MHz, CDCl3) δ 156.78, 
134.05, 129.68, 122.23, 70.11, 51.51, 37.93, 27.09, 25.47. M/z (MALDI-TOF) 835.4 m/z [M + 
Na]+. IR v = 3064; 2934; 2864; 2097; 1582; 1445; 1430; 1385; 1373; 1244; 1182; 1086; 1076; 
1044; 1025. 
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25,26,27,28-Azahexoxycalix[4]arene (35) 
NaN3 (2.6 g, 40.08 mmol) was added to a stirred solution of 33 (1.5 g, 1.67 mmol) in DMF (100 
mL) and heated for 24 hours at 70 oC. The reaction was cooled, quenched with H2O (50 mL) and 
extracted with Et2O (3 x 50 mL). The combined organic layer was dried over MgSO4 and the 
excess of solvent was removed under reduced pressure to yield the pure compound as a 
colourless oil (1.4 g, 91%). 1H NMR (400 MHz, CDCl3) δ 6.99 (d, J = 7.5 Hz, 8H, ArH), 6.69 (t, 
J = 7.5 Hz, 4H, ArH), 3.65 (s, 8H, ArCH2Ar), 3.53 (t, J = 7.2 Hz, 8H, OCH2CH2CH2CH2-
CH2CH2N3), 3.31 (t, J = 6.9 Hz, 8H, OCH2CH2CH2CH2CH2CH2N3), 1.73 – 1.58 (m, 8H, 
OCH2CH2CH2CH2CH2CH2N3), 1.57 – 1.45 (m, 8H, OCH2CH2CH2CH2CH2CH2N3), 1.41 (m, 8H, 
OCH2CH2CH2CH2CH2CH2N3), 1.36 – 1.20 (m, 8H, OCH2CH2CH2CH2CH2CH2N3). 13C NMR 
(101 MHz, CDCl3) δ 156.67, 133.88, 129.77, 121.76, 71.63, 51.59, 36.91, 30.08, 29.07, 26.96, 
25.77. M/z (MALDI-TOF) 947.5 m/z [M + Na]+. IR v = 3063; 2935; 2856; 2090; 1582; 1446; 
1428; 1379; 1348; 1242; 1191; 1183; 1087; 1077; 1037. 
5, 11, 17, 23-p-Tert-butyl-25,26,27,28-tetrapropoxycalix[4]arene (36)86 
NaH (7.36 g, 306.67 mmlol) was added to a stirred solution of 1 (25.00 g, 38.34 mmol) in DMF 
(400 mL). After 1 h n-PrBr (41.83 mL, 460.13 mmol) was added. The resulting solution was 
stirred for 5 days. H2O (150 mL) was added and the resultant precipitate collected, dissolved in a 
minimum of DCM and precipitated by the addition of MeOH to yield (5, 11, 17, 23-p-Tert-
butyl-25,26,27,28-tetrapropoxycalix[4]arene) (23.36 g, 75%) as a white powder. Mp 242-
243 °C. 1H NMR (400 MHz, CDCl3) δ 6.77 (s, 8H, ArH), 4.42 (d, J = 12.5 Hz, 4H, ArCH2Ar), 
3.81 (t, J = 7.7 Hz, 8H, OCH2CH2CH3), 3.11 (d, J = 12.5 Hz, 4H, ArCH2Ar), 2.13 – 1.85 (m, 8H, 
OCH2CH2CH3), 1.08 (s, 36H, C(CH3)3), 1.00 (t, J = 7.5 Hz, 12 H, OCH2CH2CH3). 
5,11,17,23-Tetranitro-25,26,27,28-tetrapropoxycalix[4]arene (37) 136, 160 
A mixture of 15 mL of glacial acetic acid and 15 mL of fuming nitric acid was added to a stirred 
solution of 37 (2.13 g, 2.81 mmol) in DCM (90 mL) The initially dark solution turned, after 30 
minutes, to a bright yellow colour. The reaction mixture was washed several times with water 
until a neutral pH was achieved. The organic layer was dried over MgSO4, and the solvent 
removed under reduced pressure. The resulting yellow solid was re-crystallized from 
DCM/MeOH giving the desired compound. (1.9 g, 88% yield). Mp 223-224 °C. 1H NMR (400 
MHz, CDCl3) δ 7.57 (s, 8H, ArH), 4.53 (d, J = 14.0 Hz, 4H, ArCH2Ar), 3.96 (t, J = 7.5 Hz, 8H, 
OCH2CH2CH3), 3.40 (d, J = 14.0 Hz, 4H, ArCH2Ar), 1.99 – 1.78 (m, 8H, OCH2CH2CH3), 1.02 
(t, J = 7.4 Hz, 12H, OCH2CH2CH3).  
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5,11,17,23-Tetraamino-25,26,27,28-tetrapropoxycalix[4]arene (38)147   
Tin(II)chloride di-hydrate (10.5 g, 46.6 mmol) was added to a stirred solution of 37 (1.5 g, 1.94 
mmol) in EtOH (100 mL). The mixture was heated at reflux temperature for 8 hours, cooled and 
the solvent removed under reduced pressure. The pale yellow solid was triturated and 10% 
NaOHaq (200 mL) was added. The resulting suspension was extracted with DCM (3 x 50 mL). 
The organic layer was separated, dried over MgSO4 and the solvent removed under reduced 
pressure to give the desired compound as a brown vitreous solid (1.24 g, 98% yield). Mp > 
250 °C (decomp.) 1H NMR (300 MHz, CDCl3) δ 6.06 (s, 8H, ArH), 4.31 (d, J = 13.3 Hz, 4H, 
ArCH2Ar), 3.72 (t, J = 7.5 Hz, 8H, OCH2CH2CH3), 2.91 (d, J = 13.3 Hz, 4H, ArCH2Ar), 1.99 – 
1.73 (m, 8H, OCH2CH2CH3), 0.94 (t, J = 7.4 Hz, 12H, OCH2CH2CH3). 
5,11,17,23-Tetraazido-25,26,27,28-tetrapropoxycalix[4]arene (39) 
NaNO2 (441.6 mg 6.4 mmol) was added to a stirred solution of 38 in 10% HCl (100 mL) at 0oC. 
After 20 minutes a solution of NaN3 (325 mg, 5 mmol) in H2O (5 mL) was added drop wise and 
stirred for a further 90 minutes. The formation of N2 gas was observed. The reaction was 
extracted with DCM (3x50 mL). The organic layer was separated and washed with brine (2 x 50 
mL), dried over MgSO4 and the solvent removed under reduced pressure. Purification by column 
chromatography over silica gel (DCM:n-hexane=1:1) gave the desired pure compound as off 
white solid (323 mg, 42 % yield). Mp 181-183. 1H NMR (400 MHz, CDCl3) δ 6.30 (s, 8H, 
ArH), 4.41 (d, J = 13.6 Hz, 4H, ArCH2Ar), 3.79 (t, J = 7.5 Hz, 8H, OCH2CH2CH3), 3.10 (d, J = 
13.6 Hz, 4H, ArCH2Ar), 1.95 – 1.79 (m, 8H, OCH2CH2CH3), 0.98 (t, J = 7.4 Hz, 12H, 
OCH2CH2CH3). IR v = 2964; 2934; 2873; 2340; 2103; 1586; 1463; 1435; 1382; 1288; 1262; 
1236; 1216; 1158; 1113; 1062. 
5,11,17,23-p-Tert-butyl-25,26,27-tripropoxy-28-hydroxycalix[4]arene (40)85 
BaO (17.15 g, 46.78 mmol) and Ba(OH)2.8 H2O (33.82 g, 107.35 mmol) were added to a stirred 
solution of 1 (20 g, 30.67 mmol) in DMF (500 mL) at 30 oC. After 15 minutes n-bromopropane 
(59.80 mL, 650 mmol) was added to the solution. After 48 hours the reaction was diluted with 
H2O (300 mL) and DCM (300 mL). The separated organic layer was washed with H2O (1 x 100 
mL), 10% HCl (2 x 100 mL) and brine (1 x 100 mL). The organic layer was dried over MgSO4 
and the solvent was removed under reduced pressure. The residue was precipitated from 
DCM:MeOH to give the desired product (17.4 g, 73%). Mp 114-115 °C; 1H NMR (400 MHz, 
CDCl3); 7.16 (2H, s, ArH), 7.07 (2H, s, ArH), 6.53 (4H, s, ArH), 4.38 (2H, d, J =12.8 Hz, 
ArCH2Ar), 4.35 (2H, d, J =12.8 Hz, ArCH2Ar), 3.86 (2H, t, J = 7.4 Hz, OCH2CH2CH3), 3.77 
(4H, t, J = 7.4 Hz, OCH2CH2CH3),3.25 (2H, d, J =12.8 Hz, ArCH2Ar), 3.18 (2H, d, J =12.8 Hz, 
ArCH2Ar), 2.35 (2H, m, OCH2CH2CH3), 1.93 (4H, m, OCH2CH2CH3), 1.36 (9H, s, (CH3)3Ar), 
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1.34 (9H, s, (CH3)3Ar), 1.11 (6H, t, J = 7.4 Hz, OCH2CH2CH3), 0.97 (3H, t, J = 7.4 Hz, 
OCH2CH2CH3), 0.84 (9H, s, (CH3)3Ar). 
5,11,17,23-p-Tert-butyl-25,26,27-tripropoxy-28-propargyloxycalix[4]arene (41)139  
NaH (95%, 2.58 g, 107.94 mmol) was added to a stirred solution of 40 (21 g, 26.94 mmol) in 
DMF (450 mL). After 30 minutes propargyl bromide (80%, 11.99, 107.94 mmol) was added 
drop wise and the resulting solution was stirred for 24 hours. DCM (500 mL) was added and the 
mixture was washed with H2O (2 x 500 mL) and then with brine (2 x 500 mL). The organic 
layer was dried with MgSO4 and the solvent removed under reduced pressure. The crude 
material was dissolved in DCM and precipitated with MeOH to yield the compound as a off 
white powder (20 g, 91 %). Mp 138-139 °C; 1H NMR (400 MHz, CDCl3); 7.01 (4H, s, ArH), 
6.57 (2H, s, J =2.4 Hz, ArH), 6.51 (2H, s, J =2.4 Hz, ArH), 4.97 (2H, d, J =2.4 Hz, OCH2CCH), 
4.50 (2H, d, J =12.8 Hz
 
ArCH2Ar), 4.42 (2H, d, J =12.4 Hz, ArCH2Ar), 3.90 (2H, t, J = 8.04 Hz, 
OCH2CH2CH3), 3.73 (4H, t, J = 7.6 Hz, OCH2CH2CH3),3.13 (2H, d, J =12.8 Hz, ArCH2Ar), 
3.12 (2H, d, J = 12.4 Hz, ArCH2Ar), 2.37 (1H, , OCH2CCH), 2.21 – 2.05 (2H, m, 
OCH2CH2CH3), 2.05 – 1.87 (4H, m, OCH2CH2CH3), 1.27 (9H, s, (CH3)3Ar), 1.26 (9H, s, 
(CH3)3Ar), 1.03 (6H, m, OCH2CH2CH3), 0.96 (3H, t, J = 7.5 Hz, OCH2CH2CH3), 0.89 (18H, s, 
(CH3)3Ar). 
5,11,17,23-p-Tert-butyl-25,26,27-tripropoxy-28-(3-tert-Butyldimethylsilyl)-2-
propynoxycalix[4]arene (42) 
Lithium bis(trimethylsilyl)amide (1M in THF, 4.2 mL, 4.2 mmol) was added drop wise to a 
solution at -78 oC of 41 (3.2 g, 4 mmol) in THF (50 mL). After 30 minutes a solution of tert-
butyldimethylsilyl chloride (0.90 g, 6 mmol in 5 mL of THF) was added and the reaction was 
stirred at room temperature for 16 hours. The reaction was diluted with EtOAc (20 mL) and 
washed with NH4Clsat (2 x 30 mL) and with brine (2 x 30 mL). The organic layer was dried over 
MgSO4 and concentrated. The residue was dissolved in DCM (50 mL) and precipitated with 
MeOH to yield the title compound as white crystals (3.9 g, 97%). Mp 157-159 °C; 1H NMR 
(400 MHz, CDCl3) δ 7.06 (s, 2H, ArH), 7.01 (s, 2H, ArH), 6.53 (d, J = 2.4 Hz, 2H, ArH), 6.46 
(d, J = 2.4 Hz, 2H, ArH), 5.07 (s, 2H, OCH2CCSi(CH3)2C(CH3)3), 4.47 (d, J = 13 Hz, 2H, 
ArCH2Ar), 4.42 (d, J = 12 Hz, 2H, ArCH2Ar), 3.99 – 3.87 (m, 2H, OCH2CH2CH3), 3.68 (m, 4H, 
OCH2CH2CH3), 3.12 (d, J = 12 Hz, 4H, ArCH2Ar), 3.10 (d, J = 13 Hz, 4H, ArCH2Ar), 2.19 – 
1.81 (m, 6H, OCH2CH2CH3), 1.30 (s, 9H, CH3CAr), 1.28 (s, 9H, CH3CAr), 1.07 (t, J = 7.4 Hz, 
6H, OCH2CH2CH3), 0.96 (t, J = 7.5, 3.7 Hz, 3H, OCH2CH2CH3), 0.86 (s, 18H, CH3CAr), 0.82 (s, 
9H, OCH2CCSi(CH3)2C(CH3)3), 0.05 – -0.01 (m, 6H, OCH2CCSi(CH3)2C(CH3)3). 13C NMR 
(101 MHz, CDCl3) δ 154.56, 153.22, 151.73, 145.34, 144.75, 144.13, 136.69, 135.58, 132.62, 
132.27, 125.46, 125.10, 124.64, 124.46, 104.31, 89.73, 59.47, 34.16, 33.73, 32.37, 31.87, 31.81, 
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31.34, 31.11, 26.13, 23.77, 23.63, 16.56, 10.89, 10.21, -4.58. M/z (MALDI-TOF) 944.6936 m/z 
[M + NH4]+; IR v = 2957; 2874; 2175; 1582; 1469; 1248; 1239; 1195; 1120; 1105; 1070; 1044; 
1008. 
5,11,17,23-Tetra-nitro-25,26,27-tripropoxy-28-(3-tert-Butyldimethylsilyl)-2-
propynoxycalix[4]arene (43) 
A mixture of 30 mL of glacial acetic acid and 30 mL of fuming nitric acid was added to a stirred 
solution of 42 (5.2 g, 5.62 mmol) in DCM (180 mL) When the initial dark solution turned, after 
30 minutes, to a bright yellow color the reaction was quenched with H2O (200 mL). The 
separated organic layer was washed several times with water until a neutral pH was achieved. 
The organic layer was dried over MgSO4, and the solvent removed under reduced pressure. The 
resulting crude material was re-crystallized from DCM/MeOH giving the desired compound as a 
yellow solid ( 4.9 g, 88%). Mp 243-246 °C; 1H NMR (400 MHz, CDCl3) δ 8.07 (s, 2H, ArH), 
8.06 (s, 2H, ArH), 7.15 (s, 4H, ArH), 5.00 (s, 2H, OCH2CCSi(CH3)2C(CH3)3), 4.57 (d, J = 14 Hz, 
2H, ArCH2Ar), 4.54 (d, J = 14 Hz, 2H, ArCH2Ar), 4.16 – 4.08 (m, 2H, OCH2CH2CH3), 3.86 – 
3.78 (m, 4H, OCH2CH2CH3), 3.41 (d, J = 14.0, 2H, ArCH2Ar), 3.40 (d, J = 14.0, 2H, ArCH2Ar), 
2.01 – 1.83 (m, 6H, OCH2CH2CH3), 1.10 (t, J = 7.4 Hz, 6H, OCH2CH2CH3), 0.97 (t, J = 7.4 Hz, 
3H, OCH2CH2CH3), 0.80 (s, J = 2.9 Hz, 9H, OCH2CCSi(CH3)2C(CH3)3), 0.02 (s, 6H, 
OCH2CCSi(CH3)2C(CH3)). 13C NMR (101 MHz, CDCl3) δ 162.80, 160.81, 159.81, 143.82, 
143.17, 138.35, 136.62, 134.62, 134.06, 124.91, 124.52, 123.50, 123.40, 99.93, 93.51, 78.19, 
78.03, 60.80, 31.68, 31.11, 25.87, 23.57, 23.36, 16.40, 10.66, 10.05, -4.78. M/z (MALDI-TOF) 
883.3586m/z [M + H]+; IR v = 3077; 2958; 2175; 2925; 2877; 2175; 1585; 1523; 1447; 1343; 
1262; 1201; 1095. 
5,11,17,23-Tetra-amino-25,26,27-tripropoxy-28-(3-tert-Butyldimethylsilyl)-2-
propynoxycalix[4]arene (44) 
Tin(II)chloride di-hydrate (28 g, 124.6 mmol) was added to a stirred solution of 43 (4 g, 4.45 
mmol) in EtOH (200 mL). The mixture was heated at reflux for 8 hours, cooled and the solvent 
removed under reduced pressure. The pale yellow solid was triturated with 10% NaOH and 
extracted with DCM. After separation the organic layer was dried over MgSO4 and the solvent 
removed under reduced pressure to give the desired compound as a brown vitreous solid (3.23 g, 
95%). Mp 157-159 °C; 1H NMR (400 MHz, MeOD) δ 6.56 (s, 2H, ArH ), 6.53 (s, 2H, ArH ), 
6.00 (s, 4H, ArH ), 4.76 (s, 2H, OCH2CCSi(CH3)2C(CH3)3), 4.45 (d, J = 13.5 Hz, 2H, ArCH2Ar), 
4.39 (d, J = 13.5 Hz, 2H, ArCH2Ar), 3.88 (t, J = 7.7, 2H, OCH2CH2CH3), 3.66 (t, J = 6.6 Hz, 4H, 
OCH2CH2CH3), 3.01 (d, J = 13.5 Hz, 4H, ArCH2Ar), 1.94 – 1.83 (m, 6H, OCH2CH2CH3), 1.10 
(t, J = 7.4 Hz, 6H, OCH2CH2CH3), 0.94 (t, J = 7.5 Hz, 2H, OCH2CH2CH3), 0.88 (s, 9H, 
OCH2CCSi(CH3)2C(CH3)3), 0.06 (s, 6H, OCH2CCSi(CH3)2C(CH3)3). 13C NMR (101 MHz, 
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MeOD) δ 153.71, 152.85, 149.45, 142.04, 141.96, 139.51, 138.29, 137.02, 136.51, 134.43, 
134.39, 119.59, 119.53, 118.55, 117.92, 104.71, 90.43, 78.16, 77.98, 61.03, 32.62, 31.95, 26.55, 
24.61, 24.40, 17.28, 11.44, 10.61, -4.40. M/z (MALDI-TOF) 763.4613 m/z [M + H]+; IR v = 
3347; 2958; 2360; 1735; 1607; 1465; 1384; 1247; 1214; 1005. 
5,11,17,23-Tetra-Boc-amino-25,26,27-tripropoxy-28-(3-tert-Butyldimethylsilyl)-2-
propynoxycalix[4]arene (45) 
Di-tert-butyl dicarbonate (14.6 g, 67.1 mmol) and diisopropylethylamine (11.66 mL, 67.10 
mmol) were added to a stirred solution at 0 oC of 44 (6.4 g, 8.3 mmol) in DCM (150 mL). The 
reaction was stirred for 8 h under argon atmosphere. The solution was quenched with H2O and 
the separated organic layer was washed with 10% HCl (2 x 50 mL) and with brine (50 mL). The 
organic layer was dried over MgSO4 and the solvent removed under reduced pressure. 
Purification by column chromatography over silica gel (DCM:MeOH=15:1) yielded the pure 
product as a pale yellow solid (7.04 mg, 73%). 1H NMR (400 MHz, MeOD) δ 7.09 (s, 4H, ArH), 
6.42 (s, 4H, ArH), 5.09 (s, 2H, OCH2CCSi(CH3)2C(CH3)3), 4.47 (d, J = 13.0 Hz, 2H, ArCH2Ar), 
4.43 (d, J = 13.0 Hz, 2H, ArCH2Ar), 4.01 – 3.93 (m, 2H, OCH2CH2CH3), 3.72 – 3.56 (m, 4H, 
OCH2CH2CH3), 3.08 (d, J = 13.0 Hz, 4H, ArCH2Ar), 2.14 – 1.80 (m, 6H, OCH2CH2CH3), 1.54 
(s, 18H, OC(CH3)3), 1.41 (s, 18H, OC(CH3)3), 1.11 (t, J = 7.5 Hz, 6H, OCH2CH2CH3), 0.97 (t, J 
= 7.5 Hz, 3H, OCH2CH2CH3), 0.85 (s, 9H, OCH2CCSi(CH3)2C(CH3)3), 0.03 (s, 6H, 
OCH2CCSi(CH3)2C(CH3)3). 13C NMR (101 MHz, MeOD) δ 155.99, 155.73, 155.70, 154.28, 
152.91, 151.36, 138.86, 137.46, 135.16, 134.71, 134.35, 134.27, 133.92, 121.54, 121.10, 120.90, 
120.78, 104.74, 90.97, 80.65, 80.59, 80.49, 78.47, 78.14, 60.57, 33.04, 31.89, 28.86, 28.85, 
28.82, 26.54, 24.69, 24.48, 17.22, 11.38, 10.54, -4.40. M/z (MALDI-TOF) 1180.6 m/z [M + 
NH4]+; IR v = 3318; 2961; 2928; 1703; 1601; 1519; 1470; 1366; 1245; 1151; 1063; 1033; 1003. 
5,11,17,23- Tetra-Boc-amino -25,26,27-tripropoxy-28-propargyloxycalix[4]arene (46) 
Tetra-n-butylammonium fluoride solution in THF (1 M, 30.6 mL, 30.6 mmol) was added to a 
stirred solution of 45 (7.12 g, 6.12 mmol) in THF (60 mL). After 8 h the reaction was diluted 
with EtOAc (50 mL) and quenched with NH4Cl saturated solution (100 mL). The separated 
organic layer was washed with NH4Cl saturated solution (50 mL) and brine (2 x 50 mL), dried 
over MgSO4 and the solvent removed under reduced pressure. Purification by column 
chromatography over silica gel (n-hexane:DCM:MeOH=10:10:0.5) yielded the pure product as a 
pale yellow solid (4 g, 62%). 1H NMR (400 MHz, MeOD) δ 7.06 (s, 4H, ArH), 6.43 (s, 4H, 
ArH), 4.98 (d, J = 2 Hz, 2H, OCH2CCH), 4.51 (d, J = 13 Hz, 2H, ArCH2Ar), 4.44 (d, J = 13 Hz, 
2H, ArCH2Ar), 3.97 (t, J = 8 Hz, 2H, OCH2CH2CH3), 3.69 (t, J = 7 Hz, 4H, OCH2CH2CH3), 
3.09 (d, J = 13 Hz, 2H, ArCH2Ar), 3.09 (d, J = 13 Hz, 2H, ArCH2Ar), 2.72 (t, J = 2 Hz, 1H, 
OCH2CCH), 2.10 – 1.86 (m, 6H, OCH2CH2CH3), 1.53 (s, 9H, OC(CH3)3), 1.53 (s, 9H, 
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OC(CH3)3), 1.42 (s, 18H, OC(CH3)3), 1.10 (t, J = 7.4 Hz, 6H, OCH2CH2CH3), 0.98 (t, J = 7.5 Hz, 
3H, OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 156.00, 155.83, 155.75, 154.25, 153.02, 
151.83, 138.50, 137.37, 135.07, 134.75, 134.52, 134.30, 133.91, 121.55, 121.09, 121.00, 81.73, 
80.66, 80.51, 78.44, 78.10, 76.32, 60.59, 32.74, 31.93, 28.82, 24.60, 24.45, 11.27, 10.53. M/z 
(MALDI-TOF) 1180.6 m/z [M + NH4]+; IR v = 3308; 2974; 2930; 2360; 1699; 1600; 1519; 
1471; 1415; 1390; 1366; 1213; 1151; 1064; 1004. 
5,11,17,23-Tetra-Boc-Glycine-25,26,27-tripropoxy-28-(3-tert-Butyldimethylsilyl)-2-
propynoxycalix[4]arene (47) 
A solution of Boc glycine (2.1 g, 12 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDCI) (2.48 g, 16 mmol) in DCM (100 mL) was stirred at 0oC for 40 minutes before the 
addition of a solution of 44 (1.53 g, 2 mmol) in DCM (50 mL). After 24 hours the reaction 
mixture was quenched with H2O (100 mL), the separated organic layer was washed with 10% 
HCl (2 x 100 mL) and with brine (1 x 100 mL), dried over MgSO4 and the excess of solvent was 
evaporated under reduced pressure. Purification by column chromatography over silica gel 
(EtOAc:nHexane:MeOH=1:1:0.1) yielded the desired compound as an off white solid (2.02 g, 
72%). 1H NMR (400 MHz, MeOD) δ 7.29 (s, 2H, ArH), 7.28 (s, 2H, ArH), 6.57 (s, 2H, ArH), 
6.53 (s, 2H, ArH), 5.09 (s, 2H, OCH2CCSi(CH3)2C(CH3)3), 4.50 (d, J = 13 Hz, 2H, ArCH2Ar), 
4.47 (d, J = 13 Hz, 2H, ArCH2Ar), 4.01 (t, J = 8.0 Hz, 2H, OCH2CH2CH3), 3.87 (s, 4H, 
ArNHCOCH2NHCOOC(CH3)3), 3.75 – 3.66 (m, 4H, OCH2CH2CH3), 3.64 (s, 4H, 
ArNHCOCH2NHCOOC(CH3)3), 3.12 (d, J = 13.0 Hz, 4H, ArCH2Ar), 2.09 – 1.84 (m, 6H, 
OCH2CH2CH3), 1.49 (s, 18H, OC(CH3)3), 1.44 (s, 18H, OC(CH3)3), 1.12 (t, J = 7.5 Hz, 6H, 
OCH2CH2CH3 ), 0.97 (t, J = 7.5 Hz, 3H, OCH2CH2CH3), 0.84 (s, 9H, 
OCH2CCSi(CH3)2C(CH3)3), 0.02 (s, 6H, OCH2CCSi(CH3)2C(CH3)3). 13C NMR (101 MHz, 
MeOD) δ 170.17, 170.04, 169.71, 158.50, 153.77, 152.27, 139.11, 137.61, 134.94, 134.58, 
134.47, 133.23, 122.20, 121.58, 121.48, 104.37, 91.28, 80.70, 78.50, 78.28, 60.63, 45.03, 44.73, 
32.95, 31.91, 28.77, 26.49, 24.69, 24.47, 17.21, 11.33, 10.46, -4.46. . M/z (MALDI-TOF) 
1413.7 m/z [M + Na]+; IR v = 3307; 2930; 1667; 1600; 1470; 1418; 1391; 1366; 1248; 1213; 
1163; 1028. 
5,11,17,23-Tetra-Boc-Glycine-25,26,27-tripropoxy-28- propargyloxycalix[4]arene (48) 
Tetra-n-butylammonium fluoride solution in THF (1 M, 8.36 mL, 8.36 mmol) was added to a 
stirred solution of 44 (2.35 g, 1.67 mmol) in THF (16 mL) at reflux temperature. After 8 h the 
reaction was diluted with EtOAc (25 mL) and quenched with NH4Cl saturated solution (50 mL). 
The separated organic layer was washed with NH4Cl saturated solution (25 mL) and brine (2 x 
25 mL), dried over MgSO4 and the solvent removed under reduced pressure. Purification by 
column chromatography over silica gel (EtOAc:nHexane:MeOH=1:1:0.1) yielded the pure 
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product as a pale yellow solid (1.78 g, 83.5%). Mp>186 (decompose) oC; 1H NMR (400 MHz, 
MeOD) δ 7.25 (s, 2H, ArH), 7.24 (s, 2H, ArH), 6.58 (s, 2H, ArH), 6.56 (s, 2H, ArH), 4.96 (s, 2H, 
OCH2CCH), 4.53 (d, J = 13 Hz, 2H, ArCH2Ar), 4.47 (d, J = 13 Hz, 2H, ArCH2Ar), 4.00 (t, J = 
8.0 Hz, 2H, OCH2CH2CH3), 3.85 (s, 4H, ArNHCOCH2NHCOOC(CH3)3), 3.71 (t, J = 6.7 Hz, 
4H, OCH2CH2CH3), 3.65 (s, 4H, ArNHCOCH2NHCOOC(CH3)3), 3.12 (bd, J = 13.0 Hz, 4H, 
ArCH2Ar), 2.75 (t, J = 2.3 Hz, 1H, OCH2CCH), 2.08 – 1.86 (m, 6H, OCH2CH2CH3), 1.49 (s, 
18H, OC(CH3)3), 1.45 (s, 18H, OC(CH3)3), 1.11 (t, J = 7.4 Hz, 6H, OCH2CH2CH3), 0.97 (t, J = 
7.5 Hz, 3H, OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 170.11, 169.70, 158.44, 155.16, 
153.84, 152.75, 138.64, 137.45, 134.93, 134.69, 134.49, 133.67, 133.20, 122.14, 121.72, 121.60, 
81.44, 80.70, 78.45, 78.17, 76.57, 60.72, 45.02, 44.75, 32.65, 31.95, 28.78, 24.58, 24.42, 11.26, 
10.49. M/z (MALDI-TOF) 1294.7 m/z [M + NH4]+; IR v = 3307; 2963; 2919; 2849; 2363; 
1670; 1600; 1516; 1471; 1418; 1365; 1278; 1247; 1214; 1162; 1052, 1007. 
5,11,17,23- Tetra-amino-25,26,27-tripropoxy-28-propargyloxycalix[4]arene (49) 
Tetra-n-butylammonium fluoride solution in THF (1 M, 5 mL, 5 mmol) was added to a stirred 
solution of 44 (763 mg, 1 mmol) in THF (10 mL). After 8 h the reaction was diluted with EtOAc 
(20 mL) and quenched with NH4Cl saturated solution (50 mL). The separated organic layer was 
washed with NH4Cl saturated solution (25 mL) and brine (2 x 25 mL), dried over MgSO4 and 
the solvent removed under reduced pressure to yield the desired product (408 mg, 63%), which 
was used in the following step without further purification. Mp > 160 oC (decompose); 1H NMR 
(300 MHz, CDCl3) δ 6.42 (s, 2H), 6.41 (s, 2H), 5.81 (s, 2H), 5.80 (s, 2H), 4.75 (d, J = 2.4 Hz, 
2H), 4.38 (d, J = 13.5 Hz, 2H), 4.31 (d, J = 13.1 Hz, 2H), 3.86 (t, J = 7.9 Hz, 2H), 3.60 (d, J = 
13.8 Hz, 4H), 3.22 (s, 8H), 2.94 (d, J = 13.8 Hz, 2H), 2.92 (d, J = 13.1 Hz, 2H), 2.31 (t, J = 2.4 
Hz, 1H), 1.97 – 1.74 (m, 6H), 1.03 (t, J = 7.4 Hz, 6H), 0.89 (t, J = 7.5 Hz, 3H). M/z (MALDI-
TOF 649.3745 m/z [M + NH4]+; IR v = 3290; 2966; 2878; 2160; 1584; 1515; 1452; 1340; 1303; 
1262; 1207; 1091; 1059. 
5,11,17,23-Tetra-bis-boc-guanidinium-25,26,27-tripropoxy-28- propargyloxycalix[4]arene 
(50) 
1,3-Bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (643 mg, 2.22 mmol), HgCl2 (601 mg, 
2.22 mmol) and Et3N (0.768 mL, 5.52 mmol) were added to a stirred solution at 0 oC of 49 (300 
mg, 0.46 mmol) in DMF (7 mL). After 8 h the black suspension was diluted with DCM (10 mL) 
and the solid was filtered off under reduced pressure. The excess of solvent was removed under 
reduced pressure. Purification by column chromatography over silica gel (nHexane:Et2O in 
gradient from 4:1 to 1:4) yielded the desired compound as an off white solid (431 mg, 58%). 1H 
NMR (300 MHz, CDCl3) δ 11.69 (s, 1H, NH), 11.67 (s, 1H, NH), 11.52 (s, 2H, NH), 10.30 (s, 
1H, NH), 10.21 (s, 1H, NH), 9.50 (s, 2H, NH), 7.33 (s, 2H, ArH), 7.25 (s, 2H, ArH), 6.71 (s, J = 
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2.3 Hz, 1H, ArH), 6.71 (s, 1H, ArH), 6.64 (s, 1H, ArH), 6.63 (s, 1H, ArH), 5.00 (d, J = 2.4 Hz, 
2H, OCH2CCH ), 4.50 (d, J = 13.3 Hz, 2H, ArCH2Ar), 4.42 (d, J = 12.5 Hz, 2H, ArCH2Ar), 3.98 
(t, J = 8.2, 2H, OCH2CH2CH3), 3.66 (t, J = 7.1 Hz, 4H, OCH2CH2CH3), 3.18 (d, J = 13.3 Hz, 2H, 
ArCH2Ar), 3.17 (d, J = 12.5 Hz, 2H, ArCH2Ar), 2.33 (t, J = 2.4 Hz, 1H, OCH2CCH), 2.03 – 
1.84 (m, 6H, OCH2CH2CH3), 1.52 (s, 18H, OC(CH3)3), 1.50 (s, 9H, OC(CH3)3), 1.49 (s, 9H, 
OC(CH3)3), 1.45 (s, 18H, OC(CH3)3), 1.42 (s, 18H, OC(CH3)3), 1.03 (t, J = 7.4 Hz, 6H, 
OCH2CH2CH3), 0.88 (t, J = 7.3 Hz, 3H, OCH2CH2CH3). M/z (MALDI-TOF 1634.9 m/z [M + 
NH4]+; IR v = 3263; 2972; 2878; 1716; 1621; 1455; 1409; 1393; 1366; 1249; 1214, 1142; 1102; 
1057; 1003. 
General method for the synthesis of Boc-amino-Multicalixarenes 
Generation 1 calixarene (4.5 eq) was added to a solution of central core (1 eq) in DMF (15 mL) 
in the presence of CuSO4·5H2O (26.1 mg, 0.105 mmol, 0.66 eq) and sodium ascorbate (208 mg, 
1.05 mmol, 5 eq). The reaction was stirred for 2 hours at 110oC. The solution was diluted with 
DCM (50 mL) and washed with H2O (2 x 50 mL) and brine (2 x 50 mL), dried over MgSO4 and 
concentrated. Purification by column chromatography over silica gel, (DCM:EtOAc in gradient 
from 20:1 to 5:1 ) and precipitation from DCM/n-hexane yielded the desired compounds as 
white solids.  
Multicalixarene (51) 
Generation 1 = 46 (1 g, 0.95 mmol), Central core = 10 (140 mg, 0.2 mmol) Product = 51 (770 
mg, 78.5%) Mp >213 oC (decompose). 1H NMR (400 MHz, MeOD) δ 7.95 (s, 4H, AzH), 6.85 
(s, 16H, ArH ), 6.56 (s, 28H, ArH ), 5.02 – 4.91 (m, 16H, OCH2CCAz and OCH2CH2Az), 4.51 – 
4.24 (m, 24H, ArCH2Ar and OCH2CH2Az), 4.11 (d, J = 13.5 Hz, 4H, ArCH2Ar), 3.85 – 3.63 (m, 
24H, OCH2CH2CH3), 3.13 – 3.02 (m, 12H, ArCH2Ar), 2.90 (d, J = 13 Hz, 8H, ArCH2Ar), 2.04 – 
1.71 (m, 24H, OCH2CH2CH3), 1.49 (s, 72H, OC(CH3)3), 1.45 (s, 72H, OC(CH3)3), 1.04 (t, J = 
7.5 Hz, 12H, OCH2CH2CH3), 0.83 (t, J = 7.3 Hz, 24H, OCH2CH2CH3). 13C NMR (101 MHz, 
MeOD) δ 155.91, 155.56, 154.14, 153.28, 151.56, 145.59, 136.67, 136.61, 134.55, 134.05, 
133.85, 129.82, 126.13, 124.05, 121.50, 121.39, 120.94, 80.62, 78.22, 78.04, 51.67, 32.54, 32.11, 
31.46, 24.59, 24.26, 11.28, 10.91. M/z (MALDI-TOF) 4920.7 m/z [M+Na]+; IR v = 3330; 2973; 
2930; 2874; 2360; 1706; 1596; 1520; 1476; 1365; 1214; 1152; 1043; 1001. 
Multicalixarene (52) 
Generation 1 = 46 (1 g, 0.95 mmol), 16 (170 mg, 0.2 mmol) Product = 52 (881 mg, 88%) 
Mp >180oC (decompose). 1H NMR (400 MHz, MeOD) δ 7.81 (s, 4H, AzH), 6.80 (s, 16H, 
ArH ), 6.66 – 6.47 (m, 28H, ArH ), 4.99 (s, 8H, OCH2CCAz), 4.51 (s, 8H, 
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OCH2CH2CH2CH2CH2CH2Az), 4.42 – 4.34 (m, 12H, ArCH2Ar), 4.26 (d, J = 13.0 Hz, 8H, 
ArCH2Ar), 3.94 (s, 8H, OCH2CH2CH2CH2CH2CH2Az), 3.80 – 3.69 (m, 24H, OCH2CH2CH3), 
3.13 (d, J = 14.0 Hz, 4H, ArCH2Ar), 3.05 (d, J = 13.0 Hz, 8H, ArCH2Ar), 2.90 (d, J = 13.0 Hz, 
8H, ArCH2Ar), 2.14 – 1.73 (m, 48H, OCH2CH2CH3, OCH2CH2CH2CH2CH2CH2Az, 
OCH2CH2CH2CH2CH2CH2Az and OCH2CH2CH2CH2CH2CH2Az ), 1.51 – 1.42 (m, 152H, 
OC(CH3)3, and OCH2CH2CH2CH2CH2CH2Az), 1.04 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.85 (t, 
J = 7.5 Hz, 24H, OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 157.51, 155.86, 155.57, 
153.94, 153.38, 151.63, 145.31, 136.06, 134.59, 134.07, 133.92, 129.53, 125.91, 123.34, 121.34, 
120.99, 80.59, 78.14, 78.06, 75.37, 54.80, 51.37, 32.50, 32.11, 28.95, 28.91, 28.85, 24.59, 24.27, 
11.22, 10.93. M/z (MALDI-TOF) 5032.7 m/z [M+Na]+ ; ]+; IR v = 3325; 2972; 2931; 2873; 
2363; 1712; 1596; 1519; 1474; 1366; 1215; 1153; 1062; 1001. 
Multicalixarene (53) 
Generation 1 = 46 (1 g, 0.95 mmol), 18 (194 mg, 0.2 mmol) Product 53 (626 mg, 61.4%) 
Mp >178oC (decompose). 1H NMR (400 MHz, MeOD) δ 7.78 (s, 4H, AzH), 6.93 (d, J = 7.6 Hz, 
8H, ArH), 6.80 (bs, 16H, ArH), 6.71 – 6.44 (m, 20H, ArH), 5.07 (s, 8H, OCH2CCAz), 4.47 – 
4.35 (m, 16H, OCH2CH2CH2CH2CH2CH2Az and ArCH2Ar), 4.30 (d, J = 13.0 Hz, 8H, 
ArCH2Ar), 3.77 (bs, 24H, OCH2CH2CH3), 3.65 (bs, 8H, ArCH2Ar), 3.42 – 3.35 (m, 8H, 
OCH2CH2CH2CH2CH2CH2Az), 3.05 (d, J = 13.0 Hz, 8H, ArCH2Ar), 2.96 (d, J = 13.0 Hz, 8H, 
ArCH2Ar), 2.05 – 1.79 (m, 32H, OCH2CH2CH3 and OCH2CH2CH2CH2CH2CH2Az), 1.47 (s, 
72H, OC(CH3)3), 1.46 (s, 36H, OC(CH3)3), 1.45 (s, 36H, OC(CH3)3), 1.39 – 1.34 (m, 8H, 
OCH2CH2CH2CH2CH2CH2Az), 1.31 – 1.25 (m, 16H, OCH2CH2CH2CH2CH2CH2Az and 
OCH2CH2CH2CH2CH2CH2Az), 1.02 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.91 (t, J = 7.5 Hz, 
24H, OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 158.07, 155.81, 155.65, 153.91, 153.30, 
151.62, 145.27, 136.28, 135.72, 135.21, 134.63, 134.13, 133.97, 130.83, 125.73, 122.87, 121.26, 
121.07, 80.58, 78.06, 72.04, 67.56, 54.80, 51.34, 38.39, 32.55, 32.13, 31.76, 30.94, 28.92, 28.89, 
27.73, 26.65, 24.59, 24.29, 11.23, 10.98. M/z (MALDI-TOF) 5144.7 m/z [M+Na]+ ; IR v = 
3324; 2973; 2930; 2873; 1716; 1595; 1519; 1474; 1366; 1291; 1214; 1153; 1063; 1002.  
Multicalixarene (54) 
Generation 1 = 46 (1 g, 0.95 mmol), Central core = 38 Product = 54 (770 mg, 78.5%) Mp >215 
oC (decompose). 1H NMR (400 MHz, MeOD) δ 7.59 (s, 4H, AzH), 7.06 (d, J = 7.5 Hz, 8H, 
ArH ), 6.87 (t, J = 7.5 Hz, 4H, ArH ), 6.82 (bs, 16H, ArH ), 6.65 (bs, 8H, ArH ), 6.60 (bs, 8H, 
ArH ), 5.10 (s, 8H, OCH2CCAz), 4.40 (d, J = 13.0 Hz, 8H, ArCH2Ar), 4.26 (d, J = 13.0 Hz, 8H, 
ArCH2Ar), 3.99 – 3.86 (m, 16H, OCH2CH2Az and ArCH2Ar), 3.83 – 3.67 (m, 32H, 
OCH2CH2Az and OCH2CH2CH3), 3.06 (d, J = 13.0 Hz, 8H, ArCH2Ar), 2.90 (d, J = 13.0 Hz, 8H, 
ArCH2Ar), 2.00 – 1.82 (m, 24H, OCH2CH2CH3), 1.49 (s, 72H, OC(CH3)3), 1.46 (s, 36H, 
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OC(CH3)3), 1.42 (s, 36H, OC(CH3)3), 1.05 (t, J = 7.4 Hz, 12H, OCH2CH2CH3), 0.88 (t, J = 7.3 
Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 156.97, 155.86, 155.66, 153.96, 
153.31, 151.35, 145.23, 136.48, 136.30, 135.54, 134.71, 134.10, 133.93, 130.80, 126.20, 121.31, 
121.00, 80.59, 78.18, 78.02, 50.19, 38.55, 32.60, 32.09, 28.91, 24.60, 24.26, 11.22, 10.91; M/z 
(MALDI-TOF) 4920.7 m/z [M+Na]+; IR v = 3326; 2973; 2930; 2874; 2358; 1704; 1596; 1520; 
1470; 1416; 1366; 1242; 1214; 1153; 1061; 1001.  
Multicalixarene (55) 
Generation 1 = 46 (1 g, 0.95 mmol), Central core = 34(170 mg, 0.2 mmol) Product = 55 (714 mg, 
71.4%) Mp >180oC (decompose). 1H NMR (400 MHz, MeOD) δ 7.78 (s, 4H, AzH), 6.96 (d, J 
= 7.5 Hz, 8H, ArH ), 6.77 (s, 16H, ArH ), 6.72 – 6.58 (m, 20H, ArH ), 5.16 (s, 8H, OCH2CCAz), 
4.41 (d, J = 13.0 Hz, 8H, ArCH2Ar), 4.35 – 4.26 (m, 16H, ArCH2Ar and OCH2CH2CH2CH2Az), 
3.85 – 3.72 (m, 32H, OCH2CH2CH3 and ArCH2Ar), 3.45 – 3.36 (m, 8H, OCH2CH2CH2CH2Az), 
3.06 (d, J = 13.0 Hz, 8H, ArCH2Ar), 2.95 (d, J = 13.0 Hz, 8H, ArCH2Ar), 2.02 – 1.85 (m, 24H, 
OCH2CH2CH3), 1.73 – 1.60 (m, 8H, OCH2CH2CH2CH2Az), 1.47 (s, 108H, OC(CH3)3), 1.43 (s, 
36H, OC(CH3)3), 1.30 – 1.19 (m, 8H, OCH2CH2CH2CH2Az), 1.03 (t, J = 7.5 Hz, 12H, 
OCH2CH2CH3), 0.92 (t, J = 7.5 Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 
158.17, 155.85, 155.62, 153.91, 153.42, 151.45, 145.26, 136.35, 135.75, 135.43, 134.66, 134.07, 
133.97, 130.83, 125.77, 123.38, 121.34, 120.96, 80.58, 78.10, 70.67, 67.34, 51.39, 39.09, 32.62, 
32.12, 28.91, 28.06, 27.89, 24.59, 24.33, 11.18, 10.97. M/z (MALDI-TOF) 5032.7 m/z 
[M+Na]+ ; IR v = 3329; 2973; 2930; 2873; 1705; 1595; 1515; 1475; 1415; 1366; 1243; 1214; 
1153; 1061; 1000. 
Multicalixarene (56) 
Generation 1 = 46 (1 g, 0.95 mmol), Central core = 35 (194 mg, 0.2 mmol) Product = 56 (759 
mg, 74.4%) Mp >179oC (decompose). 1H NMR (400 MHz, MeOD) δ 7.78 (s, 4H, AzH), 6.93 (d, 
J = 7.6 Hz, 8H, ArH), 6.80 (bs, 16H, ArH), 6.71 – 6.44 (m, 20H, ArH), 5.07 (s, 8H, 
OCH2CCAz), 4.47 – 4.35 (m, 16H, OCH2CH2CH2CH2CH2CH2Az and ArCH2Ar), 4.30 (d, J = 
13.0 Hz, 8H, ArCH2Ar), 3.77 (bs, 24H, OCH2CH2CH3), 3.65 (bs, 8H, ArCH2Ar), 3.42 – 3.35 (m, 
8H, OCH2CH2CH2CH2CH2CH2Az), 3.05 (d, J = 13.0 Hz, 8H, ArCH2Ar), 2.96 (d, J = 13.0 Hz, 
8H, ArCH2Ar), 2.05 – 1.79 (m, 32H, OCH2CH2CH3 and OCH2CH2CH2CH2CH2CH2Az), 1.47 (s, 
72H, OC(CH3)3), 1.46 (s, 36H, OC(CH3)3), 1.45 (s, 36H, OC(CH3)3), 1.39 – 1.34 (m, 8H, 
OCH2CH2CH2CH2CH2CH2Az), 1.31 – 1.25 (m, 16H, OCH2CH2CH2CH2CH2CH2Az and 
OCH2CH2CH2CH2CH2CH2Az), 1.02 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.91 (t, J = 7.5 Hz, 
24H, OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 158.07, 155.81, 155.65, 153.91, 153.30, 
151.62, 145.27, 136.28, 135.72, 135.21, 134.63, 134.13, 133.97, 130.83, 125.73, 122.87, 121.26, 
121.07, 80.58, 78.06, 72.04, 67.56, 54.80, 51.34, 38.39, 32.55, 32.13, 31.76, 30.94, 28.92, 28.89, 
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27.73, 26.65, 24.59, 24.29, 11.23, 10.98. M/z (MALDI-TOF) 5145.0 m/z [M+Na]+ ; IR v = 
3331; 2972; 2932; 1710; 1596; 1521; 1476; 1415; 1365; 1243; 1215; 1153; 1062; 1001. 
Multicalixarene (57) 
Generation 1 = 46 (1 g, 0.95 mmol), Central core = 9 (195 mg, 0.2) Product = 57 (775 mg, 
75.70%).Mp >219 oC (decompose); 1H NMR (400 MHz, MeOD) δ 8.04 (s, 4H, AzH), 6.85 (s, 
16H, ArH), 6.81 (s, 8H, ArH), 6.55 (s, 16H, ArH), 5.06 (s, 8H, OCH2CCAz), 4.94 (s, 8H, 
OCH2CH2Az), 4.43 – 4.25 (m, 24H, OCH2CH2Az and ArCH2Ar), 4.13 (d, J = 13.0 Hz, 4H, 
ArCH2Ar), 3.82 – 3.68 (m, 24H, OCH2CH2CH3), 3.15 – 3.02 (m, 12H, ArCH2Ar), 2.90 (d, J = 
13.5 Hz, 8H, ArCH2Ar), 1.96 – 1.75 (m, 24H, OCH2CH2CH3), 1.49 (s, 72H, OC(CH3)3), 1.45 (s, 
72H, OC(CH3)3), 1.07 (s, 36H, CH3CAr), 1.03 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.80 (t, J = 
7.4 Hz, 24H, OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 155.86, 155.56, 154.12, 153.75, 
153.23, 151.63, 146.71, 145.67, 136.66, 135.91, 135.38, 134.51, 134.07, 133.85, 126.69, 126.18, 
121.45, 121.35, 120.97, 80.57, 78.18, 78.01, 74.17, 67.72, 54.80, 51.52, 34.86, 32.58, 32.04, 
31.73, 28.98, 28.93, 28.85, 24.59, 24.24, 11.32, 10.91. M/z (MALDI-TOF) 5145.0 m/z 
[M+Na]+; IR v = 3329; 2973; 2930; 2873; 1712; 1595; 1524; 1475; 1415; 1366; 1243; 1214; 
1153; 1061; 1000. 
Multicalixarene (58) 
Generation 1 = 46 (1 g, 0.95 mmol), Central core = 15 (140 mg, 0.2 mmol) Product = 58 (614 
mg, 58%) Mp >186oC (decompose); 1H NMR (400 MHz, MeOD) δ 7.88 (s, 4H, AzH), 6.92 – 
6.70 (m, 24H, ArH ), 6.60 (s, 16H, ArH ), 5.00 (s, 8H, OCH2CCAz), 4.57 (bs, 8H, 
OCH2CH2CH2CH2Az), 4.39 (d, J = 13.0 Hz, 8H, ArCH2Ar), 4.33 (d, J = 12.0 Hz, 4H, 
ArCH2Ar), 4.26 (d, J = 13.0 Hz, 8H, ArCH2Ar), 3.90 (s, 8H, OCH2CH2CH2CH2Az), 3.74 (s, 
24H, OCH2CH2CH3), 3.11 – 3.00 (m, 12H, ArCH2Ar), 2.91 (d, J = 13.0 Hz, 8H, ArCH2Ar), 2.08 
(s, 16H, OCH2CH2CH2CH2Az and OCH2CH2CH2CH2Az), 1.99 – 1.90 (m, 8H, OCH2CH2CH3), 
1.90 – 1.77 (m, 16H, OCH2CH2CH3), 1.48 (s, 72H, OC(CH3)3), 1.46 (s, J = 2.9 Hz, 36H, 
OC(CH3)3), 1.44 (s, 36H, OC(CH3)3), 1.13 – 1.00 (m, 48H, (CH3 )3CAr and OCH2CH2CH3), 0.84 
(t, J = 7.5 Hz, 24H, OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 155.82, 155.58, 154.72, 
153.95, 153.32, 151.64, 145.66, 145.30, 136.33, 135.67, 134.92, 134.54, 134.07, 133.91, 126.29, 
125.91, 121.31, 121.00, 80.56, 78.14, 78.05, 75.67, 67.62, 54.80, 51.47, 34.77, 32.52, 32.12, 
28.96, 28.92, 28.86, 24.58, 24.27, 11.24, 10.93. M/z (MALDI-TOF) 5256.9 m/z [M+Na]+; IR v = 
3326; 2965; 2930; 2870; 1699; 1596; 1516; 1475; 1415; 1365; 1240; 1214; 1152; 1057; 1001. 
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Multicalixarene (59) 
Generation 1 = 46 (1 g, 0.95 mmol), 17 (230 mg, 0.2 mmol) Product = 17 (1.05 g, 93%), 
Mp >176oC (decompose); 1H NMR (400 MHz, MeOD) δ 7.61 (s, 4H, AzH), 6.75 – 6.50 (m, 
24H, ArH), 6.41 (s, 16H, ArH), 4.79 (s, 8H, OCH2CCAz), 4.29 – 4.12 (m, 20H, ArCH2Ar, and 
OCH2CH2CH2CH2CH2CH2Az), 4.08 (d, J = 12.5 Hz, 8H, ArCH2Ar), 3.69 – 3.45 (m, 32H, 
OCH2CH2CH3, OCH2CH2CH2CH2Az), 2.83 (d, J = 12.5 Hz, 12H, ArCH2Ar), 2.74 (d, J = 13 Hz, 
8H, ArCH2Ar), 1.87 – 1.54 (m, 40H, OCH2CH2CH3, OCH2CH2CH2CH2CH2CH2Az, and 
OCH2CH2CH2CH2CH2CH2Az), 1.32 – 1.17 (m, 156H, OCH2CH2CH2CH2CH2CH2Az and 
OC(CH3)3), 1.14 – 1.04 (m, 8H, OCH2CH2CH2CH2CH2CH2Az), 0.90 – 0.77 (m, 48H, CH3CAr 
and OCH2CH2CH3), 0.67 – 0.61 (m, 24H, OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 
155.85, 155.81, 155.63, 154.91, 153.94, 153.29, 151.68, 145.41, 145.27, 136.34, 135.57, 135.05, 
134.60, 134.11, 133.93, 126.16, 125.75, 121.39, 121.30, 121.07, 80.57, 78.15, 78.05, 76.19, 
67.70, 51.33, 34.76, 32.53, 32.14, 31.94, 31.53, 28.95, 27.96, 27.14, 24.60, 24.26, 11.24, 10.96. 
M/z (MALDI-TOF) 5369.1 m/z [M+Na]+ ; IR v = 3330; 2962; 1698; 2869; 1698; 1596; 1518; 
1478; 1414; 1365; 1241; 1214; 1152; 1061; 1002. 
Multicalixarene (60) 
Generation 1 = 46 (1 g, 0.95 mmol), 39 (151 mg, 0.2 mmol) Product = 60 (664 mg, 67%), Mp > 
216 oC (decompose); 1H NMR (400 MHz, MeOD) δ 7.76 (s, 4H, AzH), 7.21 (s, 8H, ArH), 6.80 
(s, 16H, ArH), 6.70 – 6.49 (m, 16H, ArH), 4.98 – 4.89 (m, 8H, OCH2CCAz), 4.69 (d, J = 13.5 
Hz, 4H, ArCH2Ar), 4.36 (d, J = 13.0 Hz, 8H, ArCH2Ar), 4.27 (d, J = 13.0 Hz, 8H, ArCH2Ar), 
4.12 – 3.99 (m, 8H, OCH2CH2CH3), 3.77 – 3.62 (m, 24H, OCH2CH2CH3), 3.53 (d, J = 13.5 Hz, 
4H, ArCH2Ar), 3.04 (d, J = 13.0 Hz, 8H, ArCH2Ar), 2.91 (d, J = 13.0 Hz, 8H, ArCH2Ar), 2.11 – 
2.00 (m, 8H, OCH2CH2CH3), 1.96 – 1.85 (m, 8H, OCH2CH2CH3), 1.83 – 1.71 (m, 16H, 
OCH2CH2CH3), 1.48 (s, 72H, OC(CH3)3), 1.45 (s, 36H, OC(CH3)3), 1.44 (s, 36H, OC(CH3)3), 
1.10 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 1.00 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.75 (t, J = 
7.0 Hz, 24H, OCH2CH2CH3).13C NMR (101 MHz, MeOD) δ 158.28, 155.83, 155.80, 155.66, 
153.96, 153.22, 151.81, 145.70, 137.60, 136.49, 135.56, 134.56, 134.02, 133.87, 133.11, 123.43, 
121.65, 121.30, 80.58, 78.63, 78.02, 67.85, 32.45, 32.14, 28.96, 28.93, 28.87, 24.52, 24.46, 
24.18, 11.31, 10.85; M/z (MALDI-TOF) 4976.7 m/z [M+Na]+ ; IR v = 3328; 2971; 2930; 2873; 
1698; 1595; 1519; 1475; 1415; 1365; 1292; 1215; 1153; 1062; 999.
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General method for the synthesis of Boc-Gly Multicalixarenes 
Generation 1 calixarene (5 eq) was added to a solution of central core (1 eq) in DMF (15 mL) in 
the presence of CuSO4·5H2O (100 mg, 0.4 mmol, 2 eq) and sodium ascorbate (316 mg, 1.6 
mmol, 8 eq). The reaction was stirred for 2 hours at 110oC. The solution was diluted with DCM 
(50 mL) and washed with H2O (2 x 50 mL) and brine (2 x 50 mL), dried over MgSO4 and 
concentrated. Purification by column chromatography over silica gel, (n-hexane:EtOAc:MeOH 
= 1:1:0.1) and precipitation from DCM/n-hexane yielded the desired compound as white solid. 
Multicalixarene (61) 
Generation 1 = 48 (1.05 g, 0.784 mmol), Central core = 10 ( 109mg, 0.156 mmol) Product = 61 
(400 mg, 44%). Mp > 250 oC (decompose) 1H NMR (400 MHz, MeOD) δ 8.10 (s, 4H, AzH), 
7.16 (s, 10H, ArH), 6.97 (s, 10H, ArH), 6.62 (s, 24H, ArH), 4.89 (s, 8H, OCH2CCAz), 4.35 (m, 
28H, ArCH2Ar and OCH2CH2Az), 3.94 – 3.59 (m, 56H, ArNHCOCH2NHCOOC(CH3)3 and 
OCH2CH2CH3), 3.20 – 2.97 (m, 20H, ArCH2Ar), 2.85 (s, 8H, OCH2CH2Az), 2.02 – 1.63 (m, 
24H, OCH2CH2CH3), 1.47 (s, 72H, OC(CH3)3), 1.45 (s, 36H, OC(CH3)3), 1.45 (s, 36H, 
OC(CH3)3), 1.03 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.87 – 0.66 (bs, 24H, OCH2CH2CH3). 13C 
NMR (101 MHz, MeOD) δ 170.12, 169.79, 158.44, 155.16, 153.90, 152.43, 145.39, 136.88, 
135.68, 135.25, 133.80, 133.44, 133.12, 129.84, 126.26, 124.13, 121.84, 80.76, 78.28, 78.00, 
73.68, 68.17, 51.46, 45.11, 32.43, 32.08, 30.72, 28.90, 24.56, 24.18, 11.32, 10.75. M/z 
(MALDI-TOF) 5832.9 m/z [M+Na]+ ; IR v = 3298; 2974; 2933; 2871; 1686; 1600; 1504; 1470; 
1418; 1391; 1366; 1245; 1220; 1163; 1049; 1003. 
Multicalixarene (62) 
Generation 1 = 48 (1.28 g, 1 mmol), Central core = 16 ( 162 mg, 0.2 mmol) Product = 
Multicalixarene 12, d-t-bu-C4-BocGly (331) (490 mg, 41% yield).Mp >226 oC (decompose). 
1H NMR (400 MHz, MeOD) δ 8.00 (s, 4H, AzH), 7.03 (s, 8H, ArH ), 7.00 (s, 8H, ArH ), 6.78 (s, 
8H, ArH ), 6.68 (s, 16H, ArH ), 4.94 (s, 8H, OCH2CCAz), 4.56 (bs, 8H, OCH2CH2CH2CH2Az), 
4.47 – 4.21 (m, 20H, ArCH2Ar), 3.95 – 3.63 (m, 64H, OCH2CH2CH2CH2Az, 
ArNHCOCH2NHCOOC(CH3)3, and OCH2CH2CH3), 3.23 – 2.77 (m, 20H, ArCH2Ar), 2.22 – 
2.00 (m, 16H OCH2CH2CH2CH2Az and OCH2CH2CH2CH2Az), 2.01 – 1.67 (m, 24H, 
OCH2CH2CH3), 1.46 (s, 108H, OC(CH3)3), 1.44 (s, 36H, OC(CH3)3), 1.11 – 0.96 (m, 48H, 
CH3CAr and OCH2CH2CH3), 0.80 (t, J = 7.3 Hz, 24H, OCH2CH2CH3). 13C NMR (101 MHz, 
MeOD) δ 170.01, 169.80, 158.46, 155.00, 154.72, 154.08, 152.62, 145.74, 145.19, 136.81, 
136.65, 136.13, 135.58, 134.93, 133.86, 133.45, 133.22, 126.33, 126.00, 121.99, 121.75, 80.76, 
78.24, 78.10, 75.70, 67.98, 54.83, 51.51, 45.09, 44.99, 44.92, 34.79, 32.49, 32.25, 32.10, 28.89, 
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24.59, 24.25, 11.28, 10.84. M/z (MALDI-TOF) 5946.0 m/z [M+Na]+; ; IR v = 3295; 2970; 
2934; 2876; 1682; 1598; 1504; 1470; 1418; 1391; 1365; 1247; 1218; 1163; 1048; 1003. 
Multicalixarene (63) 
Generation 1 = 48 (1.28 g, 1 mmol), Central core = 18 (185 mg, 0.2 mmol) Product = 63 (467 
mg, 39%); Mp >231 oC (decompose) 1H NMR (400 MHz, MeOD) δ 7.94 (s, 4H, AzH), 7.01 (s, 
8H, ArH), 6.99 (s, 8H, ArH), 6.73 (s, 8H, ArH), 6.71 (s, 8H, ArH), 6.57 – 6.45 (m, 12H, ArH), 
4.97 (s, 8H, OCH2CCAz), 4.37 (m, 28H, OCH2CH2CH2CH2CH2CH2Az and ArCH2Ar), 4.00 – 
3.60 (m, 64H, OCH2CH2CH2CH2CH2CH2Az, ArNHCOCH2NHCOOC(CH3)3 and 
OCH2CH2CH3), 3.12 – 2.90 (m, 20H, ArCH2Ar), 2.01 – 1.87 (m, 24H, OCH2CH2CH3, 
OCH2CH2CH2CH2CH2CH2Az and OCH2CH2CH2CH2CH2CH2Az), 1.87 – 1.72 (m, 16H, 
OCH2CH2CH3), 1.46 (m, 160H, 1.57 – 1.35, OC(CH3)3, OCH2CH2CH2CH2CH2CH2Az and 
OCH2CH2CH2CH2CH2CH2Az), 1.03 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.82 (t, J = 7.5 Hz, 
24H, OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 169.97, 169.85, 158.42, 157.68, 154.90, 
154.06, 152.70, 145.12, 136.78, 136.58, 136.16, 136.10, 135.53, 133.82, 133.47, 133.22, 129.38, 
125.81, 123.14, 121.86, 80.74, 78.18, 78.04, 75.91, 68.11, 51.27, 45.03, 32.49, 32.15, 31.86, 
31.41, 28.87, 27.86, 27.13, 24.57, 24.19, 11.31, 10.87. M/z (MALDI-TOF) 6058.3 m/z 
[M+Na]+ ; IR v = 3298; 2975; 2934; 2870; 1673; 1598; 1505; 1466; 1418; 1390; 1366; 1245; 
1216; 1161; 1049; 1001. 
Multicalixarene (64)  
Generation 1 = 48 (1 g, 0.784 mmol), Central core = 28 ( 109mg, 0.156 mmol) Product = 64 
(385 mg, 42.5%).Mp > 248 oC (decompose) 1H NMR (400 MHz, MeOD) δ 7.76 (s, 4H, AzH), 
7.01 (d, J = 6.5 Hz, 8H, ArH), 6.93 (s, 16H, ArH), 6.82 (s, 12H, ArH), 6.79 (s, 8H, ArH), 5.14 (s, 
8H, OCH2CCAz), 4.42 (d, J = 12.5 Hz, 8H, ArCH2Ar), 4.33 (d, J = 12.0 Hz, 8H, ArCH2Ar), 
3.98 (s, 8H, OCH2CH2Az), 3.88 – 3.66 (m, 72H, ArNHCOCH2NHCOOC(CH3)3, OCH2CH2Az 
and OCH2CH2CH3), 3.08 (d, J = 12.5 Hz, 8H, ArCH2Ar), 2.96 (d, J = 12.0 Hz, 8H, ArCH2Ar), 
2.00 – 1.79 (m, 24H, OCH2CH2CH3), 1.45 (s, 108H, OC(CH3)3), 1.43 (s, 36H, OC(CH3)3), 1.03 
(t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.88 (t, J = 6.5 Hz, 24H, OCH2CH2CH3). 13C NMR (101 
MHz, MeOD) δ 169.94, 158.41, 156.99, 154.80, 154.20, 152.51, 145.18, 136.49, 135.87, 135.47, 
133.97, 133.39, 130.83, 126.24, 124.86, 122.04, 81.50, 80.71, 78.08, 69.00, 67.51, 45.02, 38.52, 
32.57, 32.14, 28.86, 24.56, 24.28, 11.22, 10.96. M/z (MALDI-TOF) 5833.0 m/z [M+Na]+ ; IR v 
= 3301; 2974; 2932; 2871; 1673; 1600; 1504; 1470; 1417; 1392; 1366; 1246; 1220; 1163; 1050; 
1003. 
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Multicalixarene (65) 
Generation 1 = 48 (1.28 g, 1 mmol), Central core = 34 ( 162 mg, 0.2 mmol) Product = 65 (519 
mg, 43.9%).Mp > 230 oC (decompose). 1H NMR (400 MHz, MeOD) δ 7.94 (s, 4H, AzH), 6.95 
(s, 12H, ArH), 6.93 (s, 12H, ArH), 6.80 (s, 8H, ArH), 6.78 (s, 8H, ArH), 6.66 (t, J = 7 Hz, 4H, 
ArH), 5.15 (s, 8H, OCH2CCAz), 4.42 (d, J = 12.5 Hz, 8H, ArCH2Ar), 4.36 (d, J = 13.5 Hz, 8H, 
ArCH2Ar), 4.28 (s, 8H, OCH2CH2CH2CH2Az), 3.84 – 3.69 (m, 64H, 
ArNHCOCH2NHCOOC(CH3)3, ArCH2Ar and OCH2CH2CH3), 3.41 – 3.34 (m, 8H, 
OCH2CH2CH2CH2Az), 3.08 (d, J = 13.5 Hz, 8H, ArCH2Ar), 2.96 (d, J = 12.5 Hz, 8H, 
ArCH2Ar), 2.00 – 1.81 (m, 24H, OCH2CH2CH3), 1.67 (s, 8H, OCH2CH2CH2CH2Az), 1.46 (s, 
108H, OC(CH3)3), 1.45 (s, 36H, OC(CH3)3), 1.22 (s, 8H, OCH2CH2CH2CH2Az), 1.00 (t, J = 7.0 
Hz, 12H, OCH2CH2CH3), 0.89 (t, J = 7.0 Hz, 24H, OCH2CH2CH3). 13C NMR (101 MHz, 
MeOD) δ 169.94, 169.85, 163.08, 158.44, 158.16, 154.81, 154.25, 152.52, 145.15, 136.52, 
136.38, 135.86, 135.43, 133.42, 130.74, 125.83, 123.40, 121.93, 121.87, 80.73, 78.23, 78.14, 
70.71, 51.34, 45.01, 38.93, 32.54, 32.11, 28.85, 28.08, 27.85, 24.57, 24.32, 11.15, 10.94. M/z 
(MALDI-TOF) 5945.1 m/z [M+Na]+ ; IR v = 3308; 2974; 2931; 2876; 1675; 1599; 1503; 1474; 
1419; 1391; 1366; 1246; 1220; 1162; 1048; 1002. 
Multicalixarene (66) 
Generation 1 = 48 (1.28 g, 1 mmol), Central core = 35 (185 mg, 0.2 mmol) Product = 66 (639 
mg, 53.0 %) .Mp > 232 oC (decompose) 1H NMR (400 MHz, MeOD) δ 7.90 (s, 4H, AzH), 6.98 
(s, 16H, ArH ), 6.93 (d, J = 7.5 Hz, 8H, ArH ), 6.79 (s, 8H, ArH), 6.74 (s, 8H, ArH ), 6.62 (t, J = 
7.5 Hz, 4H, ArH ), 5.04 (s, 8H, OCH2CCAz), 4.46 – 4.29 (m, 24H, ArCH2Ar and 
OCH2CH2CH2CH2CH2CH2Az), 3.84 – 3.60 (m, 64H, ArCH2Ar, OCH2CH2CH3 and 
ArNHCOCH2NHCOOC(CH3)3), 3.40 – 3.32 (m, 8H, OCH2CH2CH2CH2CH2CH2Az), 3.10 – 
2.94 (m, 16H, ArCH2Ar), 1.96 – 1.79 (m, 32H, OCH2CH2CH3 and 
OCH2CH2CH2CH2CH2CH2Az), 1.46 (s, 144H, OC(CH3)3), 1.29 (m, 24H, 
OCH2CH2CH2CH2CH2CH2Az, OCH2CH2CH2CH2CH2CH2Az and 
OCH2CH2CH2CH2CH2CH2Az), 1.01 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.87 (t, J = 7.0 Hz, 
24H, OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 169.94, 158.44, 158.08, 154.83, 154.16, 
152.63, 145.12, 136.63, 136.53, 136.29, 136.24, 135.70, 135.23, 133.93, 133.49, 133.29, 130.80, 
125.78, 121.87, 121.80, 80.72, 78.11, 72.00, 67.68, 51.32, 44.99, 32.52, 32.13, 31.75, 30.94, 
27.73, 26.69, 24.59, 24.26, 11.28, 10.97. M/z (MALDI-TOF) 6057.3 m/z [M+Na]+ ; IR v = 
3299; 2973; 2931; 2872; 1683; 1598; 1506; 1464; 1418; 1390; 1366; 1245; 1220; 1163; 1048; 
1002. 
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Multicalixarene (67) 
Generation 1 = 48 (1 g, 0.784 mmol), Central core = 9 ( 145 mg, 0.156 mmol)Product = 67 (500 
mg, 53.1%); Mp >252 oC (decompose) 1H NMR (400 MHz, MeOD) δ 8.15 (s, 4H, AzH), 7.14 
(s, 8H, ArH), 6.99 (s, 8H, ArH), 6.84 (s, 8H, ArH), 6.63 (s, 16H, ArH), 4.96 (s, 8H, 
OCH2CCAz), 4.50 – 4.27 (m, 24H, ArCH2Ar and OCH2CH2Az), 4.18 (d, J = 11 Hz, 4H, 
ArCH2Ar), 3.91 – 3.66 (m, 56H, ArNHCOCH2NHCOOC(CH3)3 and OCH2CH2CH3), 3.22 – 3.01 
(m, 20H, ArCH2Ar and OCH2CH2CH3,), 2.89 (s, 8H, ArCH2Ar) 1.98 – 1.69 (m, 24H, 
OCH2CH2CH3), 1.47 (s, 72H, OC(CH3)3), 1.45 (s, 36H, OC(CH3)3), 1.45 – 1.42 (m, 36H), 1.08 
(s, 36H, OC(CH3)3), 1.02 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.75 (t, J = 6.5 Hz, 24H, 
OCH2CH2CH3). 13C NMR (101 MHz, MeOD) δ 170.08, 169.83, 158.45, 155.12, 153.92, 152.52, 
146.77, 145.46, 137.05, 136.86, 135.77, 135.30, 133.81, 133.46, 133.12, 126.72, 126.25, 122.21, 
121.96, 121.84, 80.75, 78.26, 78.02, 51.41, 49.64, 49.43, 49.21, 49.00, 48.79, 48.57, 48.36, 
45.10, 44.96, 34.86, 32.41, 32.00, 28.88, 24.56, 24.17, 11.32, 10.76. M/z (MALDI-TOF) 
6058.4 m/z [M+Na]+ ; IR v = 3311; 2965; 2928; 2870; 1682; 1599; 1504; 1470; 1418; 1391; 
1365; 1245; 1216; 1164; 1049; 1003. 
Multicalixarene (68) 
Generation 1 = 48 (1.28 g, 1 mmol), Central core = 15 (204 mg, 0.2 mmol) Product = 68 (559 
mg, 46%); Mp > 229 oC (decompose); 1H NMR (400 MHz, MeOD) δ 8.00 (s, 4H, AzH), 7.03 (s, 
8H, ArH ), 7.00 (s, 8H, ArH ), 6.78 (s, 8H, ArH ), 6.68 (s, 16H, ArH ), 4.94 (s, 8H, OCH2CCAz), 
4.56 (bs, 8H, OCH2CH2CH2CH2Az), 4.47 – 4.21 (m, 20H, ArCH2Ar), 3.95 – 3.63 (m, 64H, 
OCH2CH2CH2CH2Az, ArNHCOCH2NHCOOC(CH3)3, and OCH2CH2CH3), 3.23 – 2.77 (m, 20H, 
ArCH2Ar), 2.22 – 2.00 (m, 16H OCH2CH2CH2CH2Az and OCH2CH2CH2CH2Az), 2.01 – 1.67 
(m, 24H, OCH2CH2CH3), 1.46 (s, 108H, OC(CH3)3), 1.44 (s, 36H, OC(CH3)3), 1.11 – 0.96 (m, 
48H, CH3CAr and OCH2CH2CH3), 0.80 (t, J = 7.3 Hz, 24H, OCH2CH2CH3). 13C NMR (101 
MHz, MeOD) δ 170.01, 169.80, 158.46, 155.00, 154.72, 154.08, 152.62, 145.74, 145.19, 136.81, 
136.65, 136.13, 135.58, 134.93, 133.86, 133.45, 133.22, 126.33, 126.00, 121.99, 121.75, 80.76, 
78.24, 78.10, 75.70, 67.98, 54.83, 51.51, 45.09, 44.99, 44.92, 34.79, 32.49, 32.25, 32.10, 28.89, 
24.59, 24.25, 11.28, 10.84. M/z (MALDI-TOF) 6170.3 m/z [M+Na]+; IR v = 3299; 2965; 2932; 
2873; 1673; 1598; 1504; 1470; 1418; 1391; 1365; 1245; 1216; 1163; 1050; 1002. 
Multicalixarene (69) 
Generation 1 = 48 (1.28 g, 1 mmol), Central core = 17 ( 230 mg, 0.2 mmol) Product = 69 (467 
mg, 38.7 %); Mp >240 oC (decompose) 1H NMR (400 MHz, MeOD) δ 7.98 (s, 4H, AzH), 7.03 
(s, 16H, ArH ), 6.80 (s, 8H, ArH ), 6.75 (s, 8H, ArH ), 6.71 (s, 8H, ArH ), 4.98 (s, 8H, 
OCH2CCAz), 4.57 – 4.23 (m, 28H, ArCH2Ar and, OCH2CH2CH2CH2CH2CH2Az), 3.95 – 3.66 
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(m, 64H, ArNHCOCH2NHCOOC(CH3)3, OCH2CH2CH3, and OCH2CH2CH2CH2Az), 3.04 (m, 
20H, ArCH2Ar), 2.10 – 1.75 (m, 40H, OCH2CH2CH2CH2CH2CH2Az, 
OCH2CH2CH2CH2CH2CH2Az and OCH2CH2CH3 ), 1.48 (s, 160H, 
OCH2CH2CH2CH2CH2CH2Az, OCH2CH2CH2CH2CH2CH2Az and OC(CH3)3), 1.09 (s, 36H, 
CH3CAr), 1.05 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.83 (t, J = 6.9 Hz, 24H, OCH2CH2CH3). 
13C NMR (101 MHz, MeOD) δ 169.95, 169.82, 158.42, 154.92, 154.00, 152.65, 145.47, 145.13, 
136.80, 136.62, 136.03, 135.52, 135.03, 133.88, 133.49, 133.22, 133.20, 131.22, 130.38, 127.77, 
127.35, 126.20, 125.81, 125.79, 122.02, 121.92, 121.76, 121.71, 80.71, 78.20, 78.05, 76.19, 
68.03, 54.80, 51.32, 45.04, 34.76, 32.45, 32.12, 31.95, 31.53, 28.86, 28.00, 27.17, 24.58, 24.20, 
11.29, 10.86. M/z (MALDI-TOF) 6281.3 m/z [M+Na]+ ; IR v = 3299; 2965; 2933; 2868; 1673; 
1599; 1504; 1463; 1418; 1391; 1366; 1245; 1213; 1163; 1049; 1003. 
Multicalixarene (70) 
Generation 1 = 48 (1.28 g, 1 mmol), Central core = 10 (151 mg, 0.2 mmol) Product = 70 (400 
mg, 43%). M/z (MALDI-TOF) = 5889.3 m/z [M+Na]+. 
General method for the removal of boc protecting group from multicalixarenes 
HCl gas was bubbled through a solution of the Boc-protected multicalixarene (0.03 mmol) in 
DCM (5 ml) until the formation of precipitate was observed, after which time it was left fo react 
for a further 10 minutes to ensure the reaction went to completion. Argon was bubbled in to the 
suspension for 10 minutes to de gas the solution from the HCl. Removal of the solvent under 
reduced pressure yielded the desired compounds. 
Multicalixarene (71) 
Starting material = 51 (148 mg; 0.03 mmol). Product = 71 (quantitative). Mp > 260 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.04 (s, 4H, AzH), 6.98 (s, 16H, ArH), 6.73 (s, 8H, 
ArH), 6.71 (s, 8H, ArH), 6.60 – 6.46 (m, 12H, ArH), 5.16 – 5.01 (m, 16H, OCH2CCAz and 
OCH2CH2Az), 4.62 – 4.47 (m, 16H, OCH2CH2Az and ArCH2Ar), 4.43 (d, J = 13.5 Hz, 8H, 
ArCH2Ar), 4.15 (d, J = 13.0 Hz, 4H, ArCH2Ar), 3.95 – 3.82 (m, 24H), 3.38 – 3.32 (m, 8H, 
ArCH2Ar ), 3.25 (d, J =13.5 Hz, 8H, ArCH2Ar), 3.06 (d, J = 13.0 Hz, 4H, ArCH2Ar), 2.02 – 
1.79 (m, 24H, OCH2CH2CH3), 1.07 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.89 (t, J = 7.5 Hz, 24H, 
OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 158.27, 157.52, 156.68, 155.87, 144.66, 138.01, 
137.92, 137.68, 137.16, 135.49, 129.79, 126.50, 126.21, 126.02, 125.90, 124.61, 124.35, 124.19, 
124.03, 78.62, 78.51, 74.03, 67.78, 51.96, 31.97, 31.56, 24.52, 24.29, 11.06, 10.73. M/z 
(MALDI-TOF) = 3318.9 m/z [M-16HCl+Na]+. IR v = 3392; 2873; 2593; 1583; 1525; 1465; 
1386; 1213; 1147; 1091; 1038; 1000. 
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Multicalixarene (72) 
Starting material = 52 (150 mg; 0.03 mmol). Product = 72 (quantitative). Mp > 245 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.09 (s, 4H, AzH), 6.98 (d, J = 7.5 Hz, 8H, ArH), 
6.87 (s, 16H, ArH), 6.68 (t, J = 7.5 Hz, 4H, ArH), 6.64 (s, 8H, ArH), 6.62 (s, 8H, ArH), 5.17 (s, 
8H, OCH2CCAz), 4.51 (d, J = 13.5 Hz, 8H, ArCH2Ar), 4.47 (d, J = 13.5 Hz, 8H, ArCH2Ar), 
4.38 (t, J = 7.0Hz, 8H, OCH2CH2CH2CH2Az ), 3.89 (t, J = 7.5 Hz, 24H, OCH2CH2CH3), 3.76 (s, 
8H, ArCH2Ar), 3.42 (t, J = 6.5 Hz, 8H, OCH2CH2CH2CH2Az), 3.24 (d, J = 13.5 Hz, 8H, 
ArCH2Ar), 2.00 – 1.84 (m, 24H, OCH2CH2CH3), 1.82 – 1.74 (m, 8H, OCH2CH2CH2CH2Az), 
1.36 – 1.26 (m, 8H, OCH2CH2CH2CH2Az), 1.05 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.92 (t, J = 
7.5 Hz, 24H, OCH2CH2CH3).13C NMR (101 MHz, MeOD) δ 158.27, 158.07, 157.67, 155.95, 
144.42, 137.92, 137.31, 135.45, 130.84, 126.43, 126.09, 125.96, 125.88, 124.56, 124.36, 124.25, 
123.31, 78.66, 78.58, 70.91, 67.61, 51.45, 38.68, 32.01, 31.59, 28.02, 27.88, 24.55, 24.30, 10.95, 
10.68; M/z (MALDI-TOF) = 3430.9m/z [M-16HCl+Na]+. IR v = 3393; 2872; 2598; 1583; 
1524; 1463; 1386; 1214; 1147; 1093; 1038; 1000. 
Multicalixarene (73) 
Starting material = 53 (153 mg; 0.03 mmol). Product = 73 (quantitative). Mp > 239 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.11 (s, 4H, AzH), 7.00 (s, 16H, ArH), 6.73 (s, 8H, 
ArH), 6.69 (s, 8H, ArH), 6.60 – 6.41 (m, 12H, ArH), 5.09 (s, 8H, OCH2CCAz), 4.57 – 4.43 (m, 
22H, ArCH2Ar and OCH2CH2CH2CH2CH2CH2Az), 4.39 (d, J = 13.0 Hz, 4H, ArCH2Ar), 4.02 – 
3.74 (m, 32H, OCH2CH2CH3 and OCH2CH2CH2CH2CH2CH2Az), 3.41 – 3.22 (m, 16H, 
ArCH2Ar (detected by COSY)), 3.09 (d, J = 13.0 Hz, 4H, ArCH2Ar), 2.07 – 1.79 (m, 40H, 
OCH2CH2CH3, OCH2CH2CH2CH2CH2CH2Az and OCH2CH2CH2CH2CH2CH2Az), 1.59 – 1.38 
(m, 16H, OCH2CH2CH2CH2CH2CH2Az and OCH2CH2CH2CH2CH2CH2Az), 1.08 (t, J = 7.50 Hz, 
12H, OCH2CH2CH3), 0.88 (bs, 24H, OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 158.35, 
157.64, 157.53, 156.05, 138.05, 137.98, 137.68, 137.12, 136.13, 129.33, 126.34, 125.94, 125.78, 
124.73, 124.47, 124.22, 123.08, 78.68, 75.90, 68.24, 32.14, 31.60, 27.93, 27.16, 24.60, 24.36, 
11.17, 10.88.M/z (MALDI-TOF) = 3543.0 m/z [M-16HCl+Na]+; IR v = 3390; 2870; 2600; 
1583; 1524; 1464; 1386; 1215; 1147; 1089; 1038; 1000. 
Multicalixarene (74) 
Starting material = 54 (148 mg; 0.03 mmol). Product = 74 (quantitative). Mp > 248 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.13 (s, 4H, AzH), 7.08 (d, J = 7.2 Hz, 8H, ArH), 
6.97 (s, 16H, ArH), 6.89 (t, J = 7.0 Hz, 4H, ArH), 6.73 (s, 8H, ArH), 6.70 (s, 8H, ArH), 5.17 (s, 
8H, OCH2CCAz), 4.53 (d, J = 13.0 Hz, 8H, ArCH2Ar), 4.50 (d, J = 13.0 Hz, 8H, ArCH2Ar), 
4.18 (t, J = 6.0 Hz, 8H, OCH2CH2Az), 3.98 – 3.83 (m, 32H, ArCH2Ar and OCH2CH2CH3), 3.74 
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(t, J = 6.0 Hz, 8H, OCH2CH2Az), 3.40 – 3.25 (m, 16H, ArCH2Ar), 2.01 – 1.83 (m, 24H, 
OCH2CH2CH3), 1.07 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.88 (t, J = 7.5 Hz, 24H, 
OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 158.33, 157.58, 156.99, 155.96, 144.57, 138.03, 
137.98, 137.74, 137.19, 135.72, 131.11, 126.58, 126.47, 126.00, 125.87, 124.61, 124.36, 124.20, 
78.67, 78.53, 69.45, 67.69, 50.57, 38.31, 32.00, 31.58, 24.55, 24.26, 10.99, 10.63..M/z 
(MALDI-TOF) = 1099.6 m/z [M-16HCl+4H]4+. IR v = 3405; 2873; 2602; 1584; 1530; 1466; 
1386; 1217; 1147; 1096; 1041; 1000. 
Multicalixarene (75) 
Starting material = 55 (148 mg; 0.03 mmol). Product = 75 (quantitative). Mp > 245 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.09 (s, 4H, AzH), 6.98 (d, J = 7.5 Hz, 8H, ArH), 
6.87 (s, 16H, ArH), 6.68 (t, J = 7.5 Hz, 4H, ArH), 6.64 (s, 8H, ArH), 6.62 (s, 8H, ArH), 5.17 (s, 
8H, OCH2CCAz), 4.51 (d, J = 13.5 Hz, 8H, ArCH2Ar), 4.47 (d, J = 13.5 Hz, 8H, ArCH2Ar), 
4.38 (t, J = 7.0Hz, 8H, OCH2CH2CH2CH2Az ), 3.89 (t, J = 7.5 Hz, 24H, OCH2CH2CH3), 3.76 (s, 
8H, ArCH2Ar), 3.42 (t, J = 6.5 Hz, 8H, OCH2CH2CH2CH2Az), 3.24 (d, J = 13.5 Hz, 8H, 
ArCH2Ar), 2.00 – 1.84 (m, 24H, OCH2CH2CH3), 1.82 – 1.74 (m, 8H, OCH2CH2CH2CH2Az), 
1.36 – 1.26 (m, 8H, OCH2CH2CH2CH2Az), 1.05 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.92 (t, J = 
7.5 Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 158.27, 158.07, 157.67, 155.95, 
144.42, 137.92, 137.31, 135.45, 130.84, 126.43, 126.09, 125.96, 125.88, 124.56, 124.36, 124.25, 
123.31, 78.66, 78.58, 70.91, 67.61, 51.45, 38.68, 32.01, 31.59, 28.02, 27.88, 24.55, 24.30, 10.95, 
10.68.M/z (MALDI-TOF) = 3430.9 m/z [M-16HCl+Na]+. IR v = 3393; 2872; 2598; 1583; 
1524; 1463; 1386; 1214; 1147; 1093; 1038; 1000. 
Multicalixarene (76) 
Starting material = 56 (148 mg; 0.03 mmol). Product = 76 (quantitative). Mp > 245 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.09 (s, 4H, AzH), 6.98 (d, J = 7.5 Hz, 8H, ArH), 
6.87 (s, 16H, ArH), 6.68 (t, J = 7.5 Hz, 4H, ArH), 6.64 (s, 8H, ArH), 6.62 (s, 8H, ArH), 5.17 (s, 
8H, OCH2CCAz), 4.51 (d, J = 13.5 Hz, 8H, ArCH2Ar), 4.47 (d, J = 13.5 Hz, 8H, ArCH2Ar), 
4.38 (t, J = 7.0Hz, 8H, OCH2CH2CH2CH2Az ), 3.89 (t, J = 7.5 Hz, 24H, OCH2CH2CH3), 3.76 (s, 
8H, ArCH2Ar), 3.42 (t, J = 6.5 Hz, 8H, OCH2CH2CH2CH2Az), 3.24 (d, J = 13.5 Hz, 8H, 
ArCH2Ar), 2.00 – 1.84 (m, 24H, OCH2CH2CH3), 1.82 – 1.74 (m, 8H, OCH2CH2CH2CH2Az), 
1.36 – 1.26 (m, 8H, OCH2CH2CH2CH2Az), 1.05 (t, J = 7.5 Hz, 12H, OCH2CH2CH3), 0.92 (t, J = 
7.5 Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 158.27, 158.07, 157.67, 155.95, 
144.42, 137.92, 137.31, 135.45, 130.84, 126.43, 126.09, 125.96, 125.88, 124.56, 124.36, 124.25, 
123.31, 78.66, 78.58, 70.91, 67.61, 51.45, 38.68, 32.01, 31.59, 28.02, 27.88, 24.55, 24.30, 10.95, 
10.68.M/z (MALDI-TOF) = 3430.9 m/z [M-16HCl+Na]+. IR v = 3393; 2872; 2598; 1583; 
1524; 1463; 1386; 1214; 1147; 1093; 1038; 1000. 
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Multicalixarene (77) 
Starting material = 57 (153 mg; 0.03 mmol). Product = 77 (quantitative). Mp > 258 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.16 (s, 4H, AzH), 6.95 (s, 16H, ArH), 6.81 (s, 8H, 
ArH), 6.70 (s, 8H, ArH), 6.69 (s, 8H, ArH), 5.16 (t, J = 6.0 Hz, 8H, OCH2CH2Az), 5.11 (s, 8H, 
OCH2CCAz), 4.54 – 4.47 (m, 16H, OCH2CH2Az and ArCH2Ar), 4.47 – 4.40 (m, J = 13.5 Hz, 
8H, ArCH2Ar), 4.20 – 4.13 (m, J = 13.0 Hz, 4H, ArCH2Ar), 3.93 – 3.82 (m, 24H, 
OCH2CH2CH3), 3.37 – 3.29 (m, 8H ArCH2Ar), 3.27 – 3.20 (m, J = 13.5 Hz, 8H, ArCH2Ar), 
3.12 – 3.05 (d, J = 13.0 Hz, 4H, ArCH2Ar), 2.00 – 1.91 (m, 8H, OCH2CH2CH3), 1.88 – 1.79 (m, 
16H, OCH2CH2CH3), 1.10 – 1.01 (m, 48H, CH3CAr and OCH2CH2CH3), 0.89 – 0.81 (m, J = 7.5 
Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 158.27, 157.53, 155.86, 153.81, 
146.82, 137.99, 137.86, 137.70, 137.17, 134.50, 126.67, 126.00, 125.88, 124.65, 124.42, 124.22, 
78.61, 78.53, 74.13, 67.85, 51.79, 34.83, 31.94, 31.56, 24.53, 24.29, 11.10, 10.77;.M/z 
(MALDI-TOF) = 881.0136 m/z [M-16HCl+4H]4+. IR v = 3388; 2871; 2596; 1582; 1519; 1463; 
1385; 1217; 1146; 1125; 1039; 999.
 
Multicalixarene (80) 
Starting material = 60 (148 mg; 0.03 mmol). Product = 80 (quantitative). Mp > 226 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.21 (s, 4H, AzH), 7.30 (s, 8H, ArH), 7.02 – 6.94 
(m, 16H, ArH), 6.74 (s, 8H, ArH), 6.68 (s, 8H, ArH), 5.08 (s, 8H, OCH2CCAz), 4.68 (d, J = 
13.5 Hz, 4H, ArCH2Ar), 4.51 (d, J = 13.5 Hz, 8H, ArCH2Ar), 4.42 (d, J = 13.5 Hz, 8H, 
ArCH2Ar), 4.05 (t, J = 7.0 Hz, 8H, OCH2CH2CH3), 3.90 – 3.79 (m, 24H, OCH2CH2CH3), 3.53 
(d, J = 13.5 Hz, 4H, ArCH2Ar), 3.37 – 3.28 (m, 8H, ArCH2Ar), 3.24 (d, J = 13.5 Hz, 8H, 
ArCH2Ar), 2.06 – 1.91 (m, 16H, OCH2CH2CH3), 1.85 – 1.76 (m, 16H, OCH2CH2CH3), 1.12 – 
1.04 (m, 24H, OCH2CH2CH3), 0.79 (t, J = 7.5 Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, 
MeOD) δ 158.38, 158.28, 157.46, 156.00, 144.88, 138.04, 137.89, 137.76, 137.62, 137.12, 
132.87, 126.36, 125.93, 125.76, 124.65, 124.46, 124.19, 123.92, 121.19, 78.65, 78.51, 68.10, 
32.10, 31.91, 31.55, 26.12, 24.49, 24.44, 24.20, 11.08, 10.75, 10.49;.M/z (MALDI-TOF) = 
838.9640 m/z [M-16HCl+4H]4+. 
 
Multicalixarene (81) 
Starting material = 61 (174 mg; 0.03 mmol). Product = 81 (quantitative). Mp > 250 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.16 (s, 4H, AzH), 6.95 (s, 16H, ArH), 6.81 (s, 8H, 
ArH), 6.70 (s, 8H, ArH), 6.69 (s, 8H, ArH), 5.16 (t, J = 6.0 Hz, 8H, OCH2CH2Az), 5.11 (s, 8H, 
OCH2CCAz), 4.54 – 4.47 (m, 16H, OCH2CH2Az and ArCH2Ar), 4.47 – 4.40 (m, J = 13.5 Hz, 
8H, ArCH2Ar), 4.20 – 4.13 (m, J = 13.0 Hz, 4H, ArCH2Ar), 3.93 – 3.82 (m, 24H, 
OCH2CH2CH3), 3.37 – 3.29 (m, 8H ArCH2Ar), 3.27 – 3.20 (m, J = 13.5 Hz, 8H, ArCH2Ar), 
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3.12 – 3.05 (d, J = 13.0 Hz, 4H, ArCH2Ar), 2.00 – 1.91 (m, 8H, OCH2CH2CH3), 1.88 – 1.79 (m, 
16H, OCH2CH2CH3), 1.10 – 1.01 (m, 48H, CH3CAr and OCH2CH2CH3), 0.89 – 0.81 (m, J = 7.5 
Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, MeOD) δ 158.27, 157.53, 155.86, 153.81, 
146.82, 137.99, 137.86, 137.70, 137.17, 134.50, 126.67, 126.00, 125.88, 124.65, 124.42, 124.22, 
78.61, 78.53, 74.13, 67.85, 51.79, 34.83, 31.94, 31.56, 24.53, 24.29, 11.10, 10.77;.M/z 
(MALDI-TOF) = 4209.2 m/z [M-16HCl+1H] +. IR v = 3410; 2956; 2865; 1686; 1601; 1562; 
1474; 1385; 1216; 1147; 1125; 1042; 1002. 
Multicalixarene (82) 
Starting material = 62 (178 mg; 0.03 mmol). Product = 82 (quantitative). Mp > 250 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.17 (s, 4H, AzH), 7.17 (s, 8H, ArH), 7.08 (s, 8H, 
ArH), 6.77 (s, 16H, ArH), 6.71 (s, 8H, ArH), 4.85 (s, 8H, OCH2CCAz (detected by HSQC)), 
4.61 (s, 8H, OCH2CH2CH2CH2Az), 4.45 – 4.27 (m, 20H, ArCH2Ar), 3.97 – 3.71 (m, 64H, 
OCH2CH2CH3, ArNHCOCH2NH3+Cl-and OCH2CH2CH2CH2Az), 3.16 – 3.03 (m, 20H, 
ArCH2Ar), 2.13 (s, 16H, OCH2CH2CH2CH2Az and OCH2CH2CH2CH2Az), 1.95 – 1.77 (m, 24H, 
OCH2CH2CH3), 1.14 – 0.96 (m, 48H, CH3CAr and OCH2CH2CH3), 0.77 (t, J = 7.4 Hz, 24H, 
OCH2CH2CH3); 13C NMR (101 MHz, DMSO) δ 163.93, 163.85, 152.98, 152.07, 151.14, 142.99, 
135.07, 135.03, 134.04, 133.61, 132.39, 132.31, 131.82, 119.46, 76.59, 76.12, 40.71, 33.45, 
31.11, 30.71, 27.01, 26.88, 22.79, 22.27, 10.40, 9.64; M/z (MALDI-TOF) = 1137.3785 m/z 
[M-15HCl+3H] 3+. IR v = 3403; 2960; 2878; 1683; 1603; 1559; 1468; 1381; 1220; 1147; 1123; 
1044; 1003. 
Multicalixarene (83) 
Starting material = 63 (178 mg; 0.03 mmol). Product = 83 (quantitative). Mp > 215 oC 
(decompose); M/z (MALDI-TOF) = 1109.0994 m/z [M-16HCl+4H] 4+. IR v = 3403; 2958; 
2872; 1683; 1603; 1559; 1468; 1381; 1220; 1147; 1123; 1044; 1003. IR v = 3410; 2960; 2878; 
1682; 1601; 1561; 1470; 1385; 1218; 1147; 1123; 1045; 1003. 
Multicalixarene 34 (84) 
Starting material = 64 (174 mg; 0.03 mmol). Product = 84 (quantitative). Mp > 220 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 7.96 (s, 4H, AzH), 7.09 – 6.98 (m, 24H, ArH), 
6.90 – 6.79 (m, 20H, ArH), 5.11 (s, Hz, 8H, OCH2CCAz), 4.49 – 4.41 (m, 16H, ArCH2Ar), 4.07 
(s, 8H, OCH2CH2Az), 3.90 – 3.75 (m, 72H, ArCH2Ar, OCH2CH2CH3, ArNHCOCH2NH3+Cl- 
and OCH2CH2Az), 3.16 – 3.09 (m, 16H, ArCH2Ar), 2.10 – 1.74 (m, 24H, OCH2CH2CH3), 1.05 
(t, J = 7.3 Hz, 12H, OCH2CH2CH3), 0.87 (t, J = 7.2 Hz, 24H), 0.87 (t, J = 7.2 Hz, 24H, 
OCH2CH2CH3).13C NMR (101 MHz, DMSO) δ 163.94, 163.87, 155.27, 152.91, 152.23, 151.11, 
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143.09, 134.84, 134.37, 133.75, 132.39, 132.31, 131.99, 129.28, 124.73, 122.61, 119.48, 76.24, 
40.69, 40.58, 31.11, 30.83, 22.79, 22.36, 22.36, 10.35, 10.35, 9.79. M/z (MALDI-TOF) = 
4209.0 m/z [M-16HCl+H] +. IR v = 3332; 2961; 2943; 2865; 1683; 1602; 1557; 1466; 1386; 
1215; 1147; 1042; 1002. 
Multicalixarene (85) 
Starting material = 66 (178 mg; 0.03 mmol). Product = 86 (quantitative). Mp > 262 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.05 (s, 4H, AzH), 7.05 (s, 8H, ArH ), 7.03 (s, 8H, 
ArH), 6.96 (d, J = 7.0 Hz, 8H, ArH), 6.85 (s, 8H, ArH), 6.82 (s, 8H, ArH), 6.69 (t, J = 7.0 Hz, 
4H, ArH), 5.13 (s, 8H, OCH2CCAz), 4.50 – 4.39 (m, 16H, ArCH2Ar), 4.35 (s, 8H, 
OCH2CH2CH2CH2Az), 3.90 – 3.71 (m, 64H, ArNHCOCH2NH3+Cl-, OCH2CH2CH3 and 
ArCH2Ar), 3.39 (s, 8H, OCH2CH2CH2CH2Az), 3.14 (d, J = 12.5 Hz, 8H, ArCH2Ar), 3.10 (d, J = 
12.5 Hz, 8H ArCH2Ar), 1.99 – 1.83 (m, 24H, OCH2CH2CH3), 1.79 – 1.70 (m, 8H, 
OCH2CH2CH2CH2Az), 1.32 – 1.26 (m, 8H, OCH2CH2CH2CH2Az), 1.03 (t, J = 7.5 Hz, 12H, 
OCH2CH2CH3), 0.89 (t, J = 7.5 Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, DMSO) δ 
163.92, 156.37, 152.83, 152.30, 151.03, 142.93, 134.71, 134.58, 134.03, 133.63, 132.41, 132.26, 
132.01, 129.34, 124.30, 119.48, 76.52, 76.28, 69.44, 66.29, 49.15, 40.66, 40.15, 39.94, 39.73, 
39.52, 39.31, 39.10, 38.89, 31.20, 30.80, 26.28, 26.14, 22.78, 22.41, 10.29, 9.92, 9.92; M/z 
(MALDI-TOF) = 4321.4 m/z [M-16HCl+H] +. IR v = 3338; 3975; 2929; 2872; 1681; 1601; 
1465; 1385; 1220; 1147; 1044; 1002. 
Multicalixarene (86) 
Starting material = 65 (181 mg; 0.03 mmol). Product = 85 (quantitative). Mp > 260 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.04 (s, 4H, AzH), 7.09 (s, 8H, ArH), 7.07 (s, 8H, 
ArH), 6.97 (d, J = 7.00 Hz, 8H, ArH), 6.90 – 6.80 (m, 8H, ArH), 6.77 (s, 8H, ArH), 6.66 (t, J = 
7.0 Hz, 4H, ArH), 5.04 (s, 8H, OCH2CCAz), 4.62 – 4.36 (m, 24H, ArCH2Ar and 
OCH2CH2CH2CH2CH2CH2Az), 3.96 – 3.71 (m, 56H, OCH2CH2CH3 and ArNHCOCH2NH3+Cl- ), 
3.68 (s, 8H, ArCH2Ar), 3.40 (s, 8H, OCH2CH2CH2CH2CH2CH2Az), 3.13 (d, J = 12.0 Hz, 8H, 
ArCH2Ar), 3.10 (d, J = 12.0 Hz, 8H, ArCH2Ar), 2.04 – 1.73 (m, 32H, OCH2CH2CH2-
CH2CH2CH2Az and OCH2CH2CH3), 1.46 – 1.19 (m, 32H, OCH2CH2CH2CH2CH2CH2Az, OCH2-
CH2CH2CH2CH2CH2Az and OCH2CH2CH2CH2CH2CH2Az), 1.04 (t, J = 7.5 Hz, 12H, 
OCH2CH2CH3), 0.88 (t, J = 7.5 Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, DMSO) δ 
163.93, 163.86, 156.38, 152.91, 152.19, 151.10, 142.90, 134.89, 134.34, 133.82, 133.52, 132.31, 
131.92, 129.29, 124.26, 119.46, 76.53, 76.19, 49.24, 40.70, 40.59, 30.82, 30.06, 29.03, 25.94, 
24.80, 22.79, 22.34, 10.34, 9.85; M/z (MALDI-TOF) = 4433.5 m/z [M-16HCl+H] +. IR v = 
3423; 3059; 2930; 2872; 1673; 1601; 1556; 1470; 1385; 1215; 1145; 1043; 1002.
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Multicalixarene (87) 
Starting material = 67 (181 mg; 0.03 mmol). Product = 87 (quantitative). Mp > 268 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.38 (s, 4H, AzH), 7.26 (s, 8H, ArH), 7.12 (s, 8H, 
ArH), 6.88 (s, 8H, ArH), 6.71 (s, 8H, ArH), 6.67 (s, 8H, ArH), 5.07 (s, 8H, OCH2CCAz), 4.51 – 
4.33 (m, 24H, ArCH2Ar and OCH2CH2Az), 4.16 (d, J = 12.7 Hz, 4H, ArCH2Ar), 4.00 – 3.70 (m, 
64H, OCH2CH2CH3, ArNHCOCH2NH3+Cl-, OCH2CH2Az), 3.22 – 3.04 (m, 20H, ArCH2Ar), 
1.92 – 1.74 (m, 24H, OCH2CH2CH3), 1.11 (s, 36H, CH3CAr), 1.05 (t, J = 7.5 Hz, 12H, 
OCH2CH2CH3), 0.74 (t, J = 7.5 Hz, 24H, OCH2CH2CH3); 13C NMR (101 MHz, DMSO) δ 
163.95, 163.88, 152.97, 152.07, 151.06, 144.64, 143.36, 135.05, 134.04, 133.62, 132.40, 131.82, 
125.06, 124.47, 119.55, 76.58, 76.13, 54.94, 40.75, 33.52, 31.02, 22.78, 22.28, 10.41, 9.62; M/z 
(MALDI-TOF) = 4433.8 m/z [M-16HCl+H] +. IR v = 3338; 3975; 2929; 2872; 1681; 1601; 
1465; 1385; 1220; 1147; 1044; 1002. 
Multicalixarene (88) 
Starting material = 68 (184 mg; 0.03 mmol). Product = 86 (quantitative). Mp > 248 oC 
(decompose); 1H NMR (400 MHz, MeOD) δ 8.17 (s, 4H, AzH), 7.17 (s, 8H, ArH), 7.08 (s, 8H, 
ArH), 6.77 (s, 16H, ArH), 6.71 (s, 8H, ArH), 4.85 (s, 8H, OCH2CCAz (detected by HSQC)), 
4.61 (s, 8H, OCH2CH2CH2CH2Az), 4.45 – 4.27 (m, 20H, ArCH2Ar), 3.97 – 3.71 (m, 64H, 
OCH2CH2CH3, ArNHCOCH2NH3+Cl-and OCH2CH2CH2CH2Az), 3.16 – 3.03 (m, 20H, 
ArCH2Ar), 2.13 (s, 16H, OCH2CH2CH2CH2Az and OCH2CH2CH2CH2Az), 1.95 – 1.77 (m, 24H, 
OCH2CH2CH3), 1.14 – 0.96 (m, 48H, CH3CAr and OCH2CH2CH3), 0.77 (t, J = 7.4 Hz, 24H, 
OCH2CH2CH3): 13C NMR (101 MHz, DMSO) δ 163.93, 163.85, 152.98, 152.07, 151.14, 142.99, 
135.07, 135.03, 134.04, 133.61, 132.39, 132.31, 131.82, 119.46, 76.59, 76.12, 40.71, 33.45, 
31.11, 30.71, 27.01, 26.88, 22.79, 22.27, 10.40, 9.64; M/z (MALDI-TOF) = 1515.8352 m/z [M-
15HCl+3H] 3+. IR v = 3403; 2960; 2872; 1683; 1603; 1559; 1468; 1247; 1220; 1147; 1044; 1003. 
Multicalixarene (90) 
Calixarene 48 (1.27 g, 1 mmol) was added to a solution of 39 (151 mg, o.2 mmol ) in DMF (15 
mL) in the presence of CuSO4·5H2O (100 mg, 0.4 mmol,) and sodium ascorbate (316 mg, 1.6 
mmol). The reaction was stirred for 2 hours at 110oC. The solution was diluted with DCM (50 
mL) and washed with H2O (2 x 50 mL) and brine (2 x 50 mL), dried over MgSO4 and 
concentrated. Purification by column chromatography over silica gel, (n-hexane:EtOAc:MeOH 
= 1:1:0.1) and precipitation from DCM/n-hexane yielded compound 70 as a white solid (M/z 
(MALDI-TOF) = 5889.3 m/z [M+H] +).  
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Chapter 2. Calixarene glycoconjugates 
2.1 Introduction  
Interactions between proteins on the cell surface and carbohydrates are involved in a multitude 
of biological processes such as various intercellular communications, transduction events and 
adhesion of bacteria and viruses to cell surface.1 These interactions are normally very weak, 
showing association constants (Kd) around 106 M-1 for monosaccharides. Nevertheless these 
interactions can be strong and specific when a set of multivalent saccharides are joined together 
with the appropriate spatial disposition. The enhancement interaction is higher than explainable 
with an increased concentration of monovalent saccharides and is called the “cluster effect”.2 
This phenomenon makes glyco-clusters important biological tools to target proteins and their 
functions. The synthesis of multivalent saccharides has been the focus of many studies in recent 
years. Rigid molecules such as cyclodextrins, resorcinarenes and calixarenes have been used as 
backbone to anchor a number of sugar molecules.3  
The first example of calix[4]arenes glycoconjugates was described in 1994 by Dondoni et al. 
Calixarene 2 was reacted with tetra-O-acetyl-α,β-D-glucopyranose 91 under Mitsunobu 
conditions. This first attempt gave a mixture of both the α,β and the α,α-biglucoside (92 and 93) 
which were isolated in modest yields (scheme 2.1).4  
 
Scheme 2.1 First example of glycoconjugates. 
In later work5 the conditions were improved by the authors and the narrow rim of calixarene 2 
was successfully embroidered with the configurationally stable α-D-mannofuranose diacetonide 
94 to yield the the calixarene mannosides 95 and 96 (scheme 2.2). 
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Scheme 2.2: Synthesis of calixarene mannosides  
In the same publication the authors described also the synthesis of calixarenes glycosylated on 
the wide rim5. A bishydroxymethyl-substituted calix[4]arene 100 was obtained through selective 
formylation of the diametrical positions of 1,3-dipropoxycalixarene 97.6 The compound was 
oxidised to the diacid analogue 99 before alkylation of the last two free phenolic oxygens and 
consequent lock in the cone conformation. Reduction with borane (BH3) in THF gave the 
desired bis-alcohol . (scheme 2.3).  
 
Scheme 2.3: Synthesis of bis alcohol functionalised calixarene. 
The oxygens on the upper rim were then successfully coupled with 2.6 equivalents of ethyl tetra-
O-benzoyl-1-thio-β-D-galactoside 101 in the presence of copper (II) triflate (Cu(OTf)2) in 
acetonitrile at room temperature to yield after deprotection the di-glycoside 102 in 65% yield 
(scheme 2.4) .5  
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Scheme 2.4: Synthesis of Bis-Galactose Glycoconjugate  
With a similar strategy they synthesised the first tetra-O-galactosyl calix[4]arene 106, using as a 
building block the tetrahydroxymethyl substituted calix[4]arene 105. This compound was 
obtained via Duff formylation of tetrapropoxycalix[4]arene and subsequent reduction to the 
tetra-alcohol (scheme 2.5).  
 
Scheme 2.5: Tetra hydroxymethyl functionalisation of the upper rim of Calixarene 
Compound 105 was then coupled with six equivalents of the galactoside 101 to yield the desired 
compound (65%) (Scheme 2.6). 
 
 
Scheme 2.6 Synthesis of the first tetravalent calix[4]arene glycoconjugate 
The good results obtained with this approach encouraged the authors towards the use of a di-
glycoside thioethyl heptabenzoyl-β-D-lactoside 107. The reaction afforded the desired 
compound 108 in low yield when the bishydroxymethyl-substituted calix[4]arene 100 was used 
as a starting material (scheme 2.7).  
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Scheme 2.7: Di-lactoside calixarene glycoconjugate 
The tetra-substituted compound was not isolated when 105 was reacted with six equivalents of 
the di-glycoside 107. Interestingly the only product of this reaction was 11, the ether-bridged 
calixarene deriving from the acid-catalyzed intramolecular coupling of two distal 
hydroxymethyl groups (figure 2.1). Similar ether bridged structures such as 109 and 110 where 
isolated as side products also in the synthesis of 102 and 106.  
 
Figure 2.1: Ether bridged side product obtained by Dondoni et al. 
The formation of the ether-bridged side products was overcome a few years later in another 
paper from the same authors. The introduction of a longer spacer chain between the alcoholic 
oxygens and the phenyl rings on the wide rim, allowed the synthesis, in good yields, of the bis- 
and tetra- calixarene glycoconjugates. 
The bis-alcohol derivative was synthesised starting from calix[4]arene 2, which can be alkylated 
with two equivalents of allyl bromide in the presence of K2CO3 to give 112. This compound can 
undergo Claisen rearrangement to yield a calixarene with the two allyl groups on the wide rim.7 
At this stage the conformation was locked by alkylating the phenolic oxygens with iodopropane 
in the presence of NaH to give compound 113. The allyl groups were converted to alcohols 
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through hydroboration/oxidation to give the bis-alcohol derivative 114, which was glycosylated 
to give, after deprotection of the sugar moieties, compound 115 (scheme 2.8).  
 
Scheme 2.8: Synthesis of bis-glycoconjugate with three carbon atom spacer. 
The use of NaH as a base and an excess of alkylating agent in the first synthetic step led to the 
formation of the tetra-allyl derivative 116,8 which can undergo the same set of reactions 
described above to give the tetra-alcohol derivative and was successfully coupled with the 
glycoside to yield the glucoconjugate 117 (scheme 2.9). 
 
Scheme 2.9: Synthesis of tetra glycoconjugate with three carbon atom spacer 
Linkage of sugars and calix[4]arenes through amide bond formation was first explored by Roy 
and Kim.9 Their approach was successful toward the synthesis of water soluble glyco-
calix[4]arene dendrimers. The synthethic strategy followed was to attach α-Galacto-acetyl-
amine (α -GalNAc) derivative 120 to a tetra acyl chloride calix[4]arene central core 118 through 
an amide bond. The central core was synthesised starting from p-tert-butyl calix[4]arene 1. In 
the first step 1 was O-alkylated with ethyl bromoacetate in the presence of K2CO3. Subsequent 
base hydrolysis yielded the tetra-acid derivative which could be transformed to the acyl chloride 
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derivative 118 upon treatment with thionyl chloride. Coupling of 118 with the 
acetylgalactosamino derivative 120 yielded the glycoconjugate 119 (scheme 2.10).  
 
Scheme 2.10: Amide linked glycoconjugate 
The synthesis of glycocalixarenes with higher valencies were obtained by incorporating the 
galactosamine derivative in multi-branched structures (figure 2.2) before coupling with the 
calix[4]arene central core 118. In this fashion they obtained dendrimers bearing up to sixteen 
sugar moieties. 
 
Figure 2.2: Multi-branched sugars. 
Ungaro and co-workers have explored the possibility of using amide bonds to link carbohydrates 
to the wide rim of calix[4]arenes.10 In a first attempt they investigated linking galactosamine 
derivatives 123 and 124 to a calix[4]arene functionalised with two carboxylic acid groups11 99 in 
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the presence of O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
(HBTU) and triethylamine (TEA) at room temperature (scheme 2.11) Unfortunately the reaction 
did not yield the expected compound but the benzotriazole ester instead.10 The di-carboxylic 
acid was converted to the chloride derivative 125,12 but it failed again to react with the 
galactosamine derivatives 123 and 124 in the presence of TEA as base.10 The unsuccessful 
approach led the way towards the introduction of a spacer either on the calixarene or on the 
sugar. Di-p-carboxymethylcalix[4]arene 130, synthesised via hydrolysis of a cyano precursor 
according to Gutche’s method,13 failed to couple with the galactosamines 123 and 124.10 
Modified galactosamines 126 and 127 with a two carbon atoms spacer were successfully 
coupled with the Di-carboxycalix[4]arene 99 and with the acyl chloride derivative 125 to give 
the glycoconjugates 128 and 129. 
 
Scheme 2.11: Attempts towards the synthesis of Glucosamine glycoconjugates 
In the same paper, the authors describe also the synthesis of a glycoconjugates using aspartic 
acid residues as spacers (scheme 2.12). In the first approach the amino acid methyl ester 131 
was coupled with the di-carboxylic acid calixarene 99 to give 132. Demethylation and reaction 
with the glucosamine 124 yielded a complex mix of product in which the sugar-
peptidocalix[4]arene conjugate 134 could be detected by mass spectrophotomtry but could not 
be isolated. Significantly better results were obtained when the galactosamine 124 was coupled 
with the protected aminoacid first. Deprotection of the N-terminus and coupling with either 99 
or 125 yielded the desired sugar–peptidocalix[4]arene conjugates 135 which was then fully 
deprotected to give 136. 
104 
 
 
Scheme 2.12: Sugar-peptido-calixarene. 
In 1998 Felix et al. proposed another interesting route toward the synthesis of calix[4]arene 
glycoconjugates. They performed a palladium Pd(0) catalysed Suzuki cross coupling between a 
p-bromophenyl glycoside and the boronic acid derivative of a calix[4]arene 139 (scheme 2.13).14 
139 was obtained from a di-bromo precursor15 and coupled with 140 and 141 in the presence of 
tris(dibenzylideneacetone)dipalladium(0), triphenyl phosphine (PPh3) and hydrogen carbonate 
solution in 1,2-dimethoxyethane to obtain the glycoconjugates 142 and 143. 
 
Scheme 2.13: Glycoconjugation via Suzuki cross coupling.  
Glycosylation of calix[4]arenes at the lower rim was achieved via Sonogashira coupling reaction 
by Pérez-Balderas and Santoyo-González.16 p-Tert-butylcalix[4]arene 1 and calix[4]arene 2 
were alkylated with p-iodobenzyl bromide to give the 4-iodophenylcalixarenes 144 and 145 
(scheme 2.14). Propargyl mannoside 146 was coupled with the calixarene derivatives 144 and 
145 in the presence of Pd(PPh3)4 and CuI in anhydrous piperidine to yield the glycoconjugates 
147 and 148.  
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Scheme 2.14: Glycoconjugation via Sonogashira coupling. 
Another valuable route towards the synthesis of calix[4]arene glycoconjugates was first reported 
by Santoyo-González and co-workers in 2000.17 In their approach azido functionalised 
calix[4]arene 149 was linked to propargylated glucoside 150 through a thermally activated 1,3 
dipolar cycloaddition (scheme 2.16). The experiment yielded a mixture of 1,4 and 1,5 
substituted products 151 because of the lack of regioselectivity of the reaction.   
 
Scheme 2.15: First glycoconjugate formed by cycloaddition. 
The stereoselectivity gained by the use of copper (I) as catalyst,18, 19 made this reaction a useful 
tool to tether carbohydrates to calixarene scaffolds. In 2006 Dondoni and Marra reported the 
synthesis of calix[4]arene glycoconjugates linked through 1,4 substituted triazole rings.20 In their 
work they proposed two strategies, both using copper iodide as the source of copper (I). In the 
first approach the C-glycoside (scheme 2.16), functionalised on the anomeric carbon with an 
ethynyl group 152,21 was linked to calix[4]arenes 153 and 155 functionalised on the wide rim 
respectively with two and four propylazido groups obtained from polyalcohol precursors22. The 
reaction yielded the glycoconjugates 154 and 156. 
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Scheme 2.16: Dondoni’s first approach to click chemistry linked C-glycoconjugates 
In the second approach they prepared a C-glucoside bearing an azide moiety 157, which was 
linked to a calix[4]arene bearing four ethynyl groups on the wide rim 158, obtained from the 
tetra-iodo precursor,23 to yield the glycoconjugate 159 (scheme 2.18).  
 
 
Scheme 2.17: Dondoni’s second approach to click chemistry linked C-glycoconjugates 
In 2007, Bew’s group explored the potential of the “click” reaction as a tool to embroider 
calixarene scaffolds with sugar functions. In his work the propargylated O-glucoside 160 was 
clicked with an azido calixarene core synthesised from the chloromethyl precursor.24 The 
reaction took place under microwave irradiation, using copper sulphate and sodium ascorbate as 
a source of copper (I) to yield compound 162 (scheme 2.18).  
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Scheme 2.18: Bew’s Glycoconjugate 
A different approach towards the synthesis of calix[4]arene glycoconjugates was reported in a 
joint paper by Matthews and Vidal in 2009.25 The molecules proposed carried from one up to 
four glycoside units at the narrow rim of the calixarene scaffold. The tetravalent glycoconjugates 
were synthesised in the cone, 1,3-alternate and partial cone conformation. Peracetylated 
galactose and mannose were functionalised with an azido group incorporating a triethylene 
glycol chain spacer 163 and 164 (Scheme 2.19 and 2.20). The calixarene scaffold was locked in 
one of the desired conformations and functionalised with one or more propargyl groups as 
shown in the scheme 2.20. The copper catalysed cycloaddition reaction was performed with 
different copper (I) sources, at different temperatures, in different solvent and with or without 
microwave irradiation. The optimum conditions were found to be either: 
 - 0.5 equivalents of CuI and 5 equivalents of di-iso-propylethylamine (iPr2Net) in DMF at 
110oC under microwave irradiation or, 
- 0.5 equivalents of CuSO4 ·  5 H2O and 2 equivalents of sodium ascorbate in DMF at 110 oC 
under microwave irradiation 
 The aims and outcomes of their work will be discussed in details in the next section (2.2). 
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Scheme 2.19: Matthews’ and Vidal’s Glycoconjugates.  
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Scheme 2.20: Synthesis of mono-, bis-, tris-, and tetra-alkyne calixarenes in various 
conformations. 
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2.2 Preliminary results and rationale 
Matthews and Vidal aimed to target the galactose-binding lectin PA-IL from the opportunistic 
bacterium Pseudomonas aeruginosa. This bacterium is a major causative agent of lung 
infections in cystic fibrosis patients.25 The virulence of Pseudomonas aeruginosa is related to its 
cell adhesion property which is mediated by the bacterial lectins.26 Lectins are proteins which 
bind mono- and oligosaccharides reversibly with high specificity.27 They do not have catalytic 
activity and unlike antibodies they are not products of an immune response. Each lectin has two 
or more carbohydrate binding sites, therefore they do not only interact with the sugar on the cell 
surface but they can also cross-link the cells causing precipitation. This phenomenon is called 
cell agglutination. Formation of cross-links and consequent precipitation was observed also 
when lectins reacted with oligosaccharides and/or glycoproteins. Agglutination and precipitation 
can be inhibited by binding with the sugar specific for the lectins. This type of protein has been 
found in most organisms in nature such as viruses, bacteria, plants and animals and play a major 
role in cell recognitions and cell adhesion. Two different types of lectin have been isolated from 
the bacteria: PA-IL which binds D-galactose and its derivatives and PA-IIL L-fucose, D-
mannose, L-galactose and d-fructose.28 PA-IL binds selectively D-galactose with an association 
constant (K a) of 3.4x104 M-1. The binding is stronger when the sugar bears a lipophylic group 
on the anomeric position. PA-IL can also bind disaccharides having a terminal galactose 
molecule. It is a tetrameric protein and each monomer contains a sugar binding site. Occupation 
of such glycoside binding sites could prevent the cell adhesion properties of the lectin and 
therefore the associated bacterium virulence. Matthews and Vidal’s glycoconjugates were used 
to bind this type of lectin.  
In their study they synthesised seven calix[4]arene glycoconjugates in different conformations 
and with different galactose loads.25 Their work showed that multivalency plays a role in 
binding PA-IL, the tetravalent molecules are the best ligands, in agreement with the “cluster 
effect” theory. Enhanced binding was found with the molecules in the 1,3-alternate and in the 
partial cone conformation, showing that also the spatial disposition of the galactose residues has 
an effect on the binding.  
Glycoconjugates in the 1,3 alternate conformation are able to bind the carbohydrate binding sites 
located on different lectins forming branched filaments. This theory was confirmed in 2011 by 
atomic force microscopy studies, which showed images of the filaments formed by the lectins in 
the presence of the glycoclusters 179.29 In latter work the triethylene glycol linker which 
connected the sugar moieties to the calixarene scaffold was compared to newly designed 
analogues. These new linkers were the same length of the one previously used but differed in 
both flexibility and hydrophilicity (scheme 2.21). 
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The azido functionalised glycosides with the different linkers were reacted with the tetra-alkyne 
calix[4] arene in the cone, 1,3-alternate and partial cone conformation. To asses the binding 
properties as a monomer the azido-linkers were also reacted with propargyl acetate yielding after 
deacetylation the alcohol derivatives.  
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 Scheme 2.21: Development of new linkers for improved binding. 
The biological investigation of the PA-IL binding properties confirmed that the glycoconjugate 
in the 1,3-alternate conformation was the most effective in binding the lectin. Analysis of the 
monomers showed comparable binding properties for all the structures. The compound bearing 
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the aromatic linker showed the highest affinity for PA-IL unfortunately the low solubility in the 
assay media did not allow the full collection of the experimental data for the glycoconjugates 
bearing such galactoside. 
A water soluble calix[4]arene glycoconjugate, carrying the phenyl spacer, is thus the first target 
compound of this chapter.  
The results obtained by Matthews and Vidal in their work suggested also the opportunity to 
introduce sugars units into a multicalixarene structure. Polycationic multialixarenes are able to 
bind and transfect nucleic acids in to the cells.30 On the other hand, as shown by Matthews and 
Vidal’ experience, calixarenes embroidered with appropriate sugar moieties are able to bind 
selectively lectins.25 Therefore joining these two properties together it may be possible to 
synthesise a molecule able to transfect the nucleic acids selectively into the cells carrying a 
target lectin. 
Another topic which will be discussed in the chapter is the synthesis of octavalent calix[4]arenes 
able to bear two different sugar species (eg. flucose and galactose) on the upper and lower rim. 
This approach may lead to the synthesis of molecules which are able to bind at the same time 
both PA-IL and PA-IIL.  
2.3 Increasing solubility through functionalisation  
The approach chosen towards the synthesis of water soluble calix[4]arene glycoconjugates was 
the introduction of hydrophilic groups on the calixarene scaffold. Previous work in the group 
showed that the amino group in its hydrochloride form gives water solubility to single 
calix[4]arenes.30 Therefore we aim to synthesise analogues of glycoconjugate 191 and 178 
functionalised with four amino groups on the upper rim of the calixarene.  
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Figure 2.3: Target compounds 
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Following the Ryu and Zhao procedure, p-tert-butyl calix[4]arene was alkylated with propargyl 
bromide in the presence of NaH, this reaction allowed the introduction on the narrow rim of four 
alkyne functional groups and locks the scaffold in the cone conformation (scheme 2.22).31 
 
Scheme 2.22: Synthesis of tetra alkyne functionalised calixarene in the cone conformation. 
The synthetic route to introduce Boc protected amino groups on the wide rim of the calixarene 
scaffold was the same designed for the synthesis of the generation 1 calixarene 46. Initially ipso-
nitration was attempted by treating a solution of 171 in DCM with a mixture of fuming nitric 
acid and glacial acetic acid in equal volumes.32 The reaction yielded a yellow precipitate 
insoluble in both organic and inorganic solvents which was not the desired product. The failure 
of the experiment was probably due to the reaction between the electron rich alkynes and the 
electrophile nitronium ion. Acetylenes and nitronium ions are able to react in gas phase as 
reported in 2000 by Bernardi et al .33 Milder conditions, using less equivalents of the nitrating 
mixture and/or lesser reaction time did not yield the expected product. To overcome this 
problem an alkyne protecting group was required. Among the silyl protecting group tert-
butyldimethylsilyl chloride (TBDMSCl) was chosen for this purpose, the reason for this choice 
will be explained in detail in paragraph 2.4.1. The four acidic alkyne protons were removed in 
the presence of the base LiHMDS. The compound was allowed to react at -78oC for twenty 
minutes before the addition of TBDMSCl. Precipitation from DCM/MeOH yielded the pure 
compound in excellent yield (81%). After the introduction of the protecting group the 
ipsonitration could be performed. The pure product was precipitated from DCM/MeOH as a pale 
yellow solid (59%) (scheme 2.23).  
 
Scheme 2.23: TBDMS protection and ipso nitration 
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The synthesis continued with the reduction of the nitro groups to amino groups using SnCl2 
dihydrate.34 The product was recovered after basic work up and removal of the solvent as a dark 
vitreous solid (97%). The subsequent Boc protection of the four amino groups followed the 
same anhydrous conditions used for the synthesis of compound 45 already discussed in chapter 
1. Purification of the crude product over column chromatography yielded 203 (79%) (scheme 
2.24). 
 
Scheme 2.24: Nitro reduction and Boc protection of the amino derivative. 
At this stage the silyl protection was removed from the propargyl groups. As mentioned in 
chapter 1, sixteen hours stirring at room temperature in the presence of five equivalent of TBAF 
deprotected the alkynes without removing the Boc protection on the amino groups. The pure 
compound 204 was obtained after precipitation from DCM/n-Hexane (85%) (scheme 2.25). 
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Scheme 2.25: Alkyne deprotection 
Compound 204 functionalised with four alkyne groups at the lower rim and with four Boc 
protected amino groups on the wide rim was “clicked” with the azido galactose derivatives 163 
and 183. The method chosen for the cycloaddition was the one optimised by Vidal’s group 
which used as a source of Cu(I) the a mixture of CuSO4 and sodium ascorbate. The reaction was 
performed in DMF at 110oC without microwave irradiation. The products were purified by 
column chromatography to yield the pure compounds 205 and 206 (scheme 2.26). 
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Scheme 2.26: Glycoconjugation. 
Figure 2.4 is a comparison between the spectra of 205 (red) and of 206 (blue). In both spectra it 
easy to identify the click proton, with a chemical shift around 8 ppm. At 6.75 ppm both spectra 
show a broad singlet which is due to the calixarene aromatic protons. The two doublets, having a 
coupling constant of 9Hz, in the aromatic region of the spectra for compound 207 (blue) belong 
to the aromatic linker. The central area of the spectra between 5.5ppm and 3.5 ppm is not readily 
interpreted because of the overlap of galactose peaks with the signals of the linker and of the 
calixarene. Nevertheless all the multiplets could be assigned with two dimensional NMR 
experiments (COSY, HMBS and HSQC). Around 3 ppm both spectra clearly show the 
methylene bridge of the calixarenes. In the upper field region it is possible to identify the signals 
of the acetate protecting the sugar. The last peak, at 1.5 ppm, integrating for 36 protons, belongs 
to the Boc protecting group. 
 
Figure 2.4: 1H NMR spectra comparison of 205 (red) and of 206 (blue). 
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The glycoconjugates 205 and 206 were sent to the University of Lyon 1 to be deprotected and 
biologically tested on PA-IL. The removal of the Boc group can be achieved by bubbling 
gaseous HCl in to a solution in DCM of the compound, whilst the acetates can be hydrolysed 
from the sugars residue by stirring the compound with a mixture of triethylamine, methanol and 
water. 
2.4 Design of multicalixarene glycoconjugates 
Different carbohydrates have been shown to bind different lectins. Incorporating a carbohydrate 
selective for a specific lectin on a tranfection agent, could lead to molecules able to transfect 
nucleic acids in to the cells carrying such a lectin. As was shown from previous work in the 
group, cationic multicalixarenes bind and transfect nucleic acids in to the cells. In our work we 
have designed a route which would allow us to introduce sugars moieties on multicalixarenes 
with cell transfection properties. In order to be able to achieve such a result it was necessary to 
design central cores able to carry four amino functionalised generation 1 calixarenes and the 
sugars (figure 2.5). 
 
Figure 2.5: Design of Multicalixarene Glycoconjugate 
As was described on chapter 1 it is possible to synthesize multicalixarenes through narrow rim-
wide rim junctions. The generation 1 calixarenes can be functionalised at the narrow rim with an 
alkyne fuction which can be “clicked” to the wide rim of a central core functionalised with four 
azido groups. This approach opened the opportunity to introduce further functionalizations on 
the narrow rim of the central core. A retro synthetic scheme in which a central core 
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functionalised with four azido groups and four alkyne groups was reacted respectively to alkyne 
generation 1 calixarenes and azido sugars was designed (scheme 2.27). 
 
Scheme 2.27: Retro-synthetic strategy for Multicalixarene Glycoconjugates 
According to this retro-synthetic scheme it was necessary to synthesise a central core carrying 
four azido groups on the wide rim, which can be reacted with the monoalkyne functionalised 
generation 1 calixarenes, and four protected alkyne groups on the narrow rim which after the 
formation of the multicalixarene could be deprotected and “clicked” with the azido 
functionalised sugar. 
2.4.1 Synthesis of azido-alkyne functionalised central core  
As discussed in paragraph 2.3, a protecting group is required before nitration of alkyne modified 
calixarene. Whilst we came to the use of TBDMSCl, previously we considered the use of the 
trimethylsilane analogue (TMSCl). Initially the four alkyne groups were protected with 
trimethylsilyl-chloride (TMSCl)35 before performing the ipso-nitration32.  
 
Scheme 2.28: TMS protection and ipso nitration 
The tetranitro derivative in this case was obtained in low yield after a complicated purification. 
The tetranitro derivative was then reduced following the tin chloride method34 and the resulting 
amino derivative underwent substitution with the azide via the diazonium salt.36 The poor 
stability of the TMS groups in the acidic conditions necessary to form the diazonium salt gave as 
a result of the reaction a mixture of the tetra-protected, tri-protected, di-protected, mono-
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protected and unprotected compounds. This result was confirmed once the five spot identifiable 
by TLC were purified over silica gel and analysed by 1H NMR.  
 
 
Scheme 2.29: Reduction of nitro groups and substitution of amino groups via diazonium salt 
The same series of reactions were repeated again using, as the protecting group for the alkynes, 
tert-butyl-dimethylsilylchloride (TBDMSCl) which is known to be more stable37. The only 
product obtained in the synthesis was this time the tetrazazido compound with four TBDMS 
protected alkyne groups 211. 
 
Scheme 2.30: Synthesis of tetraazido functionalised central core. 
Figure 2.6 shows the spectra of all the synthetic steps of the synthesis of 211. The alkyne peaks, 
a doublet and a triplet at 4.80 ppm and at 2.47ppm respectively, in the spectrum of 171 (blue), 
disappear upon the introduction of the protecting group, to be replaced by three singlets at 4.80 
ppm, 0.88 ppm and 0.74 ppm in the spectrum of 200 (red). Comparing this spectrum with the 
spectrum of compound 201 (green) the removal of the tert-butyl group via ipso-nitration can be 
confirmed by the disappearance of the peak at 1.04 ppm and by the downfield shift of the signal 
for the aromatic protons due to the high deshilding effect of the electron withdrawing group. 
Reduction of the nitro groups in to amines, electro donating groups, produces in the spectra 
compound 202 (purple) a further upfield shift of the aromatic protons. In the last step once the 
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amino groups have been replaced by azido functions, the aromatic signal shifts again from 6.10 
ppm in 202 to 6.36 ppm in 211 (dark blue).  
  
Figure 2.6: 1H NMR Spectra of all the steps of the synthesis of 211 
2.4.2 Assembly of the multicalixarene glycoconjugate 
The first step towards the multicalixarene glycoconjugate was the assembly of the 
multicalixarene (scheme 2.27). The four azido functions of the central core 211 were clicked 
with the alkyne group of the Boc-amino functionalised generation 1 calixarene 46. The reaction 
was performed using as a source of Cu(I) the combination of copper sulphate and sodium 
ascorbate. The product was purified by column chromatography to yield the multicalixarene 212. 
At this point the alkyne protecting groups could be removed by stirring the product with TBAF 
for 16 hours at room temperature. The revealed alkynes groups of 213 were “clicked” with the 
azido-galactose derivative to obtain the multicalixarene glycoconjugate 214.  
Compound 214, the first multicalixarene glycoconjugate synthesised, once fully deprotected will 
be tested to investigate the binding towards bacterial lectins and its gene trasfection properties.    
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Scheme 2.31: Assembly of Multicalixarene Glycoconjugate 
 
2.5 Synthesis of octavalent glycoconjugates 
The azido functionalisation on the wide rim and the protected alkyne groups on the lower rim 
would allow the introduction of two different molecules on 211 via sequential CuAAC 
Reactions. This property would enable the synthesis of an octavalent calix[4]arene 
glycoconjugate bearing two different sugars on the upper and lower rim. A calixarene 
glycoconjugate with these features, could have interesting biological activity towards the 
binding of the lectins of Pseudomonas aeruginosa. For example, one bearing fucose and 
galactose, or mannose and galactose, or mannose and fucose could be prepared. Mannose and 
galactose derivatives (figure 2.7) with an alkyne functionalisation were available from Vidal’s 
laboratory. These glycosides were successfully conjugated with the central core 211, using 
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copper sulphate and sodium ascorbate as a source of copper (I) catalyst, to give respectively 217 
and 218. 
 
Scheme 2.32: Upper rim functionalisation of 211 with mannose and galactose derivatives 
To enable reaction with either azido-functionalised fucose or galactose the masked alkyne 
moieties needed to be revealed. 
The method of first choice was the treatment of the molecules with TBAF as this route had 
previously been used successfully for preparation of multicalixarenes. Unexpectedly this method 
did not yield the desired compound. The silyl protecting group was successfully removed from 
compound 218 using the alternative of HF in pyridine. 
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Scheme 2.33: Deprotection of the alkyne groups 
Although the desired compound was detected by mass spectrometry, the 1HNMR analysis was 
unexpectedly complex which could be due either to the partial loss of the protecting groups on 
the sugar or to a change of conformation of the calixarene. Dondoni et al. have shown how 
calixarene glycoconjugates bearing galactose unit on the upper rim favoured an open or flattened 
conformation.22. However, compound 219 was reacted in the presence of copper sulphate and 
sodium ascorbate with the azido flucose derivative 220 (scheme 2.34). Unfortunately the 1H 
NMR after a first purification by column chromatography was inconclusive to determinate the 
structure of the product. Compound 221 was sent for mass analysis to confirm mass before 
further purification was attempted.  
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Scheme 2.34: Attempted synthesis of Octavalent Glycoconjugate 
2.6 Conclusion and future work 
This chapter describes our approach to calixarene glycoconjugates. Previous studies carried out 
in collaboration with Dr. Sebastien Vidal from the University of Lyon 1, had developed triazole 
linked galactose glycoconjugates that showed good binding properties toward the lectin PA-IL 
from the bacteria Pseudomonas aeruginosa. For some of these compounds solubility in aqueous 
media was an issue which had limited the biological evaluation. Part of our work was focused on 
the generation of calixarene glycoconjugates functionalised with amino groups. We have 
successfully synthesised compound 205 and 206, which are now ready to undergo biological 
evaluation. The success of the synthetic route developed may allow in the near future the 
synthesis of analogues carrying on the upper rim aliphatic amines or guanidinim functions as 
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described in chapter 1. The second part of our work aimed to develop a route towards the 
synthesis of multicalixarene glycoconjugates. These molecules have potential to combine the 
cationic multicalixarenes DNA transfection properties with the specific binding of 
glycoconjugate to lectins, leading to selective delivery of genetic material to target cells. The 
achievement of this goal was possible thanks to the design of central core 211. This molecule 
has been developed to introduce in separate steps through “click” chemistry four alkyne and four 
azido functionalised molecules, in our case monoproargylated calixarene and azido sugars. With 
this approach we have also investigated the synthesis of octavalent glycoconjugates. The 
introduction into the upper rim of mannose and galactose derivative was straightforward. 
However the deprotection of the propargyl group in the presence of the sugars was troublesome. 
The problems were overcome using HF in pyridine and the synthesis of the octavalent 
glycoconjugate is waiting to be confirmed by mass spectrometry analysis. 
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2.7 Experimental 
5,11,17,23-p-Tert-butyl-25,26,27,28-tetra-(3-tert-Butyldimethylsilyl)-2-
propynoxycalix[4]arene (200)  
Lithium bis(trimethylsilyl)amide (1M in THF, 72 mL, 72 mmol) was added drop wise to a 
solution of 2 (7.20 g, 8.82 mM) in THF (80 mL) pre-cooled to -78oC. After 30 minutes a 
solution of TBDMSCl (11.39 g, 72 mmol in 20 mL of THF) was added to the reaction and 
stirred at room temperature for 16 hours. The reaction was diluted with EtOAc (40 mL) and 
washed with NH4Clsat (2 x 30 mL) water (30 mL and brine (30 mL). The organic layer was dried 
over MgSO4 and concentrated. Re-crystallisation from DCM/MeOH yielded the title compound 
as a white solid (9.04g, 81%). 1H NMR (400 MHz, CDCl3) δ 6.77 (s, 8H, ArH), 4.84 (s, 8H, 
OCH2CCSi(CH3)2C(CH3)3), 4.54 (d, J = 13 Hz, 4H, ArCH2Ar), 3.13 (d, J = 13 Hz, 4H, 
ArCH2Ar), 1.08 (s, 36H CH3CAr ), 0.90 (s, 36H, OCH2CCSi(CH3)2C(CH3)3), 0.10 (s, 24H, 
OCH2CCSi(CH3)2C(CH3)3 ). 13C NMR (100 MHz, CDCl3) δ 151.9, 145.1, 134.6, 124.7, 103.4, 
89.4, 61.2, 33.8, 23.6, 31.4, 26.1, 16.4, -4.6. IR v = 2953, 2928, 2856, 1480, 1471, 1463, 1412, 
1391, 1361, 1301, 1248, 1197. Mpt 214-216°C. 
5,11,17,23-tetra-nitro-25,26,27,28-tetra-(3-tert-butyldimethylsilyl)-2-
propynoxycalix[4]arene (201)  
A mixture of 10 ml of glacial acetic acid and 10 ml of fuming nitric acid was added to a stirred 
solution of 3 (2.00 g, 1.57 mmol) in DCM (50 ml) and stirred for 18 hours. The reaction mixture 
was washed several times with water. The organic layer was dried over MgSO4, and the solvent 
removed under reduced pressure. The resulting yellow solid was re-crystallized from 
DCM/MeOH to give the title compound as a cream solid (1.13 mg, 59% yield). 1H NMR (400 
MHz, CDCl3) δ 7.72 (s, 8H, ArH), 4.92 (s, 8H, OCH2CCSi(CH3)2C(CH3)3), 4.66 (d, J = 14 Hz, 
4H, ArCH2Ar), 3.45 (d, J = 14 Hz, 4H, ArCH2Ar), 0.87 (s, 36H, OCH2CCSi(CH3)2C(CH3)3), 
0.09 (s, 24H, OCH2CCSi(CH3)2C(CH3)3). 13C NMR (100 MHz, CDCl3) δ 159.5, 143.8, 136.1, 
124.1, 99.7, 93.2, 62.5, 32.2, 30.8, 25.6, 16.3, -4.8. IR v = 2953, 2929, 2857, 1587, 1519, 1463, 
1344, 1305, 1288, 1249, 1205. Mpt 219-221°C. 
5,11,17,23-tetra-amino-25,26,27,28-tetra-(3-tert-butyldimethylsilyl)-2-
propynoxycalix[4]arene (202)  
Tin(II)chloride di-hydrate (5.07 g, 22.2 mmol) was added to a solution of 4 (1.00 g, 0.81 mmol) 
in EtOH (50 ml). The mixture was heated at reflux temperature for 18 hours, cooled and the 
solvent removed under reduced pressure. The pale yellow solid was triturated with 10% NaOHaq 
and extracted with DCM. After separation the organic layer was dried over MgSO4 and the 
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solvent removed under reduced pressure to give the desired compound as a brown vitreous solid 
(1.36 g, 97% yield). 1H NMR (400 MHz, CDCl3) δ 6.12 (s, 8H, ArH), 4.70 (s, 8H, 
OCH2CCSi(CH3)2C(CH3)3), 4.45 (d, J = 13 Hz, 4H, ArCH2Ar), 2.94 (d, J = 13 Hz, 4H, 
ArCH2Ar), 0.91 (s, 36H, OCH2CCSi(CH3)2C(CH3)3 ), 0.09 (s, 24H, OCH2CCSi(CH3)2C(CH3)3). 
13C NMR (100 MHz, CDCl3) δ 148.1, 141.2, 136.0, 115.4, 103.6, 89.2, 61.6, 32.4, 25.9, 16.4, -
4.8. IR v = 3350, 2928, 2951, 2856, 1615, 1471, 1361, 1248, 1207, 1131. Mpt 150-152°C. 
5,11,17,23-tetra-Boc-amino-25,26,27,28-tetra-(3-tert-butyldimethylsilyl)-2-
propynoxycalix[4]arene (203)  
Di-t-butyl- dicarbonate (2.00 g, 9.2 mmol in 10 mL of anhydrous CHCl3) was added to a stirring 
solution of 5 (1.25 g, 1.15 mmol in 40 mL of anhydrous CHCl3) at 0oC in the presence of DiPEA 
(1.7 mL, 9.2 mL) as a base and stirred for 18 h under an argon atmosphere. The reaction was 
then diluted with CH2Cl2 (50 mL) and washed with water (2 x 100 mL) and brine (2 x 100 mL). 
The organic layer was dried over MgSO4 and concentrated. Purification by column 
chromatography (DCM: EtOAc 30:1 yielded the desired pure product (1.36 g, 79%).1H NMR 
(400 MHz, CDCl3) δ 6.75 (s, 8H, ArH), 6.19 (s, 4H, BocNHAr), 4.76 (s, 8H, 
OCH2CCSi(CH3)2C(CH3)3), 4.52 (d, J = 13 Hz, 4H, ArCH2Ar), 3.12 (d, J = 13 Hz, 4H, 
ArCH2Ar), 1.48 (s, 36H, (CH3)3CO), 0.90 (s, 36H, OCH2CCSi(CH3)2C(CH3)3), 0.09 (s, 24H, 
OCH2CCSi(CH3)2C(CH3)3). 13C NMR (100 MHz, CDCl3) δ 153.0, 150.9, 135.6, 133.0, 119.4, 
89.9, 61.7, 32.3, 28.40, 26.1, 16.4, -4.6. IR v = 3301, 2951, 2929, 2856, 1695, 1600, 1546, 1526, 
1472, 1416, 1362, 1298, 1247, 1211, 1156. Mpt 215-217°C. 
5,11,17,23-Tetra-Boc-amino-25,26,27,28-tetra propargyloxycalix[4]arene (204) 
TBAF solution (1M in THF, 24 ml, 24 mmol) was added to a solution of 6 (1.8 g, 1.2 mmol in 
50 ml of THF) and stirred for 18 h at room temperature. The reaction was diluted with EtOAc 
(150 ml) and stirred for a further 10 minutes in the presence of NH4Clsat( 150 mL). The organic 
layer was washed with NH4Clsat (1 x 150 mL) and brine (2 x 150 mL), dried over MgSO4 and 
concentrated. The crude compound was dissolved in DCM and precipitated with hexane to yield 
the title compound (1.05 g, 85%).
 
1H NMR (400 MHz, CDCl3) δ 6.77 (s, 8H, ArH), 6.24 (s, 4H, 
NH), 4.73 (d, J = 2.4 Hz, 8H, CH2CH), 4.58 (d, J = 13 Hz, 4H, ArCH2Ar), 3.18 (d, J = 13 Hz, 
4H, ArCH2Ar), 2.46 (t, J = 2.4 Hz, 4H, CH2CH), 1.49 (s, Hz, 36H, (CH3)3CO). 13C NMR (100 
MHz, CDCl3) δ 153.1, 151.0, 135.5, 133.2, 119.5, 80.4, 80.1, 74.8, 61.2, 32.2, 28.40. IR v = 
3292, 2977, 2922, 1699, 1600, 1524, 1475, 1416, 1392, 1366, 1294, 1244, 1208, 1149. Mpt 
150-152°C. 
Compound 205 
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GalPhNAz (302.29 mg, 0.58 mmol) was added to a solution of 7 (100 mg, 0.096 mmol) in DMF 
(10 mL) in the presence of CuSO4 · 5H2O (47.9 mg, 0.19 mmol) and sodium ascorbate (152 mg, 
0.77 mmol). The reaction was stirred for 2 hours at 110oC. The solution was diluted with EtOAc 
(40 mL) and washed with H2O (2 x 50 mL) and brine (2 x 50 mL), dried over MgSO4 and 
concentrated. Purification by column chromatography over silica gel, (EtOAc/n-
Hex/MeOH=1/1/0.2) yielded the desired compound as a off white solid (93.4 mg, 37%). 1H 
NMR (400 MHz, CDCl3) δ 7.82 (s, 4H, AzH), 6.62 (s, 8H, ArH), 6.32 (s, 4H, ArNHC(CH3)3), 
5.38 (dd, J = 3.4, 0.9 Hz, 4H, H-4’’’), 5.20 (dd, J = 10.5, 7.9 Hz, 4H, H-2’’’), 5.06 – 4.95 (m, 
12H, H-3’’’ and OCH2CCAz ), 4.57 – 4.50 (m, 12H, H-1’’’and OCH2CH2Az), 4.19 – 4.08 (m, 
12H, H-6’’’and ArCH2Ar), 3.96 – 3.90 (m, 8H, H-5’’’and OCH2CH2O), 3.84 (t, J = 5.3 Hz, 8H, 
OCH2CH2Az), 3.73 – 3.67 (m, 4H, OCH2CH2O), 3.62 – 3.58 (m, 8H, OCH2CH2O), 3.55 (s, 16H, 
OCH2CH2O), 2.89 (d, J = 13.5 Hz, 4H, ArCH2Ar), 2.14 (s, 12H, OCOCH3), 2.03 (s, 12H, 
OCOCH3), 2.02 (s, 12H, OCOCH3), 1.98 (s, 12H, OCOCH3), 1.47 (s, 36H, C(CH3)3). 
Compound 206 
Gal-TEG-Az (292.1 mg, 0.58 mmol) was added to a solution of 7 (100 mg, 0.096 mmol) in 
DMF (10 mL) in the presence of CuSO4 · 5H2O (47.9 mg, 0.19 mmol) and sodium ascorbate 
(152 mg, 0.77 mmol). The reaction was stirred for 2 hours at 110oC. The dark solution was 
diluted with EtOAc (40 mL) and washed with H2O (2 x 50 mL) and brine (2 x 50 mL), dried 
over MgSO4 and concentrated. Purification by column chromatography over silica gel 
(EtOAc/n-Hex/MeOH=1/1/0.2) yielded the desired compound as an off white solid (143 mg, 
49%) 
5,11,17,23-Tetra-azido-25,26,27,28- tetra-(3-tert-butyldimethylsilyl)-2-propynoxycalix[4]-
arene (211) 
NaNO2 (303 mg, 4.39 mmol) was added to a solution of 5 (750 mg, 0.69 mmol) in 10% HClaq 
(50 ml) and EtOH (25 ml). The reaction was stirred for 20 minutes at 0oC before the addition of 
a solution of NaN3 (223 mg, 3.34 mmol) in H2O (20 ml). The reaction was stirred for further 2 
hours and the formation of gas was observed. DCM 50 ml was added to the reaction mixture and 
the separated organic layer was then washed with brine (3 x 20 ml), dried over MgSO4 and 
concentrated. Purification by column chromatography over silica gel (DCM/nHexane=1/1) 
yielded the desired compound as a white foam (64%).1H NMR (300 MHz, CDCl3) δ 6.35 (s, 8H, 
ArH), 4.72 (s, 8H, OCH2CCSi(CH3)2C(CH3)3), 4.51 (d, J = 13 Hz, 4H, ArCH2Ar), 3.12 (d, J = 
13 Hz, 4H, ArCH2Ar), 0.87 (s, 36H, OCH2CCSi(CH3)2C(CH3)3), 0.07 (s, 24H, 
OCH2CCSi(CH3)2C(CH3)3). 1H NMR (400 MHz, CDCl3) δ 6.35 (s, 8H, ArH), 4.72 (s, 8H, 
OCH2CCSi(CH3)2C(CH3)3), 4.51 (d, J = 13 Hz, 4H, ArCH2Ar), 3.12 (d, J = 13 Hz, 4H, 
ArCH2Ar), 0.87 (s, 36H, OCH2CCSi(CH3)2C(CH3)3), 0.07 (s, 24H, OCH2CCSi(CH3)2C(CH3)3). 
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Chapter 3: Multicalixarenes 
 
3.1  Introduction 
Multicalixarenes can be described as multimeric structures formed by linking covalently two or 
more calixarenes scaffolds. Considerable effort has been placed in this area and literature shows 
many examples of these macromolecular structures, with great differences in size, shape and 
architecture. Calixarenes macrocycles linked together can form chains, tubes or dendrimers. 
 
3.1.1 Upper rim-upper rim linked multicalixarenes 
The first example of a double calix[4]arene appeared in the literature in 1989 from the group of 
Böhmer.1 This head to head dimer 222 was achieved by condensing either tetra-bromomethyl-
ated diphenols with a linear trimer or a bis-bromomethylated trimer with diphenols in refluxing 
dioxane in the presence of titanium tetrachloride (TiC14) (scheme 3.1).  
 
 
 
Scheme 3.1: First example of a calixarene dimer by Böhmer et al.  
Using the same principle Böhmer and co-workers succeeded in the synthesis of the first 
calixarene tube 223 (scheme 3.2). By reacting together, tetra-bromomethylated diphenols and 
diphenols in the same conditions in a 1:1 ratio, they obtained a bis-calixarene linked with four 
alkyl bridges.1 
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Scheme 3.2: First example of calixarene tube. 
Similar molecules were obtained a few years later by Shinkai’s group (scheme 3.3) and by 
Arduini et al. (scheme 3.4) using two different approaches. Both studies yielded bis-calixarenes 
linked at their wide rims through a methylene bridge. Shinkai’s method involved two steps, in 
the first the calixarene bromoderivative was treated with butyl lithium before reacting with a 
mono aldehyde functionalised calixarene. Reduction in the second step yielded the final product 
224.2 
 
Scheme 3.3: Head to head dimer: Shinkai’s approach. 
In Arduini’s approach the same link was obtained by reacting a more rigid calixarene, bearing 
two crown links, with para-formaldehyde, in the presence of CF3COOH as catalyst (scheme 
3.4).3 The reaction afforded a mixture of the monobridged isomers 225 and 226 which could not 
be separated. 
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Scheme 3.3: Head to head dimer by Arduini et al. 
A completely different approach towards the synthesis of bis-calixarenes linked via the wide rim 
was described by Neri et al. The bis-calixarene was obtained by joining the two units "head-to-
head" with a direct biphenyl-like para-para linkage (figure 3.1).4 The double calixarene 227 was 
obtained simply by heating p-H-calix[4]arene in CH3CN at reflux in the presence of 
FeCl3⋅6 H2O. Later work by Neri described the same reaction with calixarenes locked in the 1,3-
alternate and partial cone conformations.5  
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Figure 3.1: Calixarene dimers in different conformations by Neri et al. 
136 
 
In the same year Mogck et al. published the synthesis of covalently linked dimers 231.6 A 
monoamino calixarene was prepared through mono ipso-nitration and subsequent reduction of p-
tert-butyl calixarene tetraesters. Reaction with various di-acid chlorides yielded the respective 
double calixarenes linked through an amide bond. (figure 3.2). 
 
Figure 3.2: Di- and tri-calixarenes 
McKervey and Pitarch reported in 1996 the synthesis of macrocyclic structures obtained by 
functionalising two distal hydroxyl groups of calix[4]arenes with allyl bromide.7, 8 Due to the 
lack of a substituent on the para position of the aromatic ring, upon heating, the molecule can 
undergo a Claisen rearrangement to give a calixarene unit carrying the allyl functionalisation on 
the upper rim. Such molecules can react in the presence of an alkylidene ruthenium catalyst to 
form chains 232, cyclic dimers 233 and cyclic trimmers 234 (scheme 3.5).  
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Scheme 3.5: Calixarene chain and cyclic dimer and trimer via allyl functionalisation of the 
upper rim. 
 
3.1.2 Lower rim-lower rim linked multicalixarenes 
Böhmer has also been a pioneer of the narrow rim-narrow rim linkage. In a paper with 
McKervey they reported the first example 235 in 1990.9 They demonstrated two types of 
linkages: amide and ester (figure 3.2). They were obtained by reacting two identical calixarenes 
locked in the cone conformation and mono functionalised with an acid chloride with either 1,2-
diaminoethane or ethylene glycol.  
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Figure 3.3: First example of narrow rim-narrow rim linkage 
In another paper the same authors reported the synthesis of macrocyclic assemblies in which two 
or three calix[4]arene subunits were connected via two bridges between the oxygen atoms at the 
l- and 3-positions (figure 3.3).10 The result was achieved by using difunctional reagents such as a 
diacid dichloride, which was too rigid to allow intramolecular bridging of the calix[4]arene units. 
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Figure 3.4: Double and triple calixarene macrocycles. 
Further examples of a narrow rim narrow rim linkage were described by Kolbe and Shinkai in 
1995. In their work they connected calixarene units using dibromoalkane linkers (scheme 3.6). 
The reaction was carried out in dimethyformamide using sodium hydride as base. This allowed 
them to synthesise dimers, trimers and tetramers connected linearly 238.11 
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Scheme 3.6: Shinkai’s linear tetramer. 
More work following the same strategy allowed them to extend the linear array and to form 
macrocyclic molecules composed of up to eight calixarene units (figure 3.4).12  
 
Figure 3.5: Shinkai’s “macrocycle of macrocycles”. 
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3.1.3 Calixarene based dendrimers 
Multiple calixarene units organized in dendritic arrays have been described in literature 
since the mid 1990’s. These molecules can have either a non-calixarene central core or a 
calixarene central core. Since their discovery calixarene based dendrimers have evolved 
into large macromolecules bearing in their structures up to twenty-one calixarene units 
organised in multiple generations. 
 
3.1.3.1 Dendrimers with a calixarene central core 
 
The synthesis of the first multicalixarene dendrimers was reported in 1995 by Lhotak and 
Shinkai. The lower rim-lower rim approach used for the synthesis of multicalixarene chains and 
“macrocycle of macrocycles” enabled also the preparation of a multicalixarene with a dendritic 
structure. This molecule was a pentamer 240 obtained by reacting p-tert-butyl calix[4]arene with 
8 equivalents of the bromide derivative (scheme 3.7).11  
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Scheme 3.7: First example of a calix[4]arene based dendrimer. 
Since this first example, many other calixarene based dendrimers have been described in the 
literature. In 1998 Mogck et al. published the synthesis of covalently linked multicalixarene 
pentamers.6 A monoamino calixarene was prepared through mono ipso-nitration and subsequent 
reduction of p-tert-butyl calixarene tetraesters. Reaction with a central core locked either in the 
cone or in the 1,3-alternate conformation by four acetyl chloride functions yielded the pentamers 
shown in figure 3.5. (Figure 3.6) 
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Figure 3.6: Mogck’s Dendrimers 
Interesting dendrimeric structures were reported by Prados and de Mendoza in 2010. Their 
pentamers were synthesised by connecting four calix[6]arenes to a calix[4]arene central core 
(figure 3.7). The dendrimers were obtained by connecting the building blocks with either ureido-
phenyl13 or aza-phenyl linkers.14 
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Figure 3.7: Prados and de Mendoza’s dendrimers. 
 
3.1.3.2 Dendrimers with a non calixarene central core 
 
Mogck also explored the possibility of linking mono amino functionalised generation 1 
calixarenes to a non calixarene central core. The same approach described for the synthesis of 
dendrimeric pentamers yielded a trimer when 1,3,5-benzenetricarbonyl chloride was used as a 
central core (figure 3.8). 
 
Figure 3.8: Mogck’s Trimers 
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More examples of non-calixarene central core trimers have been reported in recent years by 
Pappalardo et al.15 Their approach, similar to the one pioneered by Mogck, used amide bonds to 
assemble dendritic structures. Nitrocalixarenes, functionalised at the lower rim with an acyl 
chloride, were linked to trivalent amino central cores. The nitro groups were subsequently 
reduced to obtain amino functionalised oligomers (scheme 3.8).  
 
Scheme 3.8: Pappalardo’s Trimers 
Another example of non-calixarene central core dendrimers is described in the work of Cheriaa, 
Abidi and Vicens (figure 3.9). The early stages of their work involved the synthesis of tri-
calixarenes using mono methoxycarbonylcalix[4]arenes linked together through tris(2-
aminoethyl)amine or “tren” bridges.16 
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Figure 3.9: “Tren” Dendrimer 
 
3.1.3.3 Large calixarene based dendrimers 
 
In the past decade a few examples of dendritic calixarenes bearing more than five calix[4]arene 
units in their structures have been reported. The first example was reported in 2002 by Szemes et 
al. They synthesised a dendritic structure bearing seven calix[4]arenes units linked through 
amide bonds, using a divergent strategy.17 A central core functionalised with two amino groups 
on the upper rim was reacted with two equivalents of generation 1 calixarene bearing an acyl 
chloride function at the lower rim and two nitro groups on the upper rim. The trimer obtained 
was treated with hydrogen in the presence of palladium on carbon to reduce the nitro groups to 
aromatic amines. Four generation 2 calixarenes functionalised with an acyl chloride group were 
coupled to the amino functionalised trimer obtaining a second generation calixarene dendrimer 
248 (figure 3.10). 
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Figure 3.10: Calixarene Septamer 
Three years after Szemes’s paper, Bu et al reported the synthesis of a similar dendritic structure, 
also bearing seven calix[4]arene units.18 Bu used a 1,3-alternate calix[4]arene crown derivative 
249 as a building block (scheme 3.9). Using a convergent strategy the generation 2 calixarenes 
were first linked to the generation 1 calixarenes and the resulting trimer linked to a central core. 
The calix[4]arene crown 249 was reduced with sodium borohydride (NaBH4) in THF to give 
250. The ester functionality of 249 was hydrolysed to give the free di-carboxylic acid which was 
used as generation 1 calixarene 251. Generation 1 and 2 were coupled together in the presence 
of N,N'-dicyclohexylcarbodiimide (DCC) and Dimethylaminopyridine (DMAP) in DCM. The 
aldehyde present on the resulting trimer 252 was then reduced using NaBH4 and coupled with 
further 230 to give the final dendrimer 254.  
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Scheme 3.9: Bu’s dendrimer 
In 2005 Cheriaa reported an extension of their work on “tren” dendrimers in the formation of 
hyper branched dendrimers (scheme 3.10)19 255 was transformed into 256 via selective 
monoalkylation. Then, 256 was reacted with 6 equiv. of di-calixarene 257 to obtain a dendrimer 
consisting of nine calixarenes. 
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Scheme 3.10: Hyper branched “Tren” dendrimer  
The largest multicalixarene known, was reported by the Matthews’ group in 2010.20 The 
structure was composed of twenty-one calix[4]arene units linked with amide bonds. Similarly to 
Bu’s approach, Lalor’s dendrimer was synthesised using a convergent strategy. p-Tert-butyl 
calixarene was locked in the cone conformation with three propyl chains and an ester. Following 
the ester hydrolysis, the free carboxylic acid was reacted with pentafluorophenol (PFP) in the 
presence of DCC to yield the generation 2 calixarene 234 (scheme 3.11). The generation 1 
calixarene was also locked in the cone conformation by three propyl chains and by a propyl 
phthalamide group. The wide rim was functionalised with four amino groups to give the 
generation 1 calixarene 260. The amino groups of 260 were coupled with four equivalent of 259 
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in the presence of di iso-propylethylamine (DIPEA) and DMAP in DCM to yield the pentamer 
261. 
The amino group, masked by the phthalamide, was revealed through treatment with hydrazine in 
ethanol. The pentamer with the primary amino function 262 was coupled with central core 263, 
locked in the 1,3-alternate conformation with four active esters. The coupling performed in the 
presence of DIPEA and DMAP yielded the largest dendrimeric multicalixarene synthesised to 
date 264.  
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Scheme 3.11: Lalor’s dendrimer 
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3.2 Aims of the chapter 
 
In the previous chapters we have reported the synthesis of several calixarene based dendrimers. 
The structures described were all prepared by reacting mono alkyne functionalised generation 1 
calixarenes with a tetra azido functionalised central core to form triazole linked multicalixarenes. 
The central cores investigated were either in the cone or in the 1,3-alternate conformation. The 
azido functionalities were introduced by two different strategies. In the first case the 
conformation of the calix[4]arene was locked in the desired conformation by reacting the four 
hydroxyl positions with either di-haloalkanes or ethyl bromoacetate, which could be converted 
into azides. In this way we succeeded in the synthesis of the structures shown in figure 3.11. 
 
Figure 3.11: Examples of multicalixarenes obtained via O-alkyl-azide functionalisation of 
central cores. 
In the second case the azido functionalities were introduced on the aromatic rings of calixarenes 
locked in the cone conformation by propyl groups. Functionalisation of the upper rim with azido 
groups was possible in three synthetic steps: ipso nitration, reduction, substitution via diazonium 
salt formation, on the para position of the tetra alkylated p-tertbutylcalix[4]arenes. The 
pentamers obtained in this fashion featured narrow rim-upper rim linkages. Multicalixarene 265 
(figure 3.12) was the first of the series to be synthesised. This prototype molecule featured tert-
butyl groups at the upper rim of the generation 1 calixarenes. However analogues of this 
molecule carrying aliphatic or aromatic amines have been successfully synthesised and their 
syntheses have been explained in details in the first chapter of this thesis.   
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Figure 3.12: Example of narrow rim-upper rim linked multicalixarenes 
This strategy allowed the introduction, at the lower rim of the calixarene, of functionalities 
which can subsequently be activated for a second “click” reaction. An example of this potential 
has been explained in chapter 2. Functionalisation of the lower rim of the central core with four 
alkyne groups in the first step of the synthesis and subsequent protection with TBDMS, allowed 
a second “click” reaction to be performed after assembly of the multicalixarene and removal of 
the protecting group. The process yielded the first multicalixarene glycoconjugate shown in 
figure 3.13. 
 
Figure 3.13: Structure of Multicalixarene Glycoconjugate 214  
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In this chapter we aim to further investigate the potential of this strategy towards the assembly 
of dendritic molecules featuring a higher number of calixarene units in their structures. 
3.3 Synthesis of nonamers 
 
The central core 211, described in chapter 2 and successfully used for the synthesis of 
multicalixarenes glycoconjugates, could be used also to synthesise multicalixarenes bearing 
eight generation 1 calixarenes. 
The tetra azido compound was reacted with four equivalent of mono alkyne functionalised 
calixarene 40 (scheme 3.12), in the presence of catalytic CuI, to yield the first example of a 
pentameric multicalixarene 266 featuring functionality at the lower rim.  
 
Scheme 3.12: Synthesis of Multicalixarene 267 
As previously, 266 was treated with TBAF to remove the silyl protecting group. Figure 3.15 
shows a comparison between the spectra of the multicalixarene before (blue) and after (red) 
deprotection. In the red spectra the peaks for the TBDMS peaks around 1.25 and 0 ppm 
disappeared upon removal of the protecting group. The presence of the alkyne terminal proton is 
confirmed by the triplet at 2.75 ppm and the doublet at 4.8 ppm with coupling constant around 2 
Hz.  
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Figure 3.14: Comparison of the 1H NMR spectra of compound 266 (blue) and compound 267 
(red) 
The four unmasked alkyne groups were then reacted with four equivalents of a calixarene 
functionalised at the lower rim with an azide. A suitable calixarene molecule for the second 
cycloaddition was prepared by alkylating the free hydroxyl group of p-tert-butyl tripropoxy 
calix[4]arene 268 with dibromo butane in the presence of NaH. In the next step the halogen was 
readily replaced by heating the compound at 70oC in DMF in the presence of sodium azide. 
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Scheme 3.13: Synthesis of mono azido functionalised generation 1 calixarene 
The mono azido functionalised calixarene obtained was “clicked” to the tetra alkyne 
functionalised multicalixarene 267. The cycloaddition was carried out using CuI as a source of 
copper (I) catalyst and yielded a multicalixarene consisting of a central core surrounded by eight 
generation 1 calix[4]arenes. 
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Scheme 3.14: Synthesis of nonamer 
Simple 1H NMR analysis of the compound proved difficult to interpret because of the overlap of 
the generation 1 calixarenes resulting in series of multiplets. However COSY analysis gave 
valuable information regarding the coupling of the multiplets and allowed the assignment of 
peaks. Figure 3.16 shows the COSY spectra for the nonamer 272. 
 
Figure 3.15: COSY acquisition for compound 272 
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In the black circles, at 4.38 ppm and 3.07 ppm, it it is possible to observe the coupling between 
the methylene bridges. In blue, at 3.79 ppm and 2.07 ppm, is highlighted the coupling between 
the methylenes of the aliphatic chain, next to the oxygens and in the middle of the chain 
respectively. The multiplet at 2.07 ppm from the methylenes located in the middle of the 
aliphatic chains shows also coupling with the multiplet at 1.01 ppm which can be assigned to the 
terminal methyl groups of the propyl chain of the generation 1 calixarenes (circled in green). 
The last coupling highlighted in red at 4.47 ppm and 2.10 ppm, refers to the methylene protons 
next to the triazole ring and the protons in the aliphatic chain on the next carbon atom.  
The signals for the click protons are normally observed as two singlets around 8 ppm and 5 ppm 
respectively. In our case, the eight triazole rings are in two different environments so we would 
expect to find two set of signals. Interestingly the 1HNMR spectrum shows a number of signals 
in the “click” proton regions. A possible explanation of this unusual behaviour is suggested by 
the analysis of the mass spectrometry result obtained for this compound (figure 3.17). The 
spectrum shows two peaks. The first, m/z = 7505.1 corresponds to the mass of the molecular ion 
plus sodium. The second peak m/z = 7631.0 is greater than the other of 126 units. This 
correspond to two atoms of copper (Mw = 63). It is possible therefore that the copper atoms are 
trapped in the molecule structure and interact with the triazole rings complicating the signals 
given by the “click” protons. 
 
Figure 3.16: Mass spectrum of compound 272 
With this method we have been successful in introducing different calixarenes through triazole 
linkages in two distinct steps.  
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An alternative approach has been developed for the introduction of alkyne functionalised 
calixarenes both at the upper and at the lower rim of a central core in subsequent steps. The 
central core designed for this purpose featured four aromatic azido groups at the upper rim and 
four halo alkane chains at the lower rim, which could be readily converted into azido chains 
once the “click” reaction at the upper rim has been performed.  
In a first attempt di-bromobutane was used to alkylate p-tert-butylcalix[4]arene (scheme 3.15).21, 
22
 NaH in DMF was used as the base to lock the molecule in the cone conformation. Ipso-
nitration of the compound23 was carried out using as nitrating agent equal volumes of fuming 
nitric acid and glacial acetic acid. The product was recovered after recrystallisation from 
DCM/MeOH as a pale yellow solid (79 %). Subsequent reduction24 of the nitro derivative 274 
with tin chloride yielded the tetra amino compound 275 in quantitative yield. 
 
Scheme 3.15: Synthesis of central core 280 
As described for the synthesis of 211 the four amino groups can be converted to azides via 
diazonium salt formation.25 Despite the stoichiometric amount of sodium azide and the 
temperature used (0oC), some of the bromines on the alkyl chain were also substituted by the 
azido anions. This problem was solved using 1-bromo-4-chlorobutane as the alkylating agent in 
the first step.21, 22 The chlorine on the chain was not reactive enough to be substituted by the 
azido groups at 0oC. Therefore the same set of reactions yielded the central core 280 featuring 
four aromatic azides at the upper rim and four halo alkyl chains at the lower rim. As was 
observed in previous examples for the synthesis of central the substitution of the aromatic amino 
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group with the azido group can be detected by the shift of signal for the aromatic protons from 
6.07 for the amino derivative (green) to 6.31 for the tetra azido compound (purple) (figure 3.18). 
 
Figure 3.17: 1H NMR spectra of compound 279 (green) and 280 (purple). 
The molecule was successfully clicked using CuI 26 as a source of copper (I) ions to the 
propargyl functionalised generation 1 calixarene 41 (scheme 3.14). The product was obtained 
after purification by column chromatography as an off white solid (52%).  
The pentamer 281 was heated at 70 oC in DMF in the presence of sodium azide. The chorines 
were successfully replaced and the tetraazido pentamer 282 was obtained by precipitation of the 
crude material from DCM/MeOH (48%). Reaction of this compound with four more equivalents 
of alkyne functionalised generation 1 calix[4]arene 41. 
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Scheme 3.16: Synthesis of the nonamer 283 
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Figure 3.18: Comparison between the spectra of compound 281 (blue) and compound 283. 
Figure 3.19 shows the spectrum of the pentamer 281 (blue) against the spectrum of the nonamer 
283 (red). Also in this case simple 1H NMR of the nonamer is difficult to interpret due to the 
overlap of the generation 1 protons. The “click” protons give multiple broad signals. COSY 
analysis gave useful information about the coupling of the protons and is reported in figure 3.20. 
 
 
Figure 3.19: COSY acquisition for compound 283 
“Click”protons regions
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The COSY spectrum clearly shows the coupling of the methylene bridges of the generation 1 
calixarenes (brown) at 4.38 and 3.11 ppm. In this molecule it is possible to distinguish also the 
coupling of the central core methylene bridges at 4.56 and 3.35 ppm (black). In green are 
highlighted the signals relative to the coupling of the terminal methyl protons of the propyl chain 
with the methylenes in the middle of the chain at 0.93 and 1.98 ppm respectively. These 
methylenes are coupled also to the ones next to the oxygens which give a signal at 3.76 ppm 
(blue). The protons of the methylenes located on the butyl chain next to the triazole ring (red) 
and the ones next to the oxygen on the other terminus of the aliphatic chain (purple) give two 
distinct signals at 4.52 and 4.01 ppm respectively. These protons are coupled to the ones in the 
middle of the chain which give a signal at 2.08 (red) and 2.06 (purple) ppm respectively. 
The mass spectrometry analysis (figure 3.12) again shows the peak of the molecular ion plus 
sodium and another peak greater of 126 units which is probably due to the complex with two 
atoms of copper. 
  
 
Figure 3.20: Mass spectrum of compound 283 
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3.4 Synthesis of henicosamers 
 
To synthesize a dentritic multicalixarene bearing twenty-one calixarene units, we opted for a 
convergent synthetic approach. The outer generation was composed of units of calixarene 41. 
The generation 1 calixarene was designed to bear four azido groups on the wide rim which 
would be able to react with the alkyne group of the generation 2 calixarenes, and a protected 
alkyne group on the lower rim, which after the formation of the pentamer could be deprotected 
and reacted with a tetrazido functionalised central core. 
Starting from 41 the alkyne group was protected with TBDMS in the presence of LiHDA in 
THF. The product, recovered after precipitation from DCM/MeOH (98%), was nitrated using 
equal amounts of fuming nitric acid and glacial acetic acid (figure 3.16). 
 
 
Scheme 3.1730: Alkyne protection and ipso-nitration 
The pale solid obtained after precipitation from DCM/ MeOH (85%) was reduced using the tin 
chloride method. The tetra amino-compound was dissolved in a mixture of 10% HCl and ethanol 
and allowed to react for twenty minutes with NaNO2 to form a diazonium salt.25 Subsequent 
addition of sodium azide yielded the tetra azido compound 284 which was recovered after 
column chromatography as an off white solid. The “click” reaction between generation 1 
calixarene 284 and generation 2 calixarene 41 yielded the pentamer 285 (scheme 3.18). 
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Scheme 3.18: Synthesis of alkyne functionalised pentamer 
The alkyne group could at this point be deprotected by treatment with TBAF in THF at reflux 
temperature and allowed to react with a tetra-azido functionalised central core. Two types of 
central core were tested. The first was locked in the cone conformation 16 and the second was 
locked it the 1,3-alternate conformation 34 (figure 3.22), their synthesis has been described in 
detail in chapter 1 
 
Figure 3.21:Azido functionalised central core in cone and 1,3-alternate conformation. 
In the final step pentamer 286 was reacted with either central core 16 or 34 to yield the two 
structures containing twenty-one calixarene scaffolds, in the cone 287 (56%) and in the 1,3-
alternate 288 (64%) conformation respectively (scheme 3.19). Copper sulphate and sodium 
ascorbate were used as a source of copper (I) ions.  
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Scheme 3.19: Synthesis of third generation multicalixarenes 
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Figure 3.23 displays a superimposition of the 1HNMR spectra for the pentamer 285 (blue), its 
deprotected derivative 286 (red) and the heneicosamers 287 (green) and 288 (purple). The 
spectra can be divided in eight regions. The first, between 6 and 8 ppm (I), shows all the signals 
relative to aromatic protons. The peaks are really difficult to assign because of the lack of 
coupling with other protons. In the second region (II) can be observed the click protons and in 
the spectra of 285 and 286 the alkyne peaks. The section III and V fall all the signals for the 
methylene bridges. The fourth section (IV) displays all the methylenes of the alkyl chains next 
to the oxygens or to the triazole ring. In section VI, around 2.5, it is possible to notice the triplet 
given by the alkyne group present in compound 286 (red). Section VII includes all the protons in 
the middle of the aliphatic chains. The last section include the terminal methyls of the propyl 
chains, the tert-butyl protons and in the spectra for compound 285 the protons for the silyl 
protecting group. 
 
 
Figure 3.22: 1H NMR spectra for compound 285 (blue), 286 (red), 287 (green) and 288 (purple) 
Interestingly MALDI TOF analysis showed different masses for the two different conformations. 
The peak for the multicalixarene with the central core in the cone conformation corresponds to 
the molecular mass of the compound plus the molecular mass of a copper sulphate pentahydrate 
molecule plus two water molecules On the other hand the value observed for the multicalixarene 
with the central core in the 1,3-alternate conformation corresponded to the molecular weight of 
the compound plus the weight of two copper sulphate penthaydrate plus two water molecules. 
I II III IV V VII VIIIVI
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3.5 Conclusions and future work 
 
In this chapter we have described a new route towards the synthesis of calixarene based 
dendrimers bearing either nine or twenty-one calixarene units in their structure distributed over 
two and three generations respectively. The calixarene building blocks were linked to the central 
core through copper(I) catalysed azide-alkyne cycloaddition using either copper iodide or a 
mixture of copper sulphate and sodium ascorbate. This result was possible because of the design 
of central cores functionalised at the upper rim with four azido function which enables the lower 
rim to carry further functionalisation such as protected alkynes or alkyl chloride chains. The 
method allows a first “click” reaction to be performed on the upper rim and then following the 
activation of the functional groups on the lower rim for a second cycloaddition. With this 
approach in the near future it could be possible to synthesise third generation calixarene 
dendrimers fully functionalised on the outer rim. Another potentially valuable area to investigate 
would be the synthesis of hybrid central cores bearing azido functionalisations on the upper rim 
and both protected alkynes and alkyl chlorides on the lower rim. This would allow a series of 
“click” reactions and therefore to use the calixarene to anchor three different molecules.  
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